WO2014073904A1 - Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient - Google Patents
Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient Download PDFInfo
- Publication number
- WO2014073904A1 WO2014073904A1 PCT/KR2013/010135 KR2013010135W WO2014073904A1 WO 2014073904 A1 WO2014073904 A1 WO 2014073904A1 KR 2013010135 W KR2013010135 W KR 2013010135W WO 2014073904 A1 WO2014073904 A1 WO 2014073904A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ylmethoxy
- phenyl
- indazol
- hex
- methyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 229940044601 receptor agonist Drugs 0.000 title claims abstract description 9
- 239000000018 receptor agonist Substances 0.000 title claims abstract description 9
- 239000004480 active ingredient Substances 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 330
- 101150108864 Ffar1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 838
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims abstract description 21
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 15
- 239000008103 glucose Substances 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- -1 1-isopropyl-1H-indol-6-ylmethyl Chemical group 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 208000002249 Diabetes Complications Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- CAPWDLCWVQDILC-NRFANRHFSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC(C)=C(N(CC(C)C)N=C2)C2=C1 CAPWDLCWVQDILC-NRFANRHFSA-N 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- SYBQOGMVLUJNJZ-QHCPKHFHSA-N (3s)-3-[4-[(1-benzyl-7-chloroindol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC=CC=3)C2=C1Cl SYBQOGMVLUJNJZ-QHCPKHFHSA-N 0.000 claims description 3
- CINZMEFJQHWHLK-VWLOTQADSA-N (3s)-3-[4-[(1-benzyl-7-methylindol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC=CC=3)C2=C1C CINZMEFJQHWHLK-VWLOTQADSA-N 0.000 claims description 3
- ODRDMXUYLJUPQW-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylindol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=CN2CC1=CC=CC=C1 ODRDMXUYLJUPQW-QHCPKHFHSA-N 0.000 claims description 3
- WMYFETILSDLKMU-NRFANRHFSA-N (3s)-3-[4-[[1-(4-fluoro-2-methylphenyl)indol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=CN2C1=CC=C(F)C=C1C WMYFETILSDLKMU-NRFANRHFSA-N 0.000 claims description 3
- BDEDXDFNEYTPNN-QHCPKHFHSA-N (3s)-3-[4-[[1-(4-fluoro-2-methylphenyl)indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2C=3C(=CC(F)=CC=3)C)C2=C1 BDEDXDFNEYTPNN-QHCPKHFHSA-N 0.000 claims description 3
- UQLHRHXQSCZSLV-QFIPXVFZSA-N (3s)-3-[4-[[1-[(2,6-difluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C(=CC=CC=3F)F)C2=C1C UQLHRHXQSCZSLV-QFIPXVFZSA-N 0.000 claims description 3
- BWIXQVHFCUJENR-SANMLTNESA-N (3s)-3-[4-[[1-[(2,6-dimethylphenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C(=CC=CC=3C)C)C2=C1C BWIXQVHFCUJENR-SANMLTNESA-N 0.000 claims description 3
- UQOHIGUWHVNCMJ-QHCPKHFHSA-N (3s)-3-[4-[[1-[(2-chlorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C(=CC=CC=3)Cl)C2=C1C UQOHIGUWHVNCMJ-QHCPKHFHSA-N 0.000 claims description 3
- VYCVQZZKZQIRAH-QHCPKHFHSA-N (3s)-3-[4-[[1-[(2-fluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C(=CC=CC=3)F)C2=C1C VYCVQZZKZQIRAH-QHCPKHFHSA-N 0.000 claims description 3
- FIGVTWVXUKBOIA-VWLOTQADSA-N (3s)-3-[4-[[1-[(4-methoxyphenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC(OC)=CC=C1CN1C2=C(C)C(COC=3C=CC(=CC=3)[C@H](CC(O)=O)C#CC)=CC=C2C=C1 FIGVTWVXUKBOIA-VWLOTQADSA-N 0.000 claims description 3
- BKWRDQKPHNKLBM-MHZLTWQESA-N (3s)-3-[4-[[1-[[3-(methoxymethyl)phenyl]methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound COCC1=CC=CC(CN2C3=C(C)C(COC=4C=CC(=CC=4)[C@H](CC(O)=O)C#CC)=CC=C3C=C2)=C1 BKWRDQKPHNKLBM-MHZLTWQESA-N 0.000 claims description 3
- CIRFHDXLDRKRPX-VWLOTQADSA-N (3s)-3-[4-[[7-methyl-1-[(2-methylphenyl)methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C(=CC=CC=3)C)C2=C1C CIRFHDXLDRKRPX-VWLOTQADSA-N 0.000 claims description 3
- LTFHORVGOFCXIU-VWLOTQADSA-N (3s)-3-[4-[[7-methyl-1-[(4-methylsulfonylphenyl)methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC(=CC=3)S(C)(=O)=O)C2=C1C LTFHORVGOFCXIU-VWLOTQADSA-N 0.000 claims description 3
- RVOLXLRJXMOROL-MHZLTWQESA-N (3s)-3-[4-[[7-methyl-1-[[3-(methylsulfonylmethyl)phenyl]methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=C(CS(C)(=O)=O)C=CC=3)C2=C1C RVOLXLRJXMOROL-MHZLTWQESA-N 0.000 claims description 3
- XWWFPFCUHUWSDK-DEOSSOPVSA-N (3s)-3-[4-[[7-methyl-1-[[4-(trifluoromethyl)phenyl]methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC(=CC=3)C(F)(F)F)C2=C1C XWWFPFCUHUWSDK-DEOSSOPVSA-N 0.000 claims description 3
- NRHSNXZPTLVQOL-UHFFFAOYSA-N 2-[6-[(1-benzyl-3-chloroindol-6-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)COC2=CC=1OCC(C=C12)=CC=C1C(Cl)=CN2CC1=CC=CC=C1 NRHSNXZPTLVQOL-UHFFFAOYSA-N 0.000 claims description 3
- FXGVRBBSMSQCCX-UHFFFAOYSA-N 2-[6-[[1-(4-fluoro-2-methylphenyl)indol-6-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CC1=CC(F)=CC=C1N1C2=CC(COC=3C=C4OCC(CC(O)=O)C4=CC=3)=CC=C2C=C1 FXGVRBBSMSQCCX-UHFFFAOYSA-N 0.000 claims description 3
- LMAOBQHLNGJYNZ-UHFFFAOYSA-N 3-[4-[(1-benzyl-2,3-dichloroindol-6-yl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C(Cl)=C(Cl)N2CC=3C=CC=CC=3)C2=C1 LMAOBQHLNGJYNZ-UHFFFAOYSA-N 0.000 claims description 3
- PFXGALBVNYFGOA-UHFFFAOYSA-N 3-[4-[(1-benzyl-3-chloroindol-6-yl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C(Cl)=CN2CC=3C=CC=CC=3)C2=C1 PFXGALBVNYFGOA-UHFFFAOYSA-N 0.000 claims description 3
- UVNLNNWZUHMFBF-UHFFFAOYSA-N 3-[4-[(1-benzyl-7-chloroindol-6-yl)methoxy]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC=CC=3)C2=C1Cl UVNLNNWZUHMFBF-UHFFFAOYSA-N 0.000 claims description 3
- SZVVZYGQPRLZHH-UHFFFAOYSA-N 3-[4-[(1-benzyl-7-chloroindol-6-yl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2CC=3C=CC=CC=3)C2=C1Cl SZVVZYGQPRLZHH-UHFFFAOYSA-N 0.000 claims description 3
- RPEYJAYXIHJNFR-UHFFFAOYSA-N 3-[4-[(1-benzyl-7-methylindol-6-yl)methoxy]phenyl]propanoic acid Chemical compound C1=CC=2C=CN(CC=3C=CC=CC=3)C=2C(C)=C1COC1=CC=C(CCC(O)=O)C=C1 RPEYJAYXIHJNFR-UHFFFAOYSA-N 0.000 claims description 3
- KECBLWBGJTUISM-UHFFFAOYSA-N 3-[4-[(1-benzylindol-6-yl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2CC=3C=CC=CC=3)C2=C1 KECBLWBGJTUISM-UHFFFAOYSA-N 0.000 claims description 3
- YSPMUJZNTVZOSD-UHFFFAOYSA-N 3-[4-[(1-thiophen-3-ylindol-6-yl)methoxy]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1OCC1=CC=C(C=CN2C3=CSC=C3)C2=C1 YSPMUJZNTVZOSD-UHFFFAOYSA-N 0.000 claims description 3
- PAAHAGPKJIKBEI-UHFFFAOYSA-N 3-[4-[(1-thiophen-3-ylindol-6-yl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2C3=CSC=C3)C2=C1 PAAHAGPKJIKBEI-UHFFFAOYSA-N 0.000 claims description 3
- KRFWEDYMXLTUDA-UHFFFAOYSA-N 3-[4-[(3-benzyl-1-methylindol-5-yl)methoxy]phenyl]propanoic acid Chemical compound C12=CC(COC=3C=CC(CCC(O)=O)=CC=3)=CC=C2N(C)C=C1CC1=CC=CC=C1 KRFWEDYMXLTUDA-UHFFFAOYSA-N 0.000 claims description 3
- OPFKYNUJGIVWEV-UHFFFAOYSA-N 3-[4-[(7-chloro-1-thiophen-3-ylindol-6-yl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2C3=CSC=C3)C2=C1Cl OPFKYNUJGIVWEV-UHFFFAOYSA-N 0.000 claims description 3
- DHVVKOLJEKQOCI-UHFFFAOYSA-N 3-[4-[(7-methyl-1-thiophen-3-ylindol-6-yl)methoxy]phenyl]propanoic acid Chemical compound C1=CC=2C=CN(C3=CSC=C3)C=2C(C)=C1COC1=CC=C(CCC(O)=O)C=C1 DHVVKOLJEKQOCI-UHFFFAOYSA-N 0.000 claims description 3
- QGTLKVBWOITQOL-UHFFFAOYSA-N 3-[4-[[1-(1H-indol-6-yl)-2-phenylpropyl]amino]phenyl]propanoic acid Chemical compound C1(=CC=CC=C1)C(C)C(C1=CC=C2C=CNC2=C1)NC1=CC=C(C=C1)CCC(=O)O QGTLKVBWOITQOL-UHFFFAOYSA-N 0.000 claims description 3
- LCPZVGNFAPSNJB-UHFFFAOYSA-N 3-[4-[[1-(4-fluoro-2-methylphenyl)indol-6-yl]methoxy]phenyl]propanoic acid Chemical compound CC1=CC(F)=CC=C1N1C2=CC(COC=3C=CC(CCC(O)=O)=CC=3)=CC=C2C=C1 LCPZVGNFAPSNJB-UHFFFAOYSA-N 0.000 claims description 3
- YKMFUUKYKHVJCO-UHFFFAOYSA-N 3-[4-[[1-(4-fluorophenyl)-7-methylindol-6-yl]methoxy]phenyl]propanoic acid Chemical compound C1=CC=2C=CN(C=3C=CC(F)=CC=3)C=2C(C)=C1COC1=CC=C(CCC(O)=O)C=C1 YKMFUUKYKHVJCO-UHFFFAOYSA-N 0.000 claims description 3
- VXVQTAGIOUFTFW-UHFFFAOYSA-N 3-[4-[[1-(4-fluorophenyl)indol-6-yl]methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2C=3C=CC(F)=CC=3)C2=C1 VXVQTAGIOUFTFW-UHFFFAOYSA-N 0.000 claims description 3
- GTNSNLPKVCQIPT-UHFFFAOYSA-N 3-[4-[[1-(cyclohexylmethyl)indol-6-yl]methoxy]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1OCC1=CC=C(C=CN2CC3CCCCC3)C2=C1 GTNSNLPKVCQIPT-UHFFFAOYSA-N 0.000 claims description 3
- AQUWZPALFKAORK-UHFFFAOYSA-N 3-[4-[[1-methyl-3-(2-methylphenyl)indol-5-yl]methoxy]phenyl]propanoic acid Chemical compound CC1=CC=CC=C1C(C1=C2)=CN(C)C1=CC=C2COC1=CC=C(CCC(O)=O)C=C1 AQUWZPALFKAORK-UHFFFAOYSA-N 0.000 claims description 3
- OYYHOYITUKJDDO-UHFFFAOYSA-N 3-[4-[[7-chloro-1-(4-fluorophenyl)indol-6-yl]methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2C=3C=CC(F)=CC=3)C2=C1Cl OYYHOYITUKJDDO-UHFFFAOYSA-N 0.000 claims description 3
- UWJMXBPNHGRNML-UHFFFAOYSA-N 3-[4-[[7-chloro-1-(cyclohexylmethyl)indol-6-yl]methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=C(C=CN2CC3CCCCC3)C2=C1Cl UWJMXBPNHGRNML-UHFFFAOYSA-N 0.000 claims description 3
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- ONGMJWZMQJOEQL-JKLGZZSBSA-N (3S)-3-[4-[1-(1H-indazol-5-yl)-2-phenylpropoxy]phenyl]hex-4-ynoic acid Chemical compound C1(=CC=CC=C1)C(C)C(OC1=CC=C(C=C1)[C@H](CC(=O)O)C#CC)C=1C=C2C=NNC2=CC1 ONGMJWZMQJOEQL-JKLGZZSBSA-N 0.000 claims description 2
- OFGRCNWEQKLDRU-FQEVSTJZSA-N (3s)-3-(1,2-oxazol-3-yl)-3-[4-[(1-propan-2-ylindazol-6-yl)methoxy]phenyl]propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=CC=C3C=NN(C3=C2)C(C)C)C=CON=1 OFGRCNWEQKLDRU-FQEVSTJZSA-N 0.000 claims description 2
- FCYUHWVTMSEHIP-FQEVSTJZSA-N (3s)-3-(1,2-oxazol-3-yl)-3-[4-[(2-propan-2-ylindazol-6-yl)methoxy]phenyl]propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC=2C=CC3=CN(N=C3C=2)C(C)C)C=CON=1 FCYUHWVTMSEHIP-FQEVSTJZSA-N 0.000 claims description 2
- SDQPUFQGBXNQFM-QFIPXVFZSA-N (3s)-3-(1,2-oxazol-3-yl)-3-[4-[[1-(pyrazin-2-ylmethyl)pyrrolo[2,3-b]pyridin-6-yl]methoxy]phenyl]propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3N=C4N(CC=5N=CC=NC=5)C=CC4=CC=3)=CC=2)C=CON=1 SDQPUFQGBXNQFM-QFIPXVFZSA-N 0.000 claims description 2
- QGQUBUPFCIVTSE-KRWDZBQOSA-N (3s)-3-[4-(1h-indazol-6-ylmethoxy)phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3C=C4NN=CC4=CC=3)=CC=2)C=CON=1 QGQUBUPFCIVTSE-KRWDZBQOSA-N 0.000 claims description 2
- FDJUCPXKPACDSL-QHCPKHFHSA-N (3s)-3-[4-[(1-benzyl-3-fluoro-7-methylindol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(F)=CN2CC=3C=CC=CC=3)C2=C1C FDJUCPXKPACDSL-QHCPKHFHSA-N 0.000 claims description 2
- OQMCKVQURBZQEB-QHCPKHFHSA-N (3s)-3-[4-[(1-benzyl-3-methyl-2-oxobenzimidazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)C(=O)N2C)C2=C1 OQMCKVQURBZQEB-QHCPKHFHSA-N 0.000 claims description 2
- TXRFGQMVIIFORO-QHCPKHFHSA-N (3s)-3-[4-[(1-benzyl-5-fluoro-7-methylindol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=C(F)C=C(C=CN2CC=3C=CC=CC=3)C2=C1C TXRFGQMVIIFORO-QHCPKHFHSA-N 0.000 claims description 2
- DBNVWLKGLCLJSI-NRFANRHFSA-N (3s)-3-[4-[(1-benzyl-5-fluoroindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C(=C1)F)=CC2=C1C=NN2CC1=CC=CC=C1 DBNVWLKGLCLJSI-NRFANRHFSA-N 0.000 claims description 2
- VFMJHBOXRQCIDA-QFIPXVFZSA-N (3s)-3-[4-[(1-benzyl-5-fluoroindol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C(=C1)F)=CC2=C1C=CN2CC1=CC=CC=C1 VFMJHBOXRQCIDA-QFIPXVFZSA-N 0.000 claims description 2
- KRTPCHLNDCELCB-DEOSSOPVSA-N (3s)-3-[4-[(1-benzyl-7-methylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC(C)=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 KRTPCHLNDCELCB-DEOSSOPVSA-N 0.000 claims description 2
- RWBPVAFMHMEVMG-SANMLTNESA-N (3s)-3-[4-[(1-benzyl-7-methylindol-6-yl)methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=C(C=3N(CC=4C=CC=CC=4)C=CC=3C=C2)C)C=CON=1 RWBPVAFMHMEVMG-SANMLTNESA-N 0.000 claims description 2
- QHLWFXNDFOIYJS-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylbenzimidazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)C=N2)C2=C1 QHLWFXNDFOIYJS-QHCPKHFHSA-N 0.000 claims description 2
- KLDAJWCLNCMSGR-QFIPXVFZSA-N (3s)-3-[4-[(1-benzylbenzotriazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)N=N2)C2=C1 KLDAJWCLNCMSGR-QFIPXVFZSA-N 0.000 claims description 2
- SKXFYZJZZOKUML-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylindazol-4-yl)methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3C=4C=NN(CC=5C=CC=CC=5)C=4C=CC=3)=CC=2)C=CON=1 SKXFYZJZZOKUML-QHCPKHFHSA-N 0.000 claims description 2
- QRGLOVCHZXXEHN-QFIPXVFZSA-N (3s)-3-[4-[(1-benzylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=NN2CC1=CC=CC=C1 QRGLOVCHZXXEHN-QFIPXVFZSA-N 0.000 claims description 2
- PWEFXYQZPPAXJW-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 PWEFXYQZPPAXJW-QHCPKHFHSA-N 0.000 claims description 2
- QXJRKSXXNYFNSH-DEOSSOPVSA-N (3s)-3-[4-[(1-benzylindazol-6-yl)methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3C=C4N(CC=5C=CC=CC=5)N=CC4=CC=3)=CC=2)C=CON=1 QXJRKSXXNYFNSH-DEOSSOPVSA-N 0.000 claims description 2
- DCNINYSGPDWNHN-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3C=CC=CC=3)C2=C1 DCNINYSGPDWNHN-QHCPKHFHSA-N 0.000 claims description 2
- LGMAYQVPKGCKOQ-DEOSSOPVSA-N (3s)-3-[4-[(1-benzylindol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)C=C2)C2=C1 LGMAYQVPKGCKOQ-DEOSSOPVSA-N 0.000 claims description 2
- PYCZCALPUPAUCF-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylpyrrolo[2,3-b]pyridin-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CN=C(N(CC=2C=CC=CC=2)C=C2)C2=C1 PYCZCALPUPAUCF-QHCPKHFHSA-N 0.000 claims description 2
- LZNKIJOBUYBLJD-DEOSSOPVSA-N (3s)-3-[4-[(1-benzylpyrrolo[2,3-b]pyridin-6-yl)methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3N=C4N(CC=5C=CC=CC=5)C=CC4=CC=3)=CC=2)C=CON=1 LZNKIJOBUYBLJD-DEOSSOPVSA-N 0.000 claims description 2
- JNJZOUZSQRGSGA-QHCPKHFHSA-N (3s)-3-[4-[(1-benzylpyrrolo[2,3-b]pyridin-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC=CC=3)C2=N1 JNJZOUZSQRGSGA-QHCPKHFHSA-N 0.000 claims description 2
- DRAUSOVSHNBJGK-SFHVURJKSA-N (3s)-3-[4-[(1-butyl-3-fluoroindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC=C2N(CCCC)N=C(F)C2=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 DRAUSOVSHNBJGK-SFHVURJKSA-N 0.000 claims description 2
- SKEJWVBBAZWSIK-FQEVSTJZSA-N (3s)-3-[4-[(1-butyl-3-methylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC=C2N(CCCC)N=C(C)C2=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 SKEJWVBBAZWSIK-FQEVSTJZSA-N 0.000 claims description 2
- KWJAVVGYJISGMW-IBGZPJMESA-N (3s)-3-[4-[(1-butylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC=C2N(CCCC)N=CC2=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 KWJAVVGYJISGMW-IBGZPJMESA-N 0.000 claims description 2
- HBAOGVBJSOARCM-NRFANRHFSA-N (3s)-3-[4-[(1-cyclopentyl-7-methylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC(C)=C(N(N=C2)C3CCCC3)C2=C1 HBAOGVBJSOARCM-NRFANRHFSA-N 0.000 claims description 2
- NHHYMWLYEDGFPI-FQEVSTJZSA-N (3s)-3-[4-[(1-cyclopentylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(N=C2)C3CCCC3)C2=C1 NHHYMWLYEDGFPI-FQEVSTJZSA-N 0.000 claims description 2
- CISJLMKEZCGVNZ-FQEVSTJZSA-N (3s)-3-[4-[(1-cyclopentylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2C3CCCC3)C2=C1 CISJLMKEZCGVNZ-FQEVSTJZSA-N 0.000 claims description 2
- UTOSAODGLASYET-KRWDZBQOSA-N (3s)-3-[4-[(1-ethyl-3-fluoro-7-methylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1=C2N(CC)N=C(F)C2=CC=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 UTOSAODGLASYET-KRWDZBQOSA-N 0.000 claims description 2
- HPEFTBLWCUGNCG-SFHVURJKSA-N (3s)-3-[4-[(1-methyl-3-propan-2-ylindazol-7-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1N(C)N=C2C(C)C HPEFTBLWCUGNCG-SFHVURJKSA-N 0.000 claims description 2
- QQIFQXKHJHBOGG-SFHVURJKSA-N (3s)-3-[4-[(1-methyl-3-propylindazol-7-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC=C2C(CCC)=NN(C)C2=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 QQIFQXKHJHBOGG-SFHVURJKSA-N 0.000 claims description 2
- APDTXKYLSVZQRB-SFHVURJKSA-N (3s)-3-[4-[(1-methylindazol-6-yl)methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=CC=C3C=NN(C3=C2)C)C=CON=1 APDTXKYLSVZQRB-SFHVURJKSA-N 0.000 claims description 2
- VERFTIYVCXAURS-SFHVURJKSA-N (3s)-3-[4-[(1-propan-2-ylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=NN2C(C)C VERFTIYVCXAURS-SFHVURJKSA-N 0.000 claims description 2
- IDDQEOJYSUDGTL-IBGZPJMESA-N (3s)-3-[4-[(1-propan-2-ylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(N=C2)C(C)C)C2=C1 IDDQEOJYSUDGTL-IBGZPJMESA-N 0.000 claims description 2
- FIOPUEKAMAQZOD-IBGZPJMESA-N (3s)-3-[4-[(1-propan-2-ylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2C(C)C)C2=C1 FIOPUEKAMAQZOD-IBGZPJMESA-N 0.000 claims description 2
- ITQSRBJHFLYZOD-SFHVURJKSA-N (3s)-3-[4-[(1-propan-2-ylpyrrolo[2,3-b]pyridin-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=NC2=C1C=CN2C(C)C ITQSRBJHFLYZOD-SFHVURJKSA-N 0.000 claims description 2
- RTAVSJJBWGOOCL-DEOSSOPVSA-N (3s)-3-[4-[(2-benzyl-7-methylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=CN(CC=3C=CC=CC=3)N=C2C(C)=C1 RTAVSJJBWGOOCL-DEOSSOPVSA-N 0.000 claims description 2
- MKGQKHLNLSXJRR-QFIPXVFZSA-N (3s)-3-[4-[(2-benzylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C1=C2)=CC=CC1=NN2CC1=CC=CC=C1 MKGQKHLNLSXJRR-QFIPXVFZSA-N 0.000 claims description 2
- ZGKMKTSJELUJTM-QHCPKHFHSA-N (3s)-3-[4-[(2-benzylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=CN(CC=3C=CC=CC=3)N=C2C=C1 ZGKMKTSJELUJTM-QHCPKHFHSA-N 0.000 claims description 2
- GJGCZAWXZDFBNE-QHCPKHFHSA-N (3s)-3-[4-[(2-benzylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=NN(CC=3C=CC=CC=3)C=C2C=C1 GJGCZAWXZDFBNE-QHCPKHFHSA-N 0.000 claims description 2
- LBBCKCVPVRXWLM-HNNXBMFYSA-N (3s)-3-[4-[(3-bromo-1-methylindazol-7-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1N(C)N=C2Br LBBCKCVPVRXWLM-HNNXBMFYSA-N 0.000 claims description 2
- ZSRCKRQREKCNIF-IBGZPJMESA-N (3s)-3-[4-[(3-butyl-1-methylindazol-7-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC=C2C(CCCC)=NN(C)C2=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 ZSRCKRQREKCNIF-IBGZPJMESA-N 0.000 claims description 2
- IKVRDMJCNZOXPG-HNNXBMFYSA-N (3s)-3-[4-[(3-fluoro-1-methylindazol-7-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1N(C)N=C2F IKVRDMJCNZOXPG-HNNXBMFYSA-N 0.000 claims description 2
- LCBDNXNALRZHCQ-KRWDZBQOSA-N (3s)-3-[4-[(3-fluoro-1-propan-2-ylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C(F)=NN2C(C)C LCBDNXNALRZHCQ-KRWDZBQOSA-N 0.000 claims description 2
- ZRWWQKVWGDLFON-FQEVSTJZSA-N (3s)-3-[4-[(3-methyl-1-propan-2-ylindazol-5-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(N=C2C)C(C)C)C2=C1 ZRWWQKVWGDLFON-FQEVSTJZSA-N 0.000 claims description 2
- VWTABTLPMHQEEX-FQEVSTJZSA-N (3s)-3-[4-[(3-methyl-1-propan-2-ylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(C)=NN2C(C)C)C2=C1 VWTABTLPMHQEEX-FQEVSTJZSA-N 0.000 claims description 2
- ZMWSDSBZQOTLDK-IBGZPJMESA-N (3s)-3-[4-[(7-methyl-1-propan-2-ylindazol-4-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C)C2=C1C=NN2C(C)C ZMWSDSBZQOTLDK-IBGZPJMESA-N 0.000 claims description 2
- TXBPHMSYLNFLNI-IBGZPJMESA-N (3s)-3-[4-[(7-methyl-1-propan-2-ylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2C(C)C)C2=C1C TXBPHMSYLNFLNI-IBGZPJMESA-N 0.000 claims description 2
- AIUDAXCSPNELSA-IBGZPJMESA-N (3s)-3-[4-[(7-methyl-1-propylindazol-6-yl)methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1=C2N(CCC)N=CC2=CC=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 AIUDAXCSPNELSA-IBGZPJMESA-N 0.000 claims description 2
- POTNBWAOOWPFDR-FQEVSTJZSA-N (3s)-3-[4-[[1-(2,2-dimethylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC(C)(C)C)C2=C1 POTNBWAOOWPFDR-FQEVSTJZSA-N 0.000 claims description 2
- LRZQDOOYOBKAIE-FQEVSTJZSA-N (3s)-3-[4-[[1-(2-ethoxyethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C=1C=C2N(CCOCC)N=CC2=CC=1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 LRZQDOOYOBKAIE-FQEVSTJZSA-N 0.000 claims description 2
- KOXXNHOWZQETBY-IBGZPJMESA-N (3s)-3-[4-[[1-(2-methoxyethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C=1C=C2N(CCOC)N=CC2=CC=1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 KOXXNHOWZQETBY-IBGZPJMESA-N 0.000 claims description 2
- YQPHSFPXWPSDFH-DEOSSOPVSA-N (3s)-3-[4-[[1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CCOCC2)=NN2CC(C)C)C2=C1 YQPHSFPXWPSDFH-DEOSSOPVSA-N 0.000 claims description 2
- LLWJIBTTZWACQY-QHCPKHFHSA-N (3s)-3-[4-[[1-(2-methylpropyl)-3-(propan-2-yloxymethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(COC(C)C)=NN2CC(C)C)C2=C1 LLWJIBTTZWACQY-QHCPKHFHSA-N 0.000 claims description 2
- BXTBMEMEIVJKAI-IBGZPJMESA-N (3s)-3-[4-[[1-(2-methylpropyl)indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=NN2CC(C)C BXTBMEMEIVJKAI-IBGZPJMESA-N 0.000 claims description 2
- XKHKRSXXIRYIQQ-FQEVSTJZSA-N (3s)-3-[4-[[1-(2-methylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC(C)C)N=C2)C2=C1 XKHKRSXXIRYIQQ-FQEVSTJZSA-N 0.000 claims description 2
- MEXAFPPPAUCOQA-NRFANRHFSA-N (3s)-3-[4-[[1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=CC=C3C=NN(C3=C2)CC(C)C)C=CON=1 MEXAFPPPAUCOQA-NRFANRHFSA-N 0.000 claims description 2
- OYBFTJPWDREONP-FQEVSTJZSA-N (3s)-3-[4-[[1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC(C)C)C2=C1 OYBFTJPWDREONP-FQEVSTJZSA-N 0.000 claims description 2
- VKJRSHSBSASCFA-IBGZPJMESA-N (3s)-3-[4-[[1-(2-methylpropyl)pyrazolo[3,4-b]pyridin-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CN=C(N(CC(C)C)N=C2)C2=C1 VKJRSHSBSASCFA-IBGZPJMESA-N 0.000 claims description 2
- ZTQSAKOXVJQYBL-IBGZPJMESA-N (3s)-3-[4-[[1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=NC2=C1C=CN2CC(C)C ZTQSAKOXVJQYBL-IBGZPJMESA-N 0.000 claims description 2
- GNVYCJOLFPTBDQ-FQEVSTJZSA-N (3s)-3-[4-[[1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CN=C(N(CC(C)C)C=C2)C2=C1 GNVYCJOLFPTBDQ-FQEVSTJZSA-N 0.000 claims description 2
- PRAUAMLXPLTSPR-NRFANRHFSA-N (3s)-3-[4-[[1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=CC=C3C=CN(C3=N2)CC(C)C)C=CON=1 PRAUAMLXPLTSPR-NRFANRHFSA-N 0.000 claims description 2
- SUNABKDUUAODTQ-FQEVSTJZSA-N (3s)-3-[4-[[1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC(C)C)C2=N1 SUNABKDUUAODTQ-FQEVSTJZSA-N 0.000 claims description 2
- OGLBCRUINDRCRM-IBGZPJMESA-N (3s)-3-[4-[[1-(2-methylsulfonylethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CCS(C)(=O)=O)N=C2)C2=C1 OGLBCRUINDRCRM-IBGZPJMESA-N 0.000 claims description 2
- XLMJIDXZLSGCDO-FQEVSTJZSA-N (3s)-3-[4-[[1-(3-methoxypropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C=1C=C2N(CCCOC)N=CC2=CC=1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 XLMJIDXZLSGCDO-FQEVSTJZSA-N 0.000 claims description 2
- TXSUHWQKPYRRNR-NRFANRHFSA-N (3s)-3-[4-[[1-(3-methylbutyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CCC(C)C)N=C2)C2=C1 TXSUHWQKPYRRNR-NRFANRHFSA-N 0.000 claims description 2
- RXRUZIVFCWNAQZ-FQEVSTJZSA-N (3s)-3-[4-[[1-(3-methylsulfonylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CCCS(C)(=O)=O)N=C2)C2=C1 RXRUZIVFCWNAQZ-FQEVSTJZSA-N 0.000 claims description 2
- MTXROGNCCPOJFD-QHCPKHFHSA-N (3s)-3-[4-[[1-(cyclohexylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC2CCCCC2)N=C2)C2=C1 MTXROGNCCPOJFD-QHCPKHFHSA-N 0.000 claims description 2
- FFHIOCHHQAQSRD-QHCPKHFHSA-N (3s)-3-[4-[[1-(cyclopentylmethyl)-7-methylindazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC(C)=C(N(CC2CCCC2)N=C2)C2=C1 FFHIOCHHQAQSRD-QHCPKHFHSA-N 0.000 claims description 2
- PUPWUIGGRZTZDG-QFIPXVFZSA-N (3s)-3-[4-[[1-(cyclopentylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC2CCCC2)N=C2)C2=C1 PUPWUIGGRZTZDG-QFIPXVFZSA-N 0.000 claims description 2
- PKSFZWNLFWCMNO-QHCPKHFHSA-N (3s)-3-[4-[[1-(cyclopentylmethyl)indazol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3C=C4N(CC5CCCC5)N=CC4=CC=3)=CC=2)C=CON=1 PKSFZWNLFWCMNO-QHCPKHFHSA-N 0.000 claims description 2
- QYHSKOFJQXHQOW-QFIPXVFZSA-N (3s)-3-[4-[[1-(cyclopentylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC3CCCC3)C2=C1 QYHSKOFJQXHQOW-QFIPXVFZSA-N 0.000 claims description 2
- VLULFWOLSFTTKX-SFHVURJKSA-N (3s)-3-[4-[[1-(cyclopropylmethyl)-3-fluoroindazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C(F)=NN2CC1CC1 VLULFWOLSFTTKX-SFHVURJKSA-N 0.000 claims description 2
- DHHOYDLYMCQLBC-IBGZPJMESA-N (3s)-3-[4-[[1-(cyclopropylmethyl)indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=NN2CC1CC1 DHHOYDLYMCQLBC-IBGZPJMESA-N 0.000 claims description 2
- YBRXCPYLFWESCG-FQEVSTJZSA-N (3s)-3-[4-[[1-(cyclopropylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC2CC2)N=C2)C2=C1 YBRXCPYLFWESCG-FQEVSTJZSA-N 0.000 claims description 2
- UEJXKDVKVBYOGJ-NRFANRHFSA-N (3s)-3-[4-[[1-(cyclopropylmethyl)indazol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3C=C4N(CC5CC5)N=CC4=CC=3)=CC=2)C=CON=1 UEJXKDVKVBYOGJ-NRFANRHFSA-N 0.000 claims description 2
- FGBGPFYQAXVHIK-AJZOCDQUSA-N (3s)-3-[4-[[1-(oxolan-2-ylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC2OCCC2)N=C2)C2=C1 FGBGPFYQAXVHIK-AJZOCDQUSA-N 0.000 claims description 2
- JINGKIFZJMMIDX-QWAKEFERSA-N (3s)-3-[4-[[1-(oxolan-3-ylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC2COCC2)N=C2)C2=C1 JINGKIFZJMMIDX-QWAKEFERSA-N 0.000 claims description 2
- QQIKEYHSPJDTPJ-NRFANRHFSA-N (3s)-3-[4-[[1-(pyridin-2-ylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2N=CC=CC=2)N=C2)C2=C1 QQIKEYHSPJDTPJ-NRFANRHFSA-N 0.000 claims description 2
- CBBPNOVLHLQVMB-QFIPXVFZSA-N (3s)-3-[4-[[1-(pyridin-3-ylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC=2C=NC=CC=2)N=C2)C2=C1 CBBPNOVLHLQVMB-QFIPXVFZSA-N 0.000 claims description 2
- YNQZXLKYZHPPLT-QFIPXVFZSA-N (3s)-3-[4-[[1-(pyridin-3-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3C=NC=CC=3)C2=C1 YNQZXLKYZHPPLT-QFIPXVFZSA-N 0.000 claims description 2
- ZUXXKNKIWFVONM-FQEVSTJZSA-N (3s)-3-[4-[[1-(pyrimidin-4-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3N=CN=CC=3)C2=C1 ZUXXKNKIWFVONM-FQEVSTJZSA-N 0.000 claims description 2
- QWIZMKIGHUAXSX-NRFANRHFSA-N (3s)-3-[4-[[1-[(1-methylpyrazol-4-yl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC3=CN(C)N=C3)C2=C1 QWIZMKIGHUAXSX-NRFANRHFSA-N 0.000 claims description 2
- FPRVNXYYUGXMRN-QFIPXVFZSA-N (3s)-3-[4-[[1-[(2,4-difluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C(=CC(F)=CC=3)F)C2=C1C FPRVNXYYUGXMRN-QFIPXVFZSA-N 0.000 claims description 2
- UGGXJAXXFAOBDB-QHCPKHFHSA-N (3s)-3-[4-[[1-[(3,4-difluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=C(F)C(F)=CC=3)C2=C1C UGGXJAXXFAOBDB-QHCPKHFHSA-N 0.000 claims description 2
- NOXDCFCNVYTRHT-QHCPKHFHSA-N (3s)-3-[4-[[1-[(3,5-difluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=C(F)C=C(F)C=3)C2=C1C NOXDCFCNVYTRHT-QHCPKHFHSA-N 0.000 claims description 2
- DBTQLCQOGBXBRJ-DEOSSOPVSA-N (3s)-3-[4-[[1-[(3-fluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=C(F)C=CC=3)C2=C1C DBTQLCQOGBXBRJ-DEOSSOPVSA-N 0.000 claims description 2
- QHJAYURAUAUABX-FQEVSTJZSA-N (3s)-3-[4-[[1-[(3-methyloxetan-3-yl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC3(C)COC3)C2=C1 QHJAYURAUAUABX-FQEVSTJZSA-N 0.000 claims description 2
- INXPWEQLUUZJII-SANMLTNESA-N (3s)-3-[4-[[1-[(4-fluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=C(C=3N(CC=4C=CC(F)=CC=4)C=CC=3C=C2)C)C=CON=1 INXPWEQLUUZJII-SANMLTNESA-N 0.000 claims description 2
- VBMFBCDJWLOEAJ-DEOSSOPVSA-N (3s)-3-[4-[[1-[(4-fluorophenyl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC(F)=CC=3)C2=C1C VBMFBCDJWLOEAJ-DEOSSOPVSA-N 0.000 claims description 2
- NFCDDUMJESGFAY-NRFANRHFSA-N (3s)-3-[4-[[1-[(4-fluorophenyl)methyl]indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=NN2CC1=CC=C(F)C=C1 NFCDDUMJESGFAY-NRFANRHFSA-N 0.000 claims description 2
- PCANSKSRTHJHLC-DEOSSOPVSA-N (3s)-3-[4-[[1-[(4-fluorophenyl)methyl]indazol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3C=C4N(CC=5C=CC(F)=CC=5)N=CC4=CC=3)=CC=2)C=CON=1 PCANSKSRTHJHLC-DEOSSOPVSA-N 0.000 claims description 2
- NJTRWZFYQVUEFY-QFIPXVFZSA-N (3s)-3-[4-[[1-[(4-fluorophenyl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3C=CC(F)=CC=3)C2=C1 NJTRWZFYQVUEFY-QFIPXVFZSA-N 0.000 claims description 2
- PUTWBHHBUCHPEM-DEOSSOPVSA-N (3s)-3-[4-[[1-[(4-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(=O)O)C=2C=CC(OCC=3N=C4N(CC=5C=CC(F)=CC=5)C=CC4=CC=3)=CC=2)C=CON=1 PUTWBHHBUCHPEM-DEOSSOPVSA-N 0.000 claims description 2
- KBUPIBBZXMJFRR-FQEVSTJZSA-N (3s)-3-[4-[[1-[(5-methylpyrazin-2-yl)methyl]indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C=NN2CC1=CN=C(C)C=N1 KBUPIBBZXMJFRR-FQEVSTJZSA-N 0.000 claims description 2
- NNIHXNCSPHTQBY-NRFANRHFSA-N (3s)-3-[4-[[1-[(5-methylpyrazin-2-yl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3N=CC(C)=NC=3)C2=C1 NNIHXNCSPHTQBY-NRFANRHFSA-N 0.000 claims description 2
- KBHYIFIERKHUGA-QHCPKHFHSA-N (3s)-3-[4-[[1-[(6-chloropyridin-3-yl)methyl]-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=NC(Cl)=CC=3)C2=C1C KBHYIFIERKHUGA-QHCPKHFHSA-N 0.000 claims description 2
- RJGYQYVWDSRQFI-QHCPKHFHSA-N (3s)-3-[4-[[1-[(6-methylpyridin-3-yl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3C=NC(C)=CC=3)C2=C1 RJGYQYVWDSRQFI-QHCPKHFHSA-N 0.000 claims description 2
- MWSVWSUEZNTBMJ-SANMLTNESA-N (3s)-3-[4-[[1-benzyl-2-(2-methoxyethyl)-7-methylindol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound CC1=C2N(CC=3C=CC=CC=3)C(CCOC)=CC2=CC=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 MWSVWSUEZNTBMJ-SANMLTNESA-N 0.000 claims description 2
- YFHGQEUWBSEKQP-FQEVSTJZSA-N (3s)-3-[4-[[1-methyl-3-(2-methylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(C)N=C2CC(C)C)C2=C1 YFHGQEUWBSEKQP-FQEVSTJZSA-N 0.000 claims description 2
- GWNAEFBEBCGDHL-IBGZPJMESA-N (3s)-3-[4-[[1-methyl-3-(2-methylpropyl)indazol-7-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1N(C)N=C2CC(C)C GWNAEFBEBCGDHL-IBGZPJMESA-N 0.000 claims description 2
- NKVVIPQBSWBOCW-QFIPXVFZSA-N (3s)-3-[4-[[1-propan-2-yl-3-(pyrazol-1-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2N=CC=C2)=NN2C(C)C)C2=C1 NKVVIPQBSWBOCW-QFIPXVFZSA-N 0.000 claims description 2
- NEVJZJORWUCNRJ-FQEVSTJZSA-N (3s)-3-[4-[[2-(2-ethoxyethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC2=NN(CCOCC)C=C2C=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 NEVJZJORWUCNRJ-FQEVSTJZSA-N 0.000 claims description 2
- DQNPJPSASYAFOM-NRFANRHFSA-N (3s)-3-[4-[[2-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC=2C=CC3=CN(N=C3C=2)CC(C)C)C=CON=1 DQNPJPSASYAFOM-NRFANRHFSA-N 0.000 claims description 2
- ODVZNPFGQMNQGQ-QWAKEFERSA-N (3s)-3-[4-[[2-(oxolan-3-ylmethyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=CN(CC3COCC3)N=C2C=C1 ODVZNPFGQMNQGQ-QWAKEFERSA-N 0.000 claims description 2
- CUJHWJBMDQNKDC-QFIPXVFZSA-N (3s)-3-[4-[[2-(pyridin-3-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=NN(CC=3C=NC=CC=3)C=C2C=C1 CUJHWJBMDQNKDC-QFIPXVFZSA-N 0.000 claims description 2
- XIGCFXDSYSADMI-NRFANRHFSA-N (3s)-3-[4-[[2-[(4-fluorophenyl)methyl]indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C1=C2)=CC=CC1=NN2CC1=CC=C(F)C=C1 XIGCFXDSYSADMI-NRFANRHFSA-N 0.000 claims description 2
- BZDFLVFSPSUBKP-QFIPXVFZSA-N (3s)-3-[4-[[2-[(4-fluorophenyl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=NN(CC=3C=CC(F)=CC=3)C=C2C=C1 BZDFLVFSPSUBKP-QFIPXVFZSA-N 0.000 claims description 2
- ISUJDGGOBLYUNJ-FQEVSTJZSA-N (3s)-3-[4-[[2-[(5-methylpyrazin-2-yl)methyl]indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C1=C2)=CC=CC1=NN2CC1=CN=C(C)C=N1 ISUJDGGOBLYUNJ-FQEVSTJZSA-N 0.000 claims description 2
- KIYMHNQULCIBKP-NRFANRHFSA-N (3s)-3-[4-[[2-[(5-methylpyrazin-2-yl)methyl]indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=NN(CC=3N=CC(C)=NC=3)C=C2C=C1 KIYMHNQULCIBKP-NRFANRHFSA-N 0.000 claims description 2
- CFWHTQUSFJXVMR-NRFANRHFSA-N (3s)-3-[4-[[3,7-dimethyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(C)=NN2CC(C)C)C2=C1C CFWHTQUSFJXVMR-NRFANRHFSA-N 0.000 claims description 2
- TXQPVUCDCVOCPC-IBGZPJMESA-N (3s)-3-[4-[[3-(2-methylpropyl)-1,2-benzoxazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(ON=C2CC(C)C)C2=C1 TXQPVUCDCVOCPC-IBGZPJMESA-N 0.000 claims description 2
- POEFHZMMIBKWEJ-IBGZPJMESA-N (3s)-3-[4-[[3-(2-methylpropyl)benzotriazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N=NN2CC(C)C)C2=C1 POEFHZMMIBKWEJ-IBGZPJMESA-N 0.000 claims description 2
- QLBWNYGUOOEXEN-QFIPXVFZSA-N (3s)-3-[4-[[3-(ethoxymethyl)-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C=1C=C2C(COCC)=NN(CC(C)C)C2=CC=1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 QLBWNYGUOOEXEN-QFIPXVFZSA-N 0.000 claims description 2
- KQHOOMVSQAYQLN-FQEVSTJZSA-N (3s)-3-[4-[[3-(fluoromethyl)-7-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CF)=NN2CC(C)C)C2=C1C KQHOOMVSQAYQLN-FQEVSTJZSA-N 0.000 claims description 2
- GHHZSFMNTRLHMG-NRFANRHFSA-N (3s)-3-[4-[[3-(methoxymethyl)-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C=1C=C2C(COC)=NN(CC(C)C)C2=CC=1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 GHHZSFMNTRLHMG-NRFANRHFSA-N 0.000 claims description 2
- GAQFSRYZTXKTTH-NRFANRHFSA-N (3s)-3-[4-[[3-(methoxymethyl)-7-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C=1C=C2C(COC)=NN(CC(C)C)C2=C(C)C=1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 GAQFSRYZTXKTTH-NRFANRHFSA-N 0.000 claims description 2
- WNOMIYLSOFOGOR-QHCPKHFHSA-N (3s)-3-[4-[[3-[(3,3-difluoropiperidin-1-yl)methyl]-1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CC(F)(F)CCC2)=CN2CC(C)C)C2=N1 WNOMIYLSOFOGOR-QHCPKHFHSA-N 0.000 claims description 2
- AXEMLRHOOCTJJK-DEOSSOPVSA-N (3s)-3-[4-[[3-[(3,3-difluoropiperidin-1-yl)methyl]-7-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CC(F)(F)CCC2)=NN2CC(C)C)C2=C1C AXEMLRHOOCTJJK-DEOSSOPVSA-N 0.000 claims description 2
- JDFBHMRRHNWTRB-QFIPXVFZSA-N (3s)-3-[4-[[3-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CC(F)(F)CC2)=CN2CC(C)C)C2=N1 JDFBHMRRHNWTRB-QFIPXVFZSA-N 0.000 claims description 2
- HRWYOCQFSYKKBE-QHCPKHFHSA-N (3s)-3-[4-[[3-[(3,3-difluoropyrrolidin-1-yl)methyl]-7-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CC(F)(F)CC2)=NN2CC(C)C)C2=C1C HRWYOCQFSYKKBE-QHCPKHFHSA-N 0.000 claims description 2
- DIELSMGYCQEJPX-ZCYQVOJMSA-N (3s)-3-[4-[[3-[[(3s)-3-fluoropyrrolidin-1-yl]methyl]-7-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2C[C@@H](F)CC2)=NN2CC(C)C)C2=C1C DIELSMGYCQEJPX-ZCYQVOJMSA-N 0.000 claims description 2
- KPTOKVNAFIXLJY-SFHVURJKSA-N (3s)-3-[4-[[3-chloro-1-(2-methylpropyl)indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C(Cl)=NN2CC(C)C KPTOKVNAFIXLJY-SFHVURJKSA-N 0.000 claims description 2
- ATPAHAPYMIKAHA-SFHVURJKSA-N (3s)-3-[4-[[3-fluoro-1-(2-methylpropyl)indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=CC2=C1C(F)=NN2CC(C)C ATPAHAPYMIKAHA-SFHVURJKSA-N 0.000 claims description 2
- XERASIVDBYNWNA-SFHVURJKSA-N (3s)-3-[4-[[3-fluoro-1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=NC2=C1C(F)=CN2CC(C)C XERASIVDBYNWNA-SFHVURJKSA-N 0.000 claims description 2
- DBSAYAAZBLSIIA-IBGZPJMESA-N (3s)-3-[4-[[3-fluoro-7-methyl-1-(2-methylpropyl)indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C)C2=C1C(F)=NN2CC(C)C DBSAYAAZBLSIIA-IBGZPJMESA-N 0.000 claims description 2
- IVAIWPONCCLIRZ-NRFANRHFSA-N (3s)-3-[4-[[3-methyl-1-(2-methylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(N(CC(C)C)N=C2C)C2=C1 IVAIWPONCCLIRZ-NRFANRHFSA-N 0.000 claims description 2
- QNJUOBSOUXJXFR-NRFANRHFSA-N (3s)-3-[4-[[3-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(C)=NN2CC(C)C)C2=C1 QNJUOBSOUXJXFR-NRFANRHFSA-N 0.000 claims description 2
- LNRYWFLBEAQBTQ-NRFANRHFSA-N (3s)-3-[4-[[3-methyl-2-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=NN(CC(C)C)C(C)=C2C=C1 LNRYWFLBEAQBTQ-NRFANRHFSA-N 0.000 claims description 2
- BCYQLWCQRCHKHW-SFHVURJKSA-N (3s)-3-[4-[[5-fluoro-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C(=C1)F)=CC2=C1C=NN2CC(C)C BCYQLWCQRCHKHW-SFHVURJKSA-N 0.000 claims description 2
- CVWDUKUGOKKIFD-FQEVSTJZSA-N (3s)-3-[4-[[6-methyl-1-(2-methylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC(C(=C1)C)=CC2=C1N(CC(C)C)N=C2 CVWDUKUGOKKIFD-FQEVSTJZSA-N 0.000 claims description 2
- HNZIUMLHECZMSF-QFIPXVFZSA-N (3s)-3-[4-[[7-chloro-1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CCOCC2)=NN2CC(C)C)C2=C1Cl HNZIUMLHECZMSF-QFIPXVFZSA-N 0.000 claims description 2
- SEZGUYLDZDAIHY-DEOSSOPVSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CCOCC2)=NN2CC(C)C)C2=C1C SEZGUYLDZDAIHY-DEOSSOPVSA-N 0.000 claims description 2
- SSCCOKLVSCZEAW-VWLOTQADSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)-3-(piperidin-1-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CCCCC2)=NN2CC(C)C)C2=C1C SSCCOKLVSCZEAW-VWLOTQADSA-N 0.000 claims description 2
- UAAFRDTTZKBSRO-QHCPKHFHSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)-3-(pyrazol-1-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2N=CC=C2)=NN2CC(C)C)C2=C1C UAAFRDTTZKBSRO-QHCPKHFHSA-N 0.000 claims description 2
- QZPWRGFIBMDMOD-DEOSSOPVSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)-3-(pyrrolidin-1-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C(CN2CCCC2)=NN2CC(C)C)C2=C1C QZPWRGFIBMDMOD-DEOSSOPVSA-N 0.000 claims description 2
- DCAMUPBDBBLTHU-FQEVSTJZSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)indazol-4-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C)C2=C1C=NN2CC(C)C DCAMUPBDBBLTHU-FQEVSTJZSA-N 0.000 claims description 2
- FMMWFIDYMSAKQV-FQEVSTJZSA-N (3s)-3-[4-[[7-methyl-1-(2-methylpropyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC(C)C)C2=C1C FMMWFIDYMSAKQV-FQEVSTJZSA-N 0.000 claims description 2
- ARKXYSCTDXBWOQ-DEOSSOPVSA-N (3s)-3-[4-[[7-methyl-1-(pyrazin-2-ylmethyl)indol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C=1([C@@H](CC(O)=O)C2=CC=C(C=C2)OCC2=C(C=3N(CC=4N=CC=NC=4)C=CC=3C=C2)C)C=CON=1 ARKXYSCTDXBWOQ-DEOSSOPVSA-N 0.000 claims description 2
- SIZPXYGHYJBCRD-QFIPXVFZSA-N (3s)-3-[4-[[7-methyl-1-(pyrazin-2-ylmethyl)indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3N=CC=NC=3)C2=C1C SIZPXYGHYJBCRD-QFIPXVFZSA-N 0.000 claims description 2
- GOEUVRKEJCLGIR-QFIPXVFZSA-N (3s)-3-[4-[[7-methyl-1-(pyridin-3-ylmethyl)indazol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=NN2CC=3C=NC=CC=3)C2=C1C GOEUVRKEJCLGIR-QFIPXVFZSA-N 0.000 claims description 2
- OWVRXTUKBJVYED-QFIPXVFZSA-N (3s)-3-[4-[[7-methyl-1-(pyrimidin-2-ylmethyl)indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3N=CC=CN=3)C2=C1C OWVRXTUKBJVYED-QFIPXVFZSA-N 0.000 claims description 2
- FZMKVSNHMTWKFZ-QFIPXVFZSA-N (3s)-3-[4-[[7-methyl-1-(pyrimidin-4-ylmethyl)indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3N=CN=CC=3)C2=C1C FZMKVSNHMTWKFZ-QFIPXVFZSA-N 0.000 claims description 2
- ZXMKYYZZLVSHQV-QFIPXVFZSA-N (3s)-3-[4-[[7-methyl-1-[(2-methyl-1,3-thiazol-4-yl)methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3N=C(C)SC=3)C2=C1C ZXMKYYZZLVSHQV-QFIPXVFZSA-N 0.000 claims description 2
- RITHBZGWDGBZSJ-VWLOTQADSA-N (3s)-3-[4-[[7-methyl-1-[(5-methylpyrazin-2-yl)methyl]indol-6-yl]methoxy]phenyl]-3-(1,2-oxazol-3-yl)propanoic acid Chemical compound C1=NC(C)=CN=C1CN1C2=C(C)C(COC=3C=CC(=CC=3)[C@H](CC(O)=O)C3=NOC=C3)=CC=C2C=C1 RITHBZGWDGBZSJ-VWLOTQADSA-N 0.000 claims description 2
- RDAIIGZKUFJNLJ-QHCPKHFHSA-N (3s)-3-[4-[[7-methyl-1-[(5-methylpyrazin-2-yl)methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3N=CC(C)=NC=3)C2=C1C RDAIIGZKUFJNLJ-QHCPKHFHSA-N 0.000 claims description 2
- ZWTSLOXFSFGMEU-VWLOTQADSA-N (3s)-3-[4-[[7-methyl-1-[(6-methylpyridin-3-yl)methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=NC(C)=CC=3)C2=C1C ZWTSLOXFSFGMEU-VWLOTQADSA-N 0.000 claims description 2
- ACKQCMPUIXHDRH-DEOSSOPVSA-N (3s)-3-[4-[[7-methyl-1-[[3-(trifluoromethyl)phenyl]methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=C(C=CC=3)C(F)(F)F)C2=C1C ACKQCMPUIXHDRH-DEOSSOPVSA-N 0.000 claims description 2
- QWRKNSHXVZYQDY-MHZLTWQESA-N (3s)-3-[4-[[7-methyl-1-[[4-(methylsulfonylmethyl)phenyl]methyl]indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC=C(C=CN2CC=3C=CC(CS(C)(=O)=O)=CC=3)C2=C1C QWRKNSHXVZYQDY-MHZLTWQESA-N 0.000 claims description 2
- KRGNUQZXPGOBEP-NRFANRHFSA-N (3s)-3-[4-[[7-methyl-2-(2-methylpropyl)indazol-5-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=CC([C@H](CC(O)=O)C#CC)=CC=C1OCC1=CC2=CN(CC(C)C)N=C2C(C)=C1 KRGNUQZXPGOBEP-NRFANRHFSA-N 0.000 claims description 2
- UOTSWJMNDHXVSR-UHFFFAOYSA-N 2-[4-[(1-benzylindazol-6-yl)methoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C(C=C1)=CC=C1OCC1=CC=C(C=NN2CC=3C=CC=CC=3)C2=C1 UOTSWJMNDHXVSR-UHFFFAOYSA-N 0.000 claims description 2
- SGHCDEJCMHCDEW-UHFFFAOYSA-N 2-[5-[(1-benzylindazol-5-yl)methoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCC2=CC=1OCC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 SGHCDEJCMHCDEW-UHFFFAOYSA-N 0.000 claims description 2
- WDYFCZBKEUBQPG-UHFFFAOYSA-N 2-[5-[(1-benzylindazol-6-yl)methoxy]-2,3-dihydro-1h-inden-1-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCC2=CC=1OCC(C=C12)=CC=C1C=NN2CC1=CC=CC=C1 WDYFCZBKEUBQPG-UHFFFAOYSA-N 0.000 claims description 2
- NKHLKPRSYVWZDO-UHFFFAOYSA-N 2-[6-[(1-benzyl-7-methylindazol-5-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=2C(C)=CC(COC=3C=C4OCC(CC(O)=O)C4=CC=3)=CC=2C=NN1CC1=CC=CC=C1 NKHLKPRSYVWZDO-UHFFFAOYSA-N 0.000 claims description 2
- XXAKFZHNDYHXGF-UHFFFAOYSA-N 2-[6-[(1-benzyl-7-methylindazol-5-yl)methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound C1=2C(C)=CC(COC=3C=C4C(CC(O)=O)CCOC4=CC=3)=CC=2C=NN1CC1=CC=CC=C1 XXAKFZHNDYHXGF-UHFFFAOYSA-N 0.000 claims description 2
- CRECIEVEHLEGIM-UHFFFAOYSA-N 2-[6-[(1-benzylindazol-5-yl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCCC2=CC=1OCC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 CRECIEVEHLEGIM-UHFFFAOYSA-N 0.000 claims description 2
- CBAOVGIBXKMQJH-UHFFFAOYSA-N 2-[6-[(1-benzylindazol-6-yl)methoxy]-1,2,3,4-tetrahydronaphthalen-1-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCCC2=CC=1OCC(C=C12)=CC=C1C=NN2CC1=CC=CC=C1 CBAOVGIBXKMQJH-UHFFFAOYSA-N 0.000 claims description 2
- LLFUARFEHSFSCE-UHFFFAOYSA-N 2-[6-[(1-benzylindazol-6-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)COC2=CC=1OCC(C=C12)=CC=C1C=NN2CC1=CC=CC=C1 LLFUARFEHSFSCE-UHFFFAOYSA-N 0.000 claims description 2
- XKAURGHKIHRYGF-UHFFFAOYSA-N 2-[6-[(1-benzylpyrrolo[2,3-b]pyridin-6-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)COC2=CC=1OCC(N=C12)=CC=C1C=CN2CC1=CC=CC=C1 XKAURGHKIHRYGF-UHFFFAOYSA-N 0.000 claims description 2
- CDWOLBZQHNDAFX-UHFFFAOYSA-N 2-[6-[(1-propan-2-ylindazol-6-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C1=C2C(CC(O)=O)COC2=CC(OCC2=CC=C3C=NN(C3=C2)C(C)C)=C1 CDWOLBZQHNDAFX-UHFFFAOYSA-N 0.000 claims description 2
- MEMXWKQEGFFLHE-UHFFFAOYSA-N 2-[6-[(2-benzylindazol-6-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)COC2=CC=1OCC(=CC1=N2)C=CC1=CN2CC1=CC=CC=C1 MEMXWKQEGFFLHE-UHFFFAOYSA-N 0.000 claims description 2
- LSPACLPCRSXDGC-UHFFFAOYSA-N 2-[6-[[1-(cyclopentylmethyl)indazol-6-yl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)COC2=CC=1OCC(C=C12)=CC=C1C=NN2CC1CCCC1 LSPACLPCRSXDGC-UHFFFAOYSA-N 0.000 claims description 2
- KJDROWINPFNDKJ-UHFFFAOYSA-N 2-[7-[(1-benzyl-7-methylindol-6-yl)methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound C1=2C(C)=C(COC=3C=C4OCCC(CC(O)=O)C4=CC=3)C=CC=2C=CN1CC1=CC=CC=C1 KJDROWINPFNDKJ-UHFFFAOYSA-N 0.000 claims description 2
- QUIQULHPBSNNIA-UHFFFAOYSA-N 2-[7-[(1-benzylindazol-5-yl)methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCOC2=CC=1OCC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 QUIQULHPBSNNIA-UHFFFAOYSA-N 0.000 claims description 2
- KDTVWMRDLOHUAS-UHFFFAOYSA-N 2-[7-[(2-benzyl-7-methylindazol-5-yl)methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound N1=C2C(C)=CC(COC=3C=C4OCCC(CC(O)=O)C4=CC=3)=CC2=CN1CC1=CC=CC=C1 KDTVWMRDLOHUAS-UHFFFAOYSA-N 0.000 claims description 2
- DCAREJQEDKPXLR-UHFFFAOYSA-N 2-[7-[1-(1H-indazol-5-yl)-2-phenylpropoxy]-3,4-dihydro-2H-chromen-4-yl]acetic acid Chemical compound C1(=CC=CC=C1)C(C)C(OC1=CC=C2C(CCOC2=C1)CC(=O)O)C=1C=C2C=NNC2=CC1 DCAREJQEDKPXLR-UHFFFAOYSA-N 0.000 claims description 2
- OLHSBUZTPKYLFC-UHFFFAOYSA-N 2-[7-[[1-(2-methylpropyl)indazol-5-yl]methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound OC(=O)CC1CCOC2=CC(OCC=3C=C4C=NN(C4=CC=3)CC(C)C)=CC=C21 OLHSBUZTPKYLFC-UHFFFAOYSA-N 0.000 claims description 2
- ZCUMCTYGPIOHIY-UHFFFAOYSA-N 2-[7-[[1-(cyclohexylmethyl)indazol-5-yl]methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCOC2=CC=1OCC(C=C1C=N2)=CC=C1N2CC1CCCCC1 ZCUMCTYGPIOHIY-UHFFFAOYSA-N 0.000 claims description 2
- CRYDRFDOBAPBOX-UHFFFAOYSA-N 2-[7-[[1-(pyridin-2-ylmethyl)indazol-5-yl]methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCOC2=CC=1OCC(C=C1C=N2)=CC=C1N2CC1=CC=CC=N1 CRYDRFDOBAPBOX-UHFFFAOYSA-N 0.000 claims description 2
- QBQFHSBBQDKBMH-UHFFFAOYSA-N 2-[7-[[1-(pyridin-3-ylmethyl)indazol-5-yl]methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound C=1C=C2C(CC(=O)O)CCOC2=CC=1OCC(C=C1C=N2)=CC=C1N2CC1=CC=CN=C1 QBQFHSBBQDKBMH-UHFFFAOYSA-N 0.000 claims description 2
- CPSSNXYLKHJNPQ-UHFFFAOYSA-N 2-[7-[[7-methyl-1-(2-methylpropyl)indazol-5-yl]methoxy]-3,4-dihydro-2h-chromen-4-yl]acetic acid Chemical compound OC(=O)CC1CCOC2=CC(OCC=3C=C4C=NN(C4=C(C)C=3)CC(C)C)=CC=C21 CPSSNXYLKHJNPQ-UHFFFAOYSA-N 0.000 claims description 2
- ZMJBDVSYSGYLAZ-UHFFFAOYSA-N 3-[4-[(1-benzyl-7-methylindol-6-yl)methoxy]-2-fluorophenyl]propanoic acid Chemical compound C1=CC=2C=CN(CC=3C=CC=CC=3)C=2C(C)=C1COC1=CC=C(CCC(O)=O)C(F)=C1 ZMJBDVSYSGYLAZ-UHFFFAOYSA-N 0.000 claims description 2
- KXIKEXLEALFLKJ-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-5-yl)methoxy]phenyl]-3-cyanopropanoic acid Chemical compound C1=CC(C(C#N)CC(=O)O)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 KXIKEXLEALFLKJ-UHFFFAOYSA-N 0.000 claims description 2
- YNNSRKZULHHBRZ-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-5-yl)methoxy]phenyl]-3-methoxypropanoic acid Chemical compound C1=CC(C(CC(O)=O)OC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 YNNSRKZULHHBRZ-UHFFFAOYSA-N 0.000 claims description 2
- UHCNWMLCPBPDQF-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-5-yl)methoxy]phenyl]butanoic acid Chemical compound C1=CC(C(CC(O)=O)C)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 UHCNWMLCPBPDQF-UHFFFAOYSA-N 0.000 claims description 2
- SNXRIOFULSNAHW-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-5-yl)methoxy]phenyl]pentanoic acid Chemical compound C1=CC(C(CC(O)=O)CC)=CC=C1OCC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 SNXRIOFULSNAHW-UHFFFAOYSA-N 0.000 claims description 2
- XJXFXMIQKHJQKK-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-6-yl)methoxy]-2-fluorophenyl]propanoic acid Chemical compound C1=C(F)C(CCC(=O)O)=CC=C1OCC1=CC=C(C=NN2CC=3C=CC=CC=3)C2=C1 XJXFXMIQKHJQKK-UHFFFAOYSA-N 0.000 claims description 2
- KDAFGDGQMOLVJL-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-6-yl)methoxy]phenyl]-3-(4,5-dihydro-1,2-oxazol-3-yl)propanoic acid Chemical compound C=1C=C(OCC=2C=C3N(CC=4C=CC=CC=4)N=CC3=CC=2)C=CC=1C(CC(=O)O)C1=NOCC1 KDAFGDGQMOLVJL-UHFFFAOYSA-N 0.000 claims description 2
- OESMKCYJMIQJBN-UHFFFAOYSA-N 3-[4-[(1-benzylindazol-6-yl)methoxy]phenyl]butanoic acid Chemical compound C1=CC(C(CC(O)=O)C)=CC=C1OCC1=CC=C(C=NN2CC=3C=CC=CC=3)C2=C1 OESMKCYJMIQJBN-UHFFFAOYSA-N 0.000 claims description 2
- HHXNSRLEQVIOPS-UHFFFAOYSA-N 3-[4-[(1-benzylindol-4-yl)methoxy]-2-fluorophenyl]propanoic acid Chemical compound C1=C(F)C(CCC(=O)O)=CC=C1OCC1=CC=CC2=C1C=CN2CC1=CC=CC=C1 HHXNSRLEQVIOPS-UHFFFAOYSA-N 0.000 claims description 2
- UFTRJOIXGYQMBC-UHFFFAOYSA-N 3-[4-[[1-(cyclopentylmethyl)indazol-6-yl]methoxy]-2-fluorophenyl]propanoic acid Chemical compound C1=C(F)C(CCC(=O)O)=CC=C1OCC1=CC=C(C=NN2CC3CCCC3)C2=C1 UFTRJOIXGYQMBC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 921
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003914 insulin secretion Effects 0.000 abstract description 8
- 238000011068 loading method Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 662
- 230000015572 biosynthetic process Effects 0.000 description 414
- 238000003786 synthesis reaction Methods 0.000 description 414
- 238000005481 NMR spectroscopy Methods 0.000 description 345
- 238000005160 1H NMR spectroscopy Methods 0.000 description 339
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 258
- 239000000203 mixture Substances 0.000 description 217
- 239000000243 solution Substances 0.000 description 136
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 133
- 230000002829 reductive effect Effects 0.000 description 124
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 118
- 239000000706 filtrate Substances 0.000 description 92
- 238000004440 column chromatography Methods 0.000 description 86
- 229940093499 ethyl acetate Drugs 0.000 description 86
- 235000019439 ethyl acetate Nutrition 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 84
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 80
- 229920006395 saturated elastomer Polymers 0.000 description 73
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 239000011780 sodium chloride Substances 0.000 description 67
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 64
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 62
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 60
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical group ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 28
- 239000007864 aqueous solution Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 23
- 229910052763 palladium Inorganic materials 0.000 description 21
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 19
- LPLOEZPPYOSNEW-UHFFFAOYSA-N methyl 1h-indazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NN=CC2=C1 LPLOEZPPYOSNEW-UHFFFAOYSA-N 0.000 description 19
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 17
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 16
- 239000012312 sodium hydride Substances 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 12
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 12
- 239000012279 sodium borohydride Substances 0.000 description 12
- 229910000033 sodium borohydride Inorganic materials 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 12
- WXOHKMNWMKZMND-UHFFFAOYSA-N 4-aminohydrocinnamic acid Chemical compound NC1=CC=C(CCC(O)=O)C=C1 WXOHKMNWMKZMND-UHFFFAOYSA-N 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 239000012280 lithium aluminium hydride Substances 0.000 description 11
- MEXWKIOTIDFYPN-UHFFFAOYSA-N methyl 1h-indazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C=NN2 MEXWKIOTIDFYPN-UHFFFAOYSA-N 0.000 description 11
- XRAMJHXWXCMGJM-UHFFFAOYSA-N methyl 3-(4-hydroxyphenyl)propionate Chemical compound COC(=O)CCC1=CC=C(O)C=C1 XRAMJHXWXCMGJM-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 239000012448 Lithium borohydride Substances 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 229960004132 diethyl ether Drugs 0.000 description 10
- QTBFPMKWQKYFLR-UHFFFAOYSA-N isobutyl chloride Chemical compound CC(C)CCl QTBFPMKWQKYFLR-UHFFFAOYSA-N 0.000 description 10
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- 239000003638 chemical reducing agent Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- XECTWNKIPYGAEE-UHFFFAOYSA-N methyl 7-methyl-1h-indazole-5-carboxylate Chemical compound COC(=O)C1=CC(C)=C2NN=CC2=C1 XECTWNKIPYGAEE-UHFFFAOYSA-N 0.000 description 9
- MTGUQGHBLCZRAM-UHFFFAOYSA-N methyl 7-methyl-1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1C MTGUQGHBLCZRAM-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 8
- 235000011054 acetic acid Nutrition 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 7
- AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical group CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 6
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 6
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 5
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 5
- 239000003377 acid catalyst Substances 0.000 description 5
- 238000006254 arylation reaction Methods 0.000 description 5
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- TUSICEWIXLMXEY-UHFFFAOYSA-N methyl 1h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NNC2=C1 TUSICEWIXLMXEY-UHFFFAOYSA-N 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- 235000019798 tripotassium phosphate Nutrition 0.000 description 5
- STUWDTUMYMCRTC-UHFFFAOYSA-N (5-methylpyrazin-2-yl)methyl methanesulfonate Chemical compound CC1=CN=C(COS(C)(=O)=O)C=N1 STUWDTUMYMCRTC-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- GAFBPZMOMITHLG-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-6-carbonitrile Chemical compound N#CC1=CC=C2C=CNC2=N1 GAFBPZMOMITHLG-UHFFFAOYSA-N 0.000 description 4
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 4
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 4
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 4
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- GEWJEKADAXWFPY-UHFFFAOYSA-N methyl 1h-indazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1NN=C2 GEWJEKADAXWFPY-UHFFFAOYSA-N 0.000 description 4
- ZQBUSCBNCSXBAK-UHFFFAOYSA-N methyl 7-chloro-1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1Cl ZQBUSCBNCSXBAK-UHFFFAOYSA-N 0.000 description 4
- QSXHEMPBSIDGIW-UHFFFAOYSA-N methyl 7-methyl-1h-indazole-4-carboxylate Chemical compound COC(=O)C1=CC=C(C)C2=C1C=NN2 QSXHEMPBSIDGIW-UHFFFAOYSA-N 0.000 description 4
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 239000012363 selectfluor Substances 0.000 description 4
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 3
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 3
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 3
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 3
- FMQRCVLVVDIQNF-UHFFFAOYSA-N 1-benzyl-3-chloroindole-6-carbaldehyde Chemical compound C12=CC(C=O)=CC=C2C(Cl)=CN1CC1=CC=CC=C1 FMQRCVLVVDIQNF-UHFFFAOYSA-N 0.000 description 3
- VSPBWOAEHQDXRD-UHFFFAOYSA-N 1h-indole-6-carbaldehyde Chemical compound O=CC1=CC=C2C=CNC2=C1 VSPBWOAEHQDXRD-UHFFFAOYSA-N 0.000 description 3
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 3
- KHCXGFNZZRXOND-UHFFFAOYSA-N 3-(bromomethyl)pyridine Chemical compound BrCC1=CC=CN=C1 KHCXGFNZZRXOND-UHFFFAOYSA-N 0.000 description 3
- DHXISZKSSIWRLH-UHFFFAOYSA-N 4,6-dichloro-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=CC2=C1Cl DHXISZKSSIWRLH-UHFFFAOYSA-N 0.000 description 3
- AJRYXJZEWFALFL-UHFFFAOYSA-N 5-bromo-3-methyl-1-(2-methylpropyl)indazole Chemical compound BrC1=CC=C2N(CC(C)C)N=C(C)C2=C1 AJRYXJZEWFALFL-UHFFFAOYSA-N 0.000 description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 3
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- OEGZIORVWKCECP-UHFFFAOYSA-N methyl 1-(pyrimidin-2-ylmethyl)indazole-3-carboxylate Chemical compound C12=CC=CC=C2C(C(=O)OC)=NN1CC1=NC=CC=N1 OEGZIORVWKCECP-UHFFFAOYSA-N 0.000 description 3
- HKTNSOWASJOYFI-UHFFFAOYSA-N methyl 1-benzylindazole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C=NN1CC1=CC=CC=C1 HKTNSOWASJOYFI-UHFFFAOYSA-N 0.000 description 3
- WEAXQUBYRSEBJD-UHFFFAOYSA-N methyl 1h-indole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C=CN2 WEAXQUBYRSEBJD-UHFFFAOYSA-N 0.000 description 3
- YHQDTMPWDNGPMD-UHFFFAOYSA-N methyl 2-(pyrimidin-2-ylmethyl)-1,3-dihydroindazole-3-carboxylate Chemical compound N1C2=CC=CC=C2C(C(=O)OC)N1CC1=NC=CC=N1 YHQDTMPWDNGPMD-UHFFFAOYSA-N 0.000 description 3
- RRAFRYWZPDNGAH-UHFFFAOYSA-N methyl 2-benzyl-1,3-dihydroindazole-6-carboxylate Chemical compound N1C2=CC(C(=O)OC)=CC=C2CN1CC1=CC=CC=C1 RRAFRYWZPDNGAH-UHFFFAOYSA-N 0.000 description 3
- CKPSQUXIPHAGLQ-UHFFFAOYSA-N methyl 3-methyl-2h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C)=NNC2=C1 CKPSQUXIPHAGLQ-UHFFFAOYSA-N 0.000 description 3
- QAFIXGZMWZPBNX-UHFFFAOYSA-N methyl 7-methyl-1h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NNC2=C1C QAFIXGZMWZPBNX-UHFFFAOYSA-N 0.000 description 3
- 229940073584 methylene chloride Drugs 0.000 description 3
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical group ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- SNAPCOCREXLOPZ-UHFFFAOYSA-N (1-benzyl-3-chloroindol-6-yl)methanol Chemical compound C12=CC(CO)=CC=C2C(Cl)=CN1CC1=CC=CC=C1 SNAPCOCREXLOPZ-UHFFFAOYSA-N 0.000 description 2
- QESWFHYHSDHISR-UHFFFAOYSA-N (1-benzyl-7-chloroindol-6-yl)methanol Chemical compound C12=C(Cl)C(CO)=CC=C2C=CN1CC1=CC=CC=C1 QESWFHYHSDHISR-UHFFFAOYSA-N 0.000 description 2
- JIGLRIFCEAXBGA-UHFFFAOYSA-N (6-methylpyridin-3-yl)methyl methanesulfonate Chemical compound CC1=CC=C(COS(C)(=O)=O)C=N1 JIGLRIFCEAXBGA-UHFFFAOYSA-N 0.000 description 2
- VIOTTYJPMGIXDM-UHFFFAOYSA-N (7-methyl-1-propan-2-ylindazol-5-yl)methanol Chemical compound OCC1=CC(C)=C2N(C(C)C)N=CC2=C1 VIOTTYJPMGIXDM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BNUVGGFDUDFBKA-UHFFFAOYSA-N 1-benzylindole-6-carbaldehyde Chemical compound C12=CC(C=O)=CC=C2C=CN1CC1=CC=CC=C1 BNUVGGFDUDFBKA-UHFFFAOYSA-N 0.000 description 2
- YBQMZYFEORLDLD-UHFFFAOYSA-N 1-benzylpyrrolo[2,3-b]pyridine-6-carboxylic acid Chemical compound C12=NC(C(=O)O)=CC=C2C=CN1CC1=CC=CC=C1 YBQMZYFEORLDLD-UHFFFAOYSA-N 0.000 description 2
- GPTVQTPMFOLLOA-UHFFFAOYSA-N 1-chloro-2-ethoxyethane Chemical compound CCOCCCl GPTVQTPMFOLLOA-UHFFFAOYSA-N 0.000 description 2
- JMEOVHKKRMLNBM-UHFFFAOYSA-N 1-fluoro-2,4,6-trimethylpyridin-1-ium Chemical compound CC1=CC(C)=[N+](F)C(C)=C1 JMEOVHKKRMLNBM-UHFFFAOYSA-N 0.000 description 2
- IWPZWGBTRCEVGT-UHFFFAOYSA-N 1-propan-2-ylindole-6-carbaldehyde Chemical compound C1=C(C=O)C=C2N(C(C)C)C=CC2=C1 IWPZWGBTRCEVGT-UHFFFAOYSA-N 0.000 description 2
- YJKMYHNMBGQQQZ-UHFFFAOYSA-N 1h-indazole-5-carbaldehyde Chemical compound O=CC1=CC=C2NN=CC2=C1 YJKMYHNMBGQQQZ-UHFFFAOYSA-N 0.000 description 2
- HAROKQXDLYCEQV-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC2=C1C=CN2 HAROKQXDLYCEQV-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- VNMORBLLLTZLLT-UHFFFAOYSA-N 2-(bromomethyl)pyrazine Chemical compound BrCC1=CN=CC=N1 VNMORBLLLTZLLT-UHFFFAOYSA-N 0.000 description 2
- GEYSGGMNQZJFIL-UHFFFAOYSA-N 2-(bromomethyl)pyrimidine Chemical compound BrCC1=NC=CC=N1 GEYSGGMNQZJFIL-UHFFFAOYSA-N 0.000 description 2
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 2
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 2
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 2
- HRRMPGSFIAVSNM-UHFFFAOYSA-N 3-bromo-2,6-dimethylaniline Chemical compound CC1=CC=C(Br)C(C)=C1N HRRMPGSFIAVSNM-UHFFFAOYSA-N 0.000 description 2
- XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 2
- OLJHLRVZAUUJST-UHFFFAOYSA-N 3-methyl-1-(2-methylpropyl)indazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(CC(C)C)N=C(C)C2=C1 OLJHLRVZAUUJST-UHFFFAOYSA-N 0.000 description 2
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 2
- JRQDVRIQJJPHEQ-UHFFFAOYSA-N 3970-35-2 Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1Cl JRQDVRIQJJPHEQ-UHFFFAOYSA-N 0.000 description 2
- AROGQTWAAJTEFR-UHFFFAOYSA-N 4-(chloromethyl)pyrimidine Chemical compound ClCC1=CC=NC=N1 AROGQTWAAJTEFR-UHFFFAOYSA-N 0.000 description 2
- JTFKASPFJNQUBL-UHFFFAOYSA-N 4-bromo-7-methyl-1h-indazole Chemical compound CC1=CC=C(Br)C2=C1NN=C2 JTFKASPFJNQUBL-UHFFFAOYSA-N 0.000 description 2
- QVBHRCAJZGMNFX-UHFFFAOYSA-N 4-fluoro-3-formylbenzonitrile Chemical compound FC1=CC=C(C#N)C=C1C=O QVBHRCAJZGMNFX-UHFFFAOYSA-N 0.000 description 2
- BOJWTAQWPVBIPG-UHFFFAOYSA-N 4-fluoro-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 BOJWTAQWPVBIPG-UHFFFAOYSA-N 0.000 description 2
- MMFGGDVQLQQQRX-UHFFFAOYSA-N 5-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC=C(Br)C=C1C=O MMFGGDVQLQQQRX-UHFFFAOYSA-N 0.000 description 2
- MUYVOGAJRCBWCY-UHFFFAOYSA-N 5-bromo-2-fluoropyridine-3-carbaldehyde Chemical compound FC1=NC=C(Br)C=C1C=O MUYVOGAJRCBWCY-UHFFFAOYSA-N 0.000 description 2
- JOTNMBLTBCGWGR-UHFFFAOYSA-N 5-bromo-3-(2-methylpropyl)-1,2-benzoxazole Chemical compound C1=C(Br)C=C2C(CC(C)C)=NOC2=C1 JOTNMBLTBCGWGR-UHFFFAOYSA-N 0.000 description 2
- UBTMYISTJIMZLU-UHFFFAOYSA-N 5-bromo-3-methyl-2-(2-methylpropyl)indazole Chemical compound C1=CC(Br)=CC2=C(C)N(CC(C)C)N=C21 UBTMYISTJIMZLU-UHFFFAOYSA-N 0.000 description 2
- KOMFMFCJWBORHL-UHFFFAOYSA-N 6-bromo-7-methyl-1h-indazole Chemical compound CC1=C(Br)C=CC2=C1NN=C2 KOMFMFCJWBORHL-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- QVKVNHNEEPQMOU-UHFFFAOYSA-N benzyl 2-(4-phenylmethoxyphenyl)cyclopropane-1-carboxylate Chemical compound C1C(C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1C(=O)OCC1=CC=CC=C1 QVKVNHNEEPQMOU-UHFFFAOYSA-N 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- BIIWHJYKXOMZCF-UHFFFAOYSA-N cyclopentylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCCC1 BIIWHJYKXOMZCF-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- KJDJPXUIZYHXEZ-UHFFFAOYSA-N hydrogen sulfate;methylaminoazanium Chemical compound CN[NH3+].OS([O-])(=O)=O KJDJPXUIZYHXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- AGNMKAZUXKXQGS-UHFFFAOYSA-N methyl 1-(2-methylpropyl)indazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C=NN2CC(C)C AGNMKAZUXKXQGS-UHFFFAOYSA-N 0.000 description 2
- FXOCVHGUUJXMBH-UHFFFAOYSA-N methyl 1-(4-fluorophenyl)-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1C1=CC=C(F)C=C1 FXOCVHGUUJXMBH-UHFFFAOYSA-N 0.000 description 2
- WNLWOEPKTFTDGX-UHFFFAOYSA-N methyl 1-benzyl-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC=C1 WNLWOEPKTFTDGX-UHFFFAOYSA-N 0.000 description 2
- UOUVWTAIXJPGTO-UHFFFAOYSA-N methyl 1-benzylpyrrolo[2,3-b]pyridine-6-carboxylate Chemical compound C12=NC(C(=O)OC)=CC=C2C=CN1CC1=CC=CC=C1 UOUVWTAIXJPGTO-UHFFFAOYSA-N 0.000 description 2
- VJJMGOYLSMSMCD-UHFFFAOYSA-N methyl 1-methylindole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C)C=CC2=C1 VJJMGOYLSMSMCD-UHFFFAOYSA-N 0.000 description 2
- YUKFEVDVULPZSM-UHFFFAOYSA-N methyl 1-propan-2-yl-3-(pyrazol-1-ylmethyl)indazole-6-carboxylate Chemical compound N=1N(C(C)C)C2=CC(C(=O)OC)=CC=C2C=1CN1C=CC=N1 YUKFEVDVULPZSM-UHFFFAOYSA-N 0.000 description 2
- XOGBBTNEIKWLPQ-UHFFFAOYSA-N methyl 1h-pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC2=C1C=CN2 XOGBBTNEIKWLPQ-UHFFFAOYSA-N 0.000 description 2
- XNOPDFAJQROROS-UHFFFAOYSA-N methyl 1h-pyrrolo[2,3-b]pyridine-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=N1 XNOPDFAJQROROS-UHFFFAOYSA-N 0.000 description 2
- RHMDISFJOKCCAQ-UHFFFAOYSA-N methyl 2-(6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate Chemical compound OC1=CC=C2C(CC(=O)OC)COC2=C1 RHMDISFJOKCCAQ-UHFFFAOYSA-N 0.000 description 2
- UNFJQHZPOXBLNH-UHFFFAOYSA-N methyl 3-amino-6-fluoro-4-iodo-2-methylbenzoate Chemical compound COC(=O)C1=C(C)C(N)=C(I)C=C1F UNFJQHZPOXBLNH-UHFFFAOYSA-N 0.000 description 2
- TZGIJSHGAUIOST-UHFFFAOYSA-N methyl 3-bromo-2h-indazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C(Br)NN=C12 TZGIJSHGAUIOST-UHFFFAOYSA-N 0.000 description 2
- OERQDIFWXAJBGK-UHFFFAOYSA-N methyl 3-chloro-1-(2-methylpropyl)indazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C(Cl)=NN2CC(C)C OERQDIFWXAJBGK-UHFFFAOYSA-N 0.000 description 2
- HHQLZINIDYNTCC-UHFFFAOYSA-N methyl 3-fluoro-7-methyl-1-(2-methylpropyl)indazole-4-carboxylate Chemical compound COC(=O)C1=CC=C(C)C2=C1C(F)=NN2CC(C)C HHQLZINIDYNTCC-UHFFFAOYSA-N 0.000 description 2
- UUOZZUCNZKGCEU-UHFFFAOYSA-N methyl 3-fluoro-7-methyl-2h-indazole-6-carboxylate Chemical compound CC1=C(C(=O)OC)C=CC2=C(F)NN=C21 UUOZZUCNZKGCEU-UHFFFAOYSA-N 0.000 description 2
- MWYRKXULSOPVEC-UHFFFAOYSA-N methyl 3-methyl-1-(2-methylpropyl)indazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(CC(C)C)N=C(C)C2=C1 MWYRKXULSOPVEC-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- TZQCMOHJNDKIEZ-UHFFFAOYSA-N n-(4-bromo-2,5-dimethylphenyl)acetamide Chemical compound CC(=O)NC1=CC(C)=C(Br)C=C1C TZQCMOHJNDKIEZ-UHFFFAOYSA-N 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- PQURBXUZKDETNZ-UHFFFAOYSA-N (1-benzyl-3-fluoro-7-methylindol-6-yl)methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C(F)=CN1CC1=CC=CC=C1 PQURBXUZKDETNZ-UHFFFAOYSA-N 0.000 description 1
- RFCRYUIOOABDPL-UHFFFAOYSA-N (1-benzyl-5-fluoro-7-methylindol-6-yl)methanol Chemical compound C1=2C(C)=C(CO)C(F)=CC=2C=CN1CC1=CC=CC=C1 RFCRYUIOOABDPL-UHFFFAOYSA-N 0.000 description 1
- OCBLZUOGSGBRBG-UHFFFAOYSA-N (1-benzyl-5-fluoroindazol-6-yl)methanol Chemical compound N1=CC=2C=C(F)C(CO)=CC=2N1CC1=CC=CC=C1 OCBLZUOGSGBRBG-UHFFFAOYSA-N 0.000 description 1
- JLHGWRCAJDQMIX-UHFFFAOYSA-N (1-benzyl-5-fluoroindol-6-yl)methanol Chemical compound C1=CC=2C=C(F)C(CO)=CC=2N1CC1=CC=CC=C1 JLHGWRCAJDQMIX-UHFFFAOYSA-N 0.000 description 1
- VHFTYPVKXJPEMB-UHFFFAOYSA-N (1-benzyl-7-methylindazol-5-yl)methanol Chemical compound C1=2C(C)=CC(CO)=CC=2C=NN1CC1=CC=CC=C1 VHFTYPVKXJPEMB-UHFFFAOYSA-N 0.000 description 1
- VQQUBOGXAPIQNR-UHFFFAOYSA-N (1-benzyl-7-methylindol-6-yl)methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=CC=C1 VQQUBOGXAPIQNR-UHFFFAOYSA-N 0.000 description 1
- FZXATBRWISKRMU-UHFFFAOYSA-N (1-benzylbenzimidazol-5-yl)methanol Chemical compound C1=NC2=CC(CO)=CC=C2N1CC1=CC=CC=C1 FZXATBRWISKRMU-UHFFFAOYSA-N 0.000 description 1
- CQNGNQOUCULTIJ-UHFFFAOYSA-N (1-benzylbenzotriazol-5-yl)methanol Chemical compound N1=NC2=CC(CO)=CC=C2N1CC1=CC=CC=C1 CQNGNQOUCULTIJ-UHFFFAOYSA-N 0.000 description 1
- DBGGZHHBSOENPR-UHFFFAOYSA-N (1-benzylindazol-4-yl)methanol Chemical compound N1=CC=2C(CO)=CC=CC=2N1CC1=CC=CC=C1 DBGGZHHBSOENPR-UHFFFAOYSA-N 0.000 description 1
- NITJCSDWTBJIGR-UHFFFAOYSA-N (1-benzylindazol-5-yl)methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1=CC=CC=C1 NITJCSDWTBJIGR-UHFFFAOYSA-N 0.000 description 1
- CFHBYQVYKDNNCG-UHFFFAOYSA-N (1-benzylindazol-6-yl)methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1=CC=CC=C1 CFHBYQVYKDNNCG-UHFFFAOYSA-N 0.000 description 1
- KWAOWHPHNOGJCT-UHFFFAOYSA-N (1-benzylindol-4-yl)methanol Chemical compound C1=CC=2C(CO)=CC=CC=2N1CC1=CC=CC=C1 KWAOWHPHNOGJCT-UHFFFAOYSA-N 0.000 description 1
- HVNIIKANJIBTGW-UHFFFAOYSA-N (1-benzylindol-5-yl)methanol Chemical compound C1=CC2=CC(CO)=CC=C2N1CC1=CC=CC=C1 HVNIIKANJIBTGW-UHFFFAOYSA-N 0.000 description 1
- AHOLPEWTBFBANN-UHFFFAOYSA-N (1-benzylpyrrolo[2,3-b]pyridin-5-yl)methanol Chemical compound C1=CC2=CC(CO)=CN=C2N1CC1=CC=CC=C1 AHOLPEWTBFBANN-UHFFFAOYSA-N 0.000 description 1
- DUAHDSXYZQKSOJ-UHFFFAOYSA-N (1-benzylpyrrolo[2,3-b]pyridin-6-yl)methanol Chemical compound C12=NC(CO)=CC=C2C=CN1CC1=CC=CC=C1 DUAHDSXYZQKSOJ-UHFFFAOYSA-N 0.000 description 1
- VBNIMQDUEJAQJK-UHFFFAOYSA-N (1-butyl-3-methylindazol-4-yl)methanol Chemical compound C1=CC=C2N(CCCC)N=C(C)C2=C1CO VBNIMQDUEJAQJK-UHFFFAOYSA-N 0.000 description 1
- MOPJTECMZYBVFX-UHFFFAOYSA-N (1-butylindazol-4-yl)methanol Chemical compound C1=CC=C2N(CCCC)N=CC2=C1CO MOPJTECMZYBVFX-UHFFFAOYSA-N 0.000 description 1
- FKXGXNABYWHPBR-UHFFFAOYSA-N (1-cyclopentyl-7-methylindazol-5-yl)methanol Chemical compound C1=2C(C)=CC(CO)=CC=2C=NN1C1CCCC1 FKXGXNABYWHPBR-UHFFFAOYSA-N 0.000 description 1
- FOHPEEUIQCXLHL-UHFFFAOYSA-N (1-cyclopentylindazol-5-yl)methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1C1CCCC1 FOHPEEUIQCXLHL-UHFFFAOYSA-N 0.000 description 1
- GNQOXAMRVSRBPW-UHFFFAOYSA-N (1-cyclopentylindazol-6-yl)methanol Chemical compound C12=CC(CO)=CC=C2C=NN1C1CCCC1 GNQOXAMRVSRBPW-UHFFFAOYSA-N 0.000 description 1
- OJNUIMYYXZFZPR-UHFFFAOYSA-N (1-ethyl-3-fluoro-7-methylindazol-6-yl)methanol Chemical compound C1=C(CO)C(C)=C2N(CC)N=C(F)C2=C1 OJNUIMYYXZFZPR-UHFFFAOYSA-N 0.000 description 1
- BVPUKTSBKDFGBN-UHFFFAOYSA-N (1-methylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(C)N=CC2=C1 BVPUKTSBKDFGBN-UHFFFAOYSA-N 0.000 description 1
- WJAFFHRGXJOQSK-UHFFFAOYSA-N (1-propan-2-ylindazol-4-yl)methanol Chemical compound C1=CC=C2N(C(C)C)N=CC2=C1CO WJAFFHRGXJOQSK-UHFFFAOYSA-N 0.000 description 1
- SBXYAWFGPQTRTI-UHFFFAOYSA-N (1-propan-2-ylindazol-5-yl)methanol Chemical compound OCC1=CC=C2N(C(C)C)N=CC2=C1 SBXYAWFGPQTRTI-UHFFFAOYSA-N 0.000 description 1
- VZKUKEKIMSDQPK-UHFFFAOYSA-N (1-propan-2-ylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(C(C)C)N=CC2=C1 VZKUKEKIMSDQPK-UHFFFAOYSA-N 0.000 description 1
- TXYIGARECUKRQA-UHFFFAOYSA-N (1-thiophen-3-ylindol-6-yl)methanol Chemical compound C12=CC(CO)=CC=C2C=CN1C=1C=CSC=1 TXYIGARECUKRQA-UHFFFAOYSA-N 0.000 description 1
- ZPUGOTYEURZDJS-UHFFFAOYSA-N (2,3-dibenzyl-1-methylindol-5-yl)methanol Chemical compound C=1C=CC=CC=1CC=1C2=CC(CO)=CC=C2N(C)C=1CC1=CC=CC=C1 ZPUGOTYEURZDJS-UHFFFAOYSA-N 0.000 description 1
- GSMBMVJZTWXJOT-UHFFFAOYSA-N (2-benzyl-7-methylindazol-5-yl)methanol Chemical compound N1=C2C(C)=CC(CO)=CC2=CN1CC1=CC=CC=C1 GSMBMVJZTWXJOT-UHFFFAOYSA-N 0.000 description 1
- CEKMDSXSXGYGLS-UHFFFAOYSA-N (2-benzylindazol-4-yl)methanol Chemical compound C1=C2C(CO)=CC=CC2=NN1CC1=CC=CC=C1 CEKMDSXSXGYGLS-UHFFFAOYSA-N 0.000 description 1
- RPFKJUZFVOZUSX-UHFFFAOYSA-N (2-benzylindazol-5-yl)methanol Chemical compound C1=C2C=C(CO)C=CC2=NN1CC1=CC=CC=C1 RPFKJUZFVOZUSX-UHFFFAOYSA-N 0.000 description 1
- BRALZLQRJPMJPL-UHFFFAOYSA-N (2-benzylindazol-6-yl)methanol Chemical compound N1=C2C=C(CO)C=CC2=CN1CC1=CC=CC=C1 BRALZLQRJPMJPL-UHFFFAOYSA-N 0.000 description 1
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
- AWZAHRIAIVONDP-UHFFFAOYSA-N (2-propan-2-ylindazol-6-yl)methanol Chemical compound C1=CC(CO)=CC2=NN(C(C)C)C=C21 AWZAHRIAIVONDP-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- OWCAEGDADACMNG-UHFFFAOYSA-N (3-benzyl-1-methylindol-5-yl)methanol Chemical compound C12=CC(CO)=CC=C2N(C)C=C1CC1=CC=CC=C1 OWCAEGDADACMNG-UHFFFAOYSA-N 0.000 description 1
- XPIICNFDSSGSDS-UHFFFAOYSA-N (3-chloro-1-methylindazol-7-yl)methanol Chemical compound C1=CC(CO)=C2N(C)N=C(Cl)C2=C1 XPIICNFDSSGSDS-UHFFFAOYSA-N 0.000 description 1
- OBCIZPGSDYGWTM-UHFFFAOYSA-N (3-fluoro-1-propan-2-ylindazol-4-yl)methanol Chemical compound C1=CC=C2N(C(C)C)N=C(F)C2=C1CO OBCIZPGSDYGWTM-UHFFFAOYSA-N 0.000 description 1
- JUNHQJLHAITFEQ-UHFFFAOYSA-N (3-methyl-1-propan-2-ylindazol-5-yl)methanol Chemical compound OCC1=CC=C2N(C(C)C)N=C(C)C2=C1 JUNHQJLHAITFEQ-UHFFFAOYSA-N 0.000 description 1
- AKGNFISMTNGTDV-UHFFFAOYSA-N (3-methyl-1-propan-2-ylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(C(C)C)N=C(C)C2=C1 AKGNFISMTNGTDV-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- MKEJPKKYVSWTJO-SANMLTNESA-N (3s)-3-[4-[[1-benzyl-2-(2-methoxyethyl)indol-6-yl]methoxy]phenyl]hex-4-ynoic acid Chemical compound C1=C2N(CC=3C=CC=CC=3)C(CCOC)=CC2=CC=C1COC1=CC=C([C@H](CC(O)=O)C#CC)C=C1 MKEJPKKYVSWTJO-SANMLTNESA-N 0.000 description 1
- CDDGNGVFPQRJJM-BYPYZUCNSA-N (3s)-3-fluoropyrrolidine Chemical compound F[C@H]1CCNC1 CDDGNGVFPQRJJM-BYPYZUCNSA-N 0.000 description 1
- UOSBHJFKMGLWGX-UHFFFAOYSA-N (5-bromo-2-fluorophenyl)methanol Chemical compound OCC1=CC(Br)=CC=C1F UOSBHJFKMGLWGX-UHFFFAOYSA-N 0.000 description 1
- ACDJWFPZJPLOCH-UHFFFAOYSA-N (7-methyl-1-propan-2-ylindazol-4-yl)methanol Chemical compound C1=CC(C)=C2N(C(C)C)N=CC2=C1CO ACDJWFPZJPLOCH-UHFFFAOYSA-N 0.000 description 1
- HPULREAGJVSXFD-UHFFFAOYSA-N (7-methyl-1-propan-2-ylindazol-6-yl)methanol Chemical compound C1=C(CO)C(C)=C2N(C(C)C)N=CC2=C1 HPULREAGJVSXFD-UHFFFAOYSA-N 0.000 description 1
- UIPRIDJVBNCDMN-UHFFFAOYSA-N (7-methyl-1-propylindazol-6-yl)methanol Chemical compound C1=C(CO)C(C)=C2N(CCC)N=CC2=C1 UIPRIDJVBNCDMN-UHFFFAOYSA-N 0.000 description 1
- ZKIWHPJIZDSHBJ-UHFFFAOYSA-N (7-methyl-1-thiophen-3-ylindol-6-yl)methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1C=1C=CSC=1 ZKIWHPJIZDSHBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- IHOGLHYDKYJDGO-UHFFFAOYSA-N 1-(1-phenylethyl)indole-6-carbaldehyde Chemical compound C1(=CC=CC=C1)C(C)N1C=CC2=CC=C(C=C12)C=O IHOGLHYDKYJDGO-UHFFFAOYSA-N 0.000 description 1
- BKGFKFXUMBBVTG-UHFFFAOYSA-N 1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazole-6-carboxylic acid Chemical compound C(C(C)C)N1N=C(C2=CC=C(C=C12)C(=O)O)CN1CCOCC1 BKGFKFXUMBBVTG-UHFFFAOYSA-N 0.000 description 1
- WDAIXBQLPOLRLB-UHFFFAOYSA-N 1-(2-methylpropyl)pyrrolo[2,3-b]pyridine-6-carbonitrile Chemical compound C1=C(C#N)N=C2N(CC(C)C)C=CC2=C1 WDAIXBQLPOLRLB-UHFFFAOYSA-N 0.000 description 1
- CAUXBJCZKVCKPY-UHFFFAOYSA-N 1-(4-fluorophenyl)indole-6-carbaldehyde Chemical compound C1=CC(F)=CC=C1N1C2=CC(C=O)=CC=C2C=C1 CAUXBJCZKVCKPY-UHFFFAOYSA-N 0.000 description 1
- YZEFSUIYSBYRLE-UHFFFAOYSA-N 1-(5-bromo-2-hydroxyphenyl)-3-methylbutan-1-one Chemical compound CC(C)CC(=O)C1=CC(Br)=CC=C1O YZEFSUIYSBYRLE-UHFFFAOYSA-N 0.000 description 1
- IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 1
- PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- WGVYCXYGPNNUQA-UHFFFAOYSA-N 1-(bromomethyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1CBr WGVYCXYGPNNUQA-UHFFFAOYSA-N 0.000 description 1
- KVSVNRFSKRFPIL-UHFFFAOYSA-N 1-(bromomethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CBr)=C1 KVSVNRFSKRFPIL-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 1
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 1
- HGKPAXHJTMHWAH-UHFFFAOYSA-N 1-(bromomethyl)-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(CBr)C=C1 HGKPAXHJTMHWAH-UHFFFAOYSA-N 0.000 description 1
- TZPQZPKQEQZDNC-UHFFFAOYSA-N 1-benzyl-2,3-dichloroindole-6-carbaldehyde Chemical compound ClC1=C(Cl)C2=CC=C(C=O)C=C2N1CC1=CC=CC=C1 TZPQZPKQEQZDNC-UHFFFAOYSA-N 0.000 description 1
- MEHFMHGEMUOYNN-UHFFFAOYSA-N 1-benzyl-5-(hydroxymethyl)-3-methylbenzimidazol-2-one Chemical compound O=C1N(C)C2=CC(CO)=CC=C2N1CC1=CC=CC=C1 MEHFMHGEMUOYNN-UHFFFAOYSA-N 0.000 description 1
- XQENYCPLPOBFSJ-UHFFFAOYSA-N 1-benzyl-7-chloroindole-6-carbaldehyde Chemical compound C1=2C(Cl)=C(C=O)C=CC=2C=CN1CC1=CC=CC=C1 XQENYCPLPOBFSJ-UHFFFAOYSA-N 0.000 description 1
- FLPAUMBYKJCMAY-UHFFFAOYSA-N 1-benzylpyrrolo[2,3-b]pyridine-6-carbonitrile Chemical compound C12=NC(C#N)=CC=C2C=CN1CC1=CC=CC=C1 FLPAUMBYKJCMAY-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- RJPNVPITBYXBNB-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methylbenzene Chemical compound CC1=CC(F)=CC=C1Br RJPNVPITBYXBNB-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- GWWPTVCJCQLJKN-UHFFFAOYSA-N 1-butyl-3-fluoro-4-methylindazole Chemical compound C1=CC=C2N(CCCC)N=C(F)C2=C1C GWWPTVCJCQLJKN-UHFFFAOYSA-N 0.000 description 1
- PRIGFEJKMMRJSF-UHFFFAOYSA-M 1-fluoro-2,4,6-trimethylpyridin-1-ium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.CC1=CC(C)=[N+](F)C(C)=C1 PRIGFEJKMMRJSF-UHFFFAOYSA-M 0.000 description 1
- CJTZXIJETZZARD-UHFFFAOYSA-N 1-iodo-2,2-dimethylpropane Chemical compound CC(C)(C)CI CJTZXIJETZZARD-UHFFFAOYSA-N 0.000 description 1
- XICXZRCWIRBPAD-UHFFFAOYSA-N 1-methyl-3-(2-methylpropyl)indazole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(CC(C)C)=NN(C)C2=C1 XICXZRCWIRBPAD-UHFFFAOYSA-N 0.000 description 1
- ZJNQCWORULEVED-UHFFFAOYSA-N 1-methyl-3-(2-methylpropyl)indazole-7-carbonitrile Chemical compound C1=CC=C2C(CC(C)C)=NN(C)C2=C1C#N ZJNQCWORULEVED-UHFFFAOYSA-N 0.000 description 1
- HOYRZUGOHAGURO-UHFFFAOYSA-N 1-methyl-3-propan-2-ylindazole-7-carbonitrile Chemical compound C1=CC=C2C(C(C)C)=NN(C)C2=C1C#N HOYRZUGOHAGURO-UHFFFAOYSA-N 0.000 description 1
- ZEBCMCNLWGCCIX-UHFFFAOYSA-N 1-methyl-3-propylindazole-7-carbonitrile Chemical compound C1=CC=C2C(CCC)=NN(C)C2=C1C#N ZEBCMCNLWGCCIX-UHFFFAOYSA-N 0.000 description 1
- FLLBYTRYZVMNFQ-UHFFFAOYSA-N 1-o-tert-butyl 6-o-methyl 3-(bromomethyl)indazole-1,6-dicarboxylate Chemical compound COC(=O)C1=CC=C2C(CBr)=NN(C(=O)OC(C)(C)C)C2=C1 FLLBYTRYZVMNFQ-UHFFFAOYSA-N 0.000 description 1
- IIXFZKCVHFOVPA-UHFFFAOYSA-N 1-o-tert-butyl 6-o-methyl 3-(morpholin-4-ylmethyl)indazole-1,6-dicarboxylate Chemical compound N=1N(C(=O)OC(C)(C)C)C2=CC(C(=O)OC)=CC=C2C=1CN1CCOCC1 IIXFZKCVHFOVPA-UHFFFAOYSA-N 0.000 description 1
- AEJQOHGGNCPJLF-UHFFFAOYSA-N 1-o-tert-butyl 6-o-methyl 3-methylindazole-1,6-dicarboxylate Chemical compound COC(=O)C1=CC=C2C(C)=NN(C(=O)OC(C)(C)C)C2=C1 AEJQOHGGNCPJLF-UHFFFAOYSA-N 0.000 description 1
- PMBPAKUABGGVJW-UHFFFAOYSA-N 1-thiophen-3-ylindole-6-carbaldehyde Chemical compound C12=CC(C=O)=CC=C2C=CN1C=1C=CSC=1 PMBPAKUABGGVJW-UHFFFAOYSA-N 0.000 description 1
- YPQAFWHSMWWPLX-UHFFFAOYSA-N 1975-50-4 Chemical compound CC1=C(C(O)=O)C=CC=C1[N+]([O-])=O YPQAFWHSMWWPLX-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- WZCQPVLAXQMTJO-UHFFFAOYSA-N 1h-indazol-6-ylmethanol Chemical compound OCC1=CC=C2C=NNC2=C1 WZCQPVLAXQMTJO-UHFFFAOYSA-N 0.000 description 1
- DRAQIXNADYAISI-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound N#CC1=CN=C2NC=CC2=C1 DRAQIXNADYAISI-UHFFFAOYSA-N 0.000 description 1
- LDJMQIKMKHNGDB-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=N1 LDJMQIKMKHNGDB-UHFFFAOYSA-N 0.000 description 1
- LSXJPJGBWSZHTM-UHFFFAOYSA-N 2-(bromomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CBr LSXJPJGBWSZHTM-UHFFFAOYSA-N 0.000 description 1
- PSRARXVEBZQEML-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1CBr PSRARXVEBZQEML-UHFFFAOYSA-N 0.000 description 1
- JQDNCGRNPYKRAO-UHFFFAOYSA-N 2-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=CC=N1 JQDNCGRNPYKRAO-UHFFFAOYSA-N 0.000 description 1
- HQBGVAPBGXWXSW-UHFFFAOYSA-N 2-fluoro-3-(1-hydroxy-2-methylpropyl)benzonitrile Chemical compound CC(C)C(O)C1=CC=CC(C#N)=C1F HQBGVAPBGXWXSW-UHFFFAOYSA-N 0.000 description 1
- YEZAVONJWFXKCA-UHFFFAOYSA-N 2-fluoro-3-(1-hydroxy-3-methylbutyl)benzonitrile Chemical compound CC(C)CC(O)C1=CC=CC(C#N)=C1F YEZAVONJWFXKCA-UHFFFAOYSA-N 0.000 description 1
- SYFQMQYVAFDFGJ-UHFFFAOYSA-N 2-fluoro-3-(1-hydroxybutan-2-yl)benzonitrile Chemical compound CCC(CO)C1=CC=CC(C#N)=C1F SYFQMQYVAFDFGJ-UHFFFAOYSA-N 0.000 description 1
- SXPHJCBWPBYKST-UHFFFAOYSA-N 2-fluoro-3-(1-hydroxypentyl)benzonitrile Chemical compound CCCCC(O)C1=CC=CC(C#N)=C1F SXPHJCBWPBYKST-UHFFFAOYSA-N 0.000 description 1
- UDKCUDPHDOJBPZ-UHFFFAOYSA-N 2-fluoro-3-(2-methylpropanoyl)benzonitrile Chemical compound CC(C)C(=O)C1=CC=CC(C#N)=C1F UDKCUDPHDOJBPZ-UHFFFAOYSA-N 0.000 description 1
- CCWOBNQACUSPFA-UHFFFAOYSA-N 2-fluoro-3-(3-methylbutanoyl)benzonitrile Chemical compound CC(C)CC(=O)C1=CC=CC(C#N)=C1F CCWOBNQACUSPFA-UHFFFAOYSA-N 0.000 description 1
- XXIFXLORXBDBLO-UHFFFAOYSA-N 2-fluoro-3-pentanoylbenzonitrile Chemical compound CCCCC(=O)C1=CC=CC(C#N)=C1F XXIFXLORXBDBLO-UHFFFAOYSA-N 0.000 description 1
- UBAWHHHAAFFKGE-UHFFFAOYSA-N 2-fluoro-4-methyl-5-nitrobenzoic acid Chemical compound CC1=CC(F)=C(C(O)=O)C=C1[N+]([O-])=O UBAWHHHAAFFKGE-UHFFFAOYSA-N 0.000 description 1
- ALFWHEYHCZRVLO-UHFFFAOYSA-N 2-fluoro-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(F)=C1 ALFWHEYHCZRVLO-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- ABXBBEBCOITZEX-UHFFFAOYSA-N 2-methylsulfonylethyl methanesulfonate Chemical compound CS(=O)(=O)CCOS(C)(=O)=O ABXBBEBCOITZEX-UHFFFAOYSA-N 0.000 description 1
- UOGQPXQDNUHUIB-UHFFFAOYSA-N 3,3-difluoropiperidine Chemical compound FC1(F)CCCNC1 UOGQPXQDNUHUIB-UHFFFAOYSA-N 0.000 description 1
- YYVPZQADFREIFR-UHFFFAOYSA-N 3,3-difluoropyrrolidine;hydrochloride Chemical compound [Cl-].FC1(F)CC[NH2+]C1 YYVPZQADFREIFR-UHFFFAOYSA-N 0.000 description 1
- RBAVFNOGEPCOQI-UHFFFAOYSA-N 3,5-dimethyl-4-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1[N+]([O-])=O RBAVFNOGEPCOQI-UHFFFAOYSA-N 0.000 description 1
- PXPFCIHIAZRPKJ-UHFFFAOYSA-N 3-(2-methylpropyl)-1,2-benzoxazole-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(CC(C)C)=NOC2=C1 PXPFCIHIAZRPKJ-UHFFFAOYSA-N 0.000 description 1
- FNHPUOJKUXFUKN-UHFFFAOYSA-N 3-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=CN=C1 FNHPUOJKUXFUKN-UHFFFAOYSA-N 0.000 description 1
- JWRJYZDZZPEPNA-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)-2H-indazole-6-carboxylic acid Chemical compound N1(CCOCC1)CC1=NNC2=CC(=CC=C12)C(=O)O JWRJYZDZZPEPNA-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LETQDGGXBXPZIL-UHFFFAOYSA-N 3-butanoyl-2-fluorobenzonitrile Chemical compound CCCC(=O)C1=CC=CC(C#N)=C1F LETQDGGXBXPZIL-UHFFFAOYSA-N 0.000 description 1
- ZEPCLCYGRPNUSD-UHFFFAOYSA-N 3-butyl-1-methylindazole-7-carbonitrile Chemical compound C1=CC=C2C(CCCC)=NN(C)C2=C1C#N ZEPCLCYGRPNUSD-UHFFFAOYSA-N 0.000 description 1
- WVZBIQSKLXJFNX-UHFFFAOYSA-N 3-fluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 WVZBIQSKLXJFNX-UHFFFAOYSA-N 0.000 description 1
- FRQCAZXFZRBMRX-UHFFFAOYSA-N 3-methoxypropyl methanesulfonate Chemical compound COCCCOS(C)(=O)=O FRQCAZXFZRBMRX-UHFFFAOYSA-N 0.000 description 1
- DOTPHVKCGKWIGU-UHFFFAOYSA-N 3-methyl-1-(2-methylpropyl)indazole-5-carbonitrile Chemical compound N#CC1=CC=C2N(CC(C)C)N=C(C)C2=C1 DOTPHVKCGKWIGU-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- BZQGPGKJLOOSFU-UHFFFAOYSA-N 3-methylsulfonylpropyl methanesulfonate Chemical compound CS(=O)(=O)CCCOS(C)(=O)=O BZQGPGKJLOOSFU-UHFFFAOYSA-N 0.000 description 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- OKLBYPMDIRXALH-UHFFFAOYSA-N 4-(bromomethyl)pyrimidine Chemical compound BrCC1=CC=NC=N1 OKLBYPMDIRXALH-UHFFFAOYSA-N 0.000 description 1
- QKWSLYINUYKIRF-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=CSC=N1 QKWSLYINUYKIRF-UHFFFAOYSA-N 0.000 description 1
- AQBBZYVPKBIILN-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole Chemical compound CC1=NC(CCl)=CS1 AQBBZYVPKBIILN-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- ZQVKTHRQIXSMGY-UHFFFAOYSA-N 4-Ethylbenzoic acid Chemical compound CCC1=CC=C(C(O)=O)C=C1 ZQVKTHRQIXSMGY-UHFFFAOYSA-N 0.000 description 1
- XACWSBWCLJXKGI-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxybenzaldehyde Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C(C=O)C=C1 XACWSBWCLJXKGI-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- HNTZVGMWXCFCTA-UHFFFAOYSA-N 4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=NC2=C1C=CN2 HNTZVGMWXCFCTA-UHFFFAOYSA-N 0.000 description 1
- DUTYVLOGZGRKMA-UHFFFAOYSA-N 4-ethyl-3-nitrobenzoic acid Chemical compound CCC1=CC=C(C(O)=O)C=C1[N+]([O-])=O DUTYVLOGZGRKMA-UHFFFAOYSA-N 0.000 description 1
- IDRMZGPORPGSKH-UHFFFAOYSA-N 4-fluoro-3-(3-methylbutanoyl)benzonitrile Chemical compound CC(C)CC(=O)C1=CC(C#N)=CC=C1F IDRMZGPORPGSKH-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- YJOULMMJZAADRY-UHFFFAOYSA-N 5-(bromomethyl)-2-chloropyridine Chemical compound ClC1=CC=C(CBr)C=N1 YJOULMMJZAADRY-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- BASYLPMLKGQZOG-UHFFFAOYSA-N 5-bromo-1h-pyrazolo[3,4-b]pyridine Chemical compound BrC1=CN=C2NN=CC2=C1 BASYLPMLKGQZOG-UHFFFAOYSA-N 0.000 description 1
- LPTVWZSQAIDCEB-UHFFFAOYSA-N 5-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CN=C2NC=CC2=C1 LPTVWZSQAIDCEB-UHFFFAOYSA-N 0.000 description 1
- XDJNHYAQZWCIAH-UHFFFAOYSA-N 5-bromo-3-methyl-2h-indazole Chemical compound C1=CC(Br)=CC2=C(C)NN=C21 XDJNHYAQZWCIAH-UHFFFAOYSA-N 0.000 description 1
- CZTNKNQTVYXSBM-UHFFFAOYSA-N 5-bromo-6-methyl-1-(2-methylpropyl)indazole Chemical compound BrC1=C(C)C=C2N(CC(C)C)N=CC2=C1 CZTNKNQTVYXSBM-UHFFFAOYSA-N 0.000 description 1
- UTDBMGRTYFPTEC-UHFFFAOYSA-N 5-bromo-6-methyl-1h-indazole Chemical compound C1=C(Br)C(C)=CC2=C1C=NN2 UTDBMGRTYFPTEC-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- VQOREXCROVBWPH-UHFFFAOYSA-N 6-methyl-1-(2-methylpropyl)indazole-5-carbonitrile Chemical compound N#CC1=C(C)C=C2N(CC(C)C)N=CC2=C1 VQOREXCROVBWPH-UHFFFAOYSA-N 0.000 description 1
- JTVLGTSEOQKYBE-UHFFFAOYSA-N 7-chloro-1-(4-fluorophenyl)indole-6-carbaldehyde Chemical compound C1=CC(F)=CC=C1N1C2=C(Cl)C(C=O)=CC=C2C=C1 JTVLGTSEOQKYBE-UHFFFAOYSA-N 0.000 description 1
- WMLCCFXOODAIER-UHFFFAOYSA-N 7-chloro-1-(cyclohexylmethyl)indole-6-carbaldehyde Chemical compound C1=2C(Cl)=C(C=O)C=CC=2C=CN1CC1CCCCC1 WMLCCFXOODAIER-UHFFFAOYSA-N 0.000 description 1
- RYDWMRDKQBPICK-UHFFFAOYSA-N 7-chloro-1-thiophen-3-ylindole-6-carbaldehyde Chemical compound C1=2C(Cl)=C(C=O)C=CC=2C=CN1C=1C=CSC=1 RYDWMRDKQBPICK-UHFFFAOYSA-N 0.000 description 1
- RWHUWCQJGDUVIZ-UHFFFAOYSA-N 7-chloro-1h-indole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CNC2=C1Cl RWHUWCQJGDUVIZ-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- IDPSBCGULRWNLH-UHFFFAOYSA-N FC1=CC=C(C=C1)N1C=CC2=CC=C(C(=C12)C)CO Chemical compound FC1=CC=C(C=C1)N1C=CC2=CC=C(C(=C12)C)CO IDPSBCGULRWNLH-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 229940125827 GPR40 agonist Drugs 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NMMIHXMBOZYNET-UHFFFAOYSA-N Methyl picolinate Chemical compound COC(=O)C1=CC=CC=N1 NMMIHXMBOZYNET-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XBIPYGGLNOJMBI-UHFFFAOYSA-N [1-(1-phenylethyl)indazol-5-yl]methanol Chemical compound C1(=CC=CC=C1)C(C)N1N=CC2=CC(=CC=C12)CO XBIPYGGLNOJMBI-UHFFFAOYSA-N 0.000 description 1
- HYSVDVVOIPIDST-UHFFFAOYSA-N [1-(2,2-dimethylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C=C2N(CC(C)(C)C)N=CC2=C1 HYSVDVVOIPIDST-UHFFFAOYSA-N 0.000 description 1
- MBKCMSGXLFIYOG-UHFFFAOYSA-N [1-(2-ethoxyethyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CCOCC)N=CC2=C1 MBKCMSGXLFIYOG-UHFFFAOYSA-N 0.000 description 1
- DSUDRNJXRAKNJF-UHFFFAOYSA-N [1-(2-methoxyethyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CCOC)N=CC2=C1 DSUDRNJXRAKNJF-UHFFFAOYSA-N 0.000 description 1
- HHUKLYDZXQPCJB-UHFFFAOYSA-N [1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C=C2N(CC(C)C)N=C1CN1CCOCC1 HHUKLYDZXQPCJB-UHFFFAOYSA-N 0.000 description 1
- IZKFPRZUNKYBPI-UHFFFAOYSA-N [1-(2-methylpropyl)-3-(propan-2-yloxymethyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C=C2N(CC(C)C)N=C(COC(C)C)C2=C1 IZKFPRZUNKYBPI-UHFFFAOYSA-N 0.000 description 1
- URMFTJKILCWJLD-UHFFFAOYSA-N [1-(2-methylpropyl)indazol-4-yl]methanol Chemical compound C1=CC=C2N(CC(C)C)N=CC2=C1CO URMFTJKILCWJLD-UHFFFAOYSA-N 0.000 description 1
- TXQSMRNWNPWINM-UHFFFAOYSA-N [1-(2-methylpropyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CC(C)C)N=CC2=C1 TXQSMRNWNPWINM-UHFFFAOYSA-N 0.000 description 1
- ALWGYPMYNKYCJQ-UHFFFAOYSA-N [1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C=C2N(CC(C)C)N=CC2=C1 ALWGYPMYNKYCJQ-UHFFFAOYSA-N 0.000 description 1
- QNSAYRSMROUSQJ-UHFFFAOYSA-N [1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-4-yl]methanol Chemical compound C1=CN=C2N(CC(C)C)C=CC2=C1CO QNSAYRSMROUSQJ-UHFFFAOYSA-N 0.000 description 1
- ZBJLTRKUYVHPNE-UHFFFAOYSA-N [1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-5-yl]methanol Chemical compound OCC1=CN=C2N(CC(C)C)C=CC2=C1 ZBJLTRKUYVHPNE-UHFFFAOYSA-N 0.000 description 1
- YJDFJWGTBNGFKT-UHFFFAOYSA-N [1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methanol Chemical compound C1=C(CO)N=C2N(CC(C)C)C=CC2=C1 YJDFJWGTBNGFKT-UHFFFAOYSA-N 0.000 description 1
- CXTCAHYDYZWMJY-UHFFFAOYSA-N [1-(2-methylsulfonylethyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CCS(=O)(=O)C)N=CC2=C1 CXTCAHYDYZWMJY-UHFFFAOYSA-N 0.000 description 1
- JBCOKMKLIBKBJW-UHFFFAOYSA-N [1-(3-methoxypropyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CCCOC)N=CC2=C1 JBCOKMKLIBKBJW-UHFFFAOYSA-N 0.000 description 1
- DRWBHHYIKHNIHS-UHFFFAOYSA-N [1-(3-methylbutyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CCC(C)C)N=CC2=C1 DRWBHHYIKHNIHS-UHFFFAOYSA-N 0.000 description 1
- JLLYKGSPQCMJBM-UHFFFAOYSA-N [1-(3-methylsulfonylpropyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CCCS(=O)(=O)C)N=CC2=C1 JLLYKGSPQCMJBM-UHFFFAOYSA-N 0.000 description 1
- DJOVMWOEPVAVRF-UHFFFAOYSA-N [1-(4-fluoro-2-methylphenyl)indol-4-yl]methanol Chemical compound CC1=CC(F)=CC=C1N1C2=CC=CC(CO)=C2C=C1 DJOVMWOEPVAVRF-UHFFFAOYSA-N 0.000 description 1
- WQRLNCTTYDFSSL-UHFFFAOYSA-N [1-(4-fluoro-2-methylphenyl)indol-6-yl]methanol Chemical compound CC1=CC(F)=CC=C1N1C2=CC(CO)=CC=C2C=C1 WQRLNCTTYDFSSL-UHFFFAOYSA-N 0.000 description 1
- ZKRWOEAIJGFQOF-UHFFFAOYSA-N [1-(cyclohexylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1CCCCC1 ZKRWOEAIJGFQOF-UHFFFAOYSA-N 0.000 description 1
- ATYNVVLIZGZMHS-UHFFFAOYSA-N [1-(cyclohexylmethyl)indol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=CN1CC1CCCCC1 ATYNVVLIZGZMHS-UHFFFAOYSA-N 0.000 description 1
- KQKVSRWEFRPWNA-UHFFFAOYSA-N [1-(cyclopentylmethyl)-7-methylindazol-5-yl]methanol Chemical compound C1=2C(C)=CC(CO)=CC=2C=NN1CC1CCCC1 KQKVSRWEFRPWNA-UHFFFAOYSA-N 0.000 description 1
- WBWOSNMVIPKFEN-UHFFFAOYSA-N [1-(cyclopentylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1CCCC1 WBWOSNMVIPKFEN-UHFFFAOYSA-N 0.000 description 1
- ILILPKFPFPJISP-UHFFFAOYSA-N [1-(cyclopentylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1CCCC1 ILILPKFPFPJISP-UHFFFAOYSA-N 0.000 description 1
- XDZJUBWSKIKDLX-UHFFFAOYSA-N [1-(cyclopropylmethyl)-3-fluoroindazol-4-yl]methanol Chemical compound N1=C(F)C=2C(CO)=CC=CC=2N1CC1CC1 XDZJUBWSKIKDLX-UHFFFAOYSA-N 0.000 description 1
- HWMKXCFPJSEWQF-UHFFFAOYSA-N [1-(cyclopropylmethyl)indazol-4-yl]methanol Chemical compound N1=CC=2C(CO)=CC=CC=2N1CC1CC1 HWMKXCFPJSEWQF-UHFFFAOYSA-N 0.000 description 1
- ZLLLKKXQXWUJBD-UHFFFAOYSA-N [1-(cyclopropylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1CC1 ZLLLKKXQXWUJBD-UHFFFAOYSA-N 0.000 description 1
- YWVCWYGPMZLXGU-UHFFFAOYSA-N [1-(cyclopropylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1CC1 YWVCWYGPMZLXGU-UHFFFAOYSA-N 0.000 description 1
- DYRAASALTBMBCM-UHFFFAOYSA-N [1-(oxolan-2-ylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1CCCO1 DYRAASALTBMBCM-UHFFFAOYSA-N 0.000 description 1
- XJPVVCJSRYFVPM-UHFFFAOYSA-N [1-(oxolan-3-ylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1CCOC1 XJPVVCJSRYFVPM-UHFFFAOYSA-N 0.000 description 1
- OUVWLTOXSAOVLR-UHFFFAOYSA-N [1-(pyrazin-2-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1=CN=CC=N1 OUVWLTOXSAOVLR-UHFFFAOYSA-N 0.000 description 1
- AWKXPGJBUVEGIW-UHFFFAOYSA-N [1-(pyrazin-2-ylmethyl)pyrrolo[2,3-b]pyridin-6-yl]methanol Chemical compound C12=NC(CO)=CC=C2C=CN1CC1=CN=CC=N1 AWKXPGJBUVEGIW-UHFFFAOYSA-N 0.000 description 1
- JUZNKEBAGHRJRB-UHFFFAOYSA-N [1-(pyridin-2-ylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1=CC=CC=N1 JUZNKEBAGHRJRB-UHFFFAOYSA-N 0.000 description 1
- ZSDARHHJVAYCRQ-UHFFFAOYSA-N [1-(pyridin-3-ylmethyl)indazol-5-yl]methanol Chemical compound N1=CC2=CC(CO)=CC=C2N1CC1=CC=CN=C1 ZSDARHHJVAYCRQ-UHFFFAOYSA-N 0.000 description 1
- JKRJBOYZFQLEGT-UHFFFAOYSA-N [1-(pyridin-3-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1=CC=CN=C1 JKRJBOYZFQLEGT-UHFFFAOYSA-N 0.000 description 1
- ZDCNZBOLQHUSTJ-UHFFFAOYSA-N [1-(pyrimidin-2-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1=NC=CC=N1 ZDCNZBOLQHUSTJ-UHFFFAOYSA-N 0.000 description 1
- OQBPSXMBUSYXIG-UHFFFAOYSA-N [1-(pyrimidin-4-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1=CC=NC=N1 OQBPSXMBUSYXIG-UHFFFAOYSA-N 0.000 description 1
- OKENEZNLINWYMA-UHFFFAOYSA-N [1-[(1-methylpyrazol-4-yl)methyl]indazol-6-yl]methanol Chemical compound C1=NN(C)C=C1CN1C2=CC(CO)=CC=C2C=N1 OKENEZNLINWYMA-UHFFFAOYSA-N 0.000 description 1
- NOWDMDKBOQGZGV-UHFFFAOYSA-N [1-[(2,4-difluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(F)C=C1F NOWDMDKBOQGZGV-UHFFFAOYSA-N 0.000 description 1
- LOGOWNGGRSMROH-UHFFFAOYSA-N [1-[(2,6-difluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=C(F)C=CC=C1F LOGOWNGGRSMROH-UHFFFAOYSA-N 0.000 description 1
- PVEWVDPEMCAADA-UHFFFAOYSA-N [1-[(2,6-dimethylphenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound CC1=CC=CC(C)=C1CN1C2=C(C)C(CO)=CC=C2C=C1 PVEWVDPEMCAADA-UHFFFAOYSA-N 0.000 description 1
- VRAPFNCGRWYNND-UHFFFAOYSA-N [1-[(2-chlorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=CC=C1Cl VRAPFNCGRWYNND-UHFFFAOYSA-N 0.000 description 1
- LKZHUBWCESOROK-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=CC=C1F LKZHUBWCESOROK-UHFFFAOYSA-N 0.000 description 1
- WIZOIUIGIPQDNP-UHFFFAOYSA-N [1-[(3,4-difluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(F)C(F)=C1 WIZOIUIGIPQDNP-UHFFFAOYSA-N 0.000 description 1
- VLGNWXHJBRMTHO-UHFFFAOYSA-N [1-[(3,5-difluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC(F)=CC(F)=C1 VLGNWXHJBRMTHO-UHFFFAOYSA-N 0.000 description 1
- LNTJBUNPIBMCLY-UHFFFAOYSA-N [1-[(3-fluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=CC(F)=C1 LNTJBUNPIBMCLY-UHFFFAOYSA-N 0.000 description 1
- OCABPFFFLQAPOE-UHFFFAOYSA-N [1-[(3-methyloxetan-3-yl)methyl]indazol-6-yl]methanol Chemical compound N1=CC2=CC=C(CO)C=C2N1CC1(C)COC1 OCABPFFFLQAPOE-UHFFFAOYSA-N 0.000 description 1
- CZGBJOQCSQTELM-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(F)C=C1 CZGBJOQCSQTELM-UHFFFAOYSA-N 0.000 description 1
- FMDCPQGPZHBWHS-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]indazol-4-yl]methanol Chemical compound N1=CC=2C(CO)=CC=CC=2N1CC1=CC=C(F)C=C1 FMDCPQGPZHBWHS-UHFFFAOYSA-N 0.000 description 1
- HBXWIOCERCZUQR-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1=CC=C(F)C=C1 HBXWIOCERCZUQR-UHFFFAOYSA-N 0.000 description 1
- UTTOMYCQKFDLOG-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-6-yl]methanol Chemical compound C12=NC(CO)=CC=C2C=CN1CC1=CC=C(F)C=C1 UTTOMYCQKFDLOG-UHFFFAOYSA-N 0.000 description 1
- ZSMHKEPCABZRJO-UHFFFAOYSA-N [1-[(4-methoxyphenyl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=CC(OC)=CC=C1CN1C2=C(C)C(CO)=CC=C2C=C1 ZSMHKEPCABZRJO-UHFFFAOYSA-N 0.000 description 1
- ASRKBERWJOPCAS-UHFFFAOYSA-N [1-[(5-methylpyrazin-2-yl)methyl]indazol-4-yl]methanol Chemical compound C1=NC(C)=CN=C1CN1C2=CC=CC(CO)=C2C=N1 ASRKBERWJOPCAS-UHFFFAOYSA-N 0.000 description 1
- CJLYUEUKFDRRCW-UHFFFAOYSA-N [1-[(5-methylpyrazin-2-yl)methyl]indazol-6-yl]methanol Chemical compound C1=NC(C)=CN=C1CN1C2=CC(CO)=CC=C2C=N1 CJLYUEUKFDRRCW-UHFFFAOYSA-N 0.000 description 1
- MREWGJCLIHJTJX-UHFFFAOYSA-N [1-[(6-chloropyridin-3-yl)methyl]-7-methylindol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(Cl)N=C1 MREWGJCLIHJTJX-UHFFFAOYSA-N 0.000 description 1
- RRLGHZCYZYHVKV-UHFFFAOYSA-N [1-[(6-methylpyridin-3-yl)methyl]indazol-6-yl]methanol Chemical compound C1=NC(C)=CC=C1CN1C2=CC(CO)=CC=C2C=N1 RRLGHZCYZYHVKV-UHFFFAOYSA-N 0.000 description 1
- JDWYEXRIBBHIBE-UHFFFAOYSA-N [1-[[3-(methoxymethyl)phenyl]methyl]-7-methylindol-6-yl]methanol Chemical compound COCC1=CC=CC(CN2C3=C(C)C(CO)=CC=C3C=C2)=C1 JDWYEXRIBBHIBE-UHFFFAOYSA-N 0.000 description 1
- YHQGVYHKJAOGNM-UHFFFAOYSA-N [1-benzyl-2-(2-methoxyethyl)indol-6-yl]methanol Chemical compound COCCC1=CC2=CC=C(CO)C=C2N1CC1=CC=CC=C1 YHQGVYHKJAOGNM-UHFFFAOYSA-N 0.000 description 1
- YHIWIALKFQAHTA-UHFFFAOYSA-N [1-methyl-3-(2-methylphenyl)indol-5-yl]methanol Chemical compound CC1=CC=CC=C1C1=CN(C)C2=CC=C(CO)C=C12 YHIWIALKFQAHTA-UHFFFAOYSA-N 0.000 description 1
- AGJAJJAJFOKTPB-UHFFFAOYSA-N [1-methyl-3-(2-methylpropyl)indazol-5-yl]methanol Chemical compound C1=C(CO)C=C2C(CC(C)C)=NN(C)C2=C1 AGJAJJAJFOKTPB-UHFFFAOYSA-N 0.000 description 1
- KIAOUOOOMNBPIA-UHFFFAOYSA-N [1-propan-2-yl-3-(pyrazol-1-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C=C2N(C(C)C)N=C1CN1C=CC=N1 KIAOUOOOMNBPIA-UHFFFAOYSA-N 0.000 description 1
- JMAPSEOVGUEORV-UHFFFAOYSA-N [2-(2-ethoxyethyl)indazol-5-yl]methanol Chemical compound C1=C(CO)C=CC2=NN(CCOCC)C=C21 JMAPSEOVGUEORV-UHFFFAOYSA-N 0.000 description 1
- DDDNHRDOUFNVLD-UHFFFAOYSA-N [2-(2-methylpropyl)-1,3-dihydroindazol-6-yl]methanol Chemical compound C1=C(CO)C=C2NN(CC(C)C)CC2=C1 DDDNHRDOUFNVLD-UHFFFAOYSA-N 0.000 description 1
- DXBVSWPXYYSRSG-UHFFFAOYSA-N [2-(oxolan-3-ylmethyl)indazol-5-yl]methanol Chemical compound C1=C2C=C(CO)C=CC2=NN1CC1CCOC1 DXBVSWPXYYSRSG-UHFFFAOYSA-N 0.000 description 1
- MESTWPGZQRWNLO-UHFFFAOYSA-N [2-(pyridin-3-ylmethyl)indazol-6-yl]methanol Chemical compound N1=C2C=C(CO)C=CC2=CN1CC1=CC=CN=C1 MESTWPGZQRWNLO-UHFFFAOYSA-N 0.000 description 1
- XYGVUDUEPAUMQZ-UHFFFAOYSA-N [2-(pyrimidin-2-ylmethyl)indazol-6-yl]methanol Chemical compound N1=C2C=C(CO)C=CC2=CN1CC1=NC=CC=N1 XYGVUDUEPAUMQZ-UHFFFAOYSA-N 0.000 description 1
- JFMFRBHUMABKNJ-UHFFFAOYSA-N [2-(pyrimidin-4-ylmethyl)indazol-6-yl]methanol Chemical compound N1=C2C=C(CO)C=CC2=CN1CC1=CC=NC=N1 JFMFRBHUMABKNJ-UHFFFAOYSA-N 0.000 description 1
- LANLTXBJNYUANU-UHFFFAOYSA-N [2-[(4-fluorophenyl)methyl]indazol-4-yl]methanol Chemical compound C1=C2C(CO)=CC=CC2=NN1CC1=CC=C(F)C=C1 LANLTXBJNYUANU-UHFFFAOYSA-N 0.000 description 1
- BWWWLCIZKDDEJG-UHFFFAOYSA-N [2-[(4-fluorophenyl)methyl]indazol-6-yl]methanol Chemical compound N1=C2C=C(CO)C=CC2=CN1CC1=CC=C(F)C=C1 BWWWLCIZKDDEJG-UHFFFAOYSA-N 0.000 description 1
- JSDKTKYJXASHQX-UHFFFAOYSA-N [2-[(5-methylpyrazin-2-yl)methyl]indazol-4-yl]methanol Chemical compound C1=NC(C)=CN=C1CN1N=C2C=CC=C(CO)C2=C1 JSDKTKYJXASHQX-UHFFFAOYSA-N 0.000 description 1
- TWWZLYQICVQJMD-UHFFFAOYSA-N [2-[(5-methylpyrazin-2-yl)methyl]indazol-6-yl]methanol Chemical compound C1=NC(C)=CN=C1CN1N=C2C=C(CO)C=CC2=C1 TWWZLYQICVQJMD-UHFFFAOYSA-N 0.000 description 1
- BWVBBPMPKRQQTQ-UHFFFAOYSA-N [3,7-dimethyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C(C)=C2N(CC(C)C)N=C(C)C2=C1 BWVBBPMPKRQQTQ-UHFFFAOYSA-N 0.000 description 1
- ZKJQSXKXJZIRRV-UHFFFAOYSA-N [3-(2-methylpropyl)-1,2-benzoxazol-5-yl]methanol Chemical compound C1=C(CO)C=C2C(CC(C)C)=NOC2=C1 ZKJQSXKXJZIRRV-UHFFFAOYSA-N 0.000 description 1
- CXYKQCYDLZUPBP-UHFFFAOYSA-N [3-(2-methylpropyl)benzotriazol-4-yl]methanol Chemical compound C1=CC(CO)=C2N(CC(C)C)N=NC2=C1 CXYKQCYDLZUPBP-UHFFFAOYSA-N 0.000 description 1
- KQWXVCBUYABEEV-UHFFFAOYSA-N [3-(ethoxymethyl)-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound OCC1=CC=C2C(COCC)=NN(CC(C)C)C2=C1 KQWXVCBUYABEEV-UHFFFAOYSA-N 0.000 description 1
- ARIDQAZOVFFLLF-UHFFFAOYSA-N [3-(fluoromethyl)-7-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C(C)=C2N(CC(C)C)N=C(CF)C2=C1 ARIDQAZOVFFLLF-UHFFFAOYSA-N 0.000 description 1
- ZTXNBQDYUFGDSE-UHFFFAOYSA-N [3-(methoxymethyl)-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound OCC1=CC=C2C(COC)=NN(CC(C)C)C2=C1 ZTXNBQDYUFGDSE-UHFFFAOYSA-N 0.000 description 1
- HGQWYYCBMBXCTH-UHFFFAOYSA-N [3-(methoxymethyl)-7-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound OCC1=CC=C2C(COC)=NN(CC(C)C)C2=C1C HGQWYYCBMBXCTH-UHFFFAOYSA-N 0.000 description 1
- NUMAHDSGJXUMND-UHFFFAOYSA-N [3-(methylsulfonylmethyl)phenyl]methyl methanesulfonate Chemical compound CS(=O)(=O)CC1=CC=CC(COS(C)(=O)=O)=C1 NUMAHDSGJXUMND-UHFFFAOYSA-N 0.000 description 1
- NMHTZKWXSKNRCK-UHFFFAOYSA-N [3-[(3,3-difluoro-2,4-dihydropyridin-1-yl)methyl]-7-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1CC(F)(F)CC=C1 NMHTZKWXSKNRCK-UHFFFAOYSA-N 0.000 description 1
- ZOLFQJYEKJMWIJ-UHFFFAOYSA-N [3-[(3,3-difluoropiperidin-1-yl)methyl]-1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methanol Chemical compound C12=CC=C(CO)N=C2N(CC(C)C)C=C1CN1CCCC(F)(F)C1 ZOLFQJYEKJMWIJ-UHFFFAOYSA-N 0.000 description 1
- NGDGGJQVRNBMQM-UHFFFAOYSA-N [3-[(3,3-difluoropiperidin-1-yl)methyl]-7-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1CCCC(F)(F)C1 NGDGGJQVRNBMQM-UHFFFAOYSA-N 0.000 description 1
- VNLRKSCYOWDBFL-UHFFFAOYSA-N [3-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-6-yl]methanol Chemical compound C12=CC=C(CO)N=C2N(CC(C)C)C=C1CN1CCC(F)(F)C1 VNLRKSCYOWDBFL-UHFFFAOYSA-N 0.000 description 1
- DOIRIWLYGGIPKF-HNNXBMFYSA-N [3-[[(3s)-3-fluoropyrrolidin-1-yl]methyl]-7-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1CC[C@H](F)C1 DOIRIWLYGGIPKF-HNNXBMFYSA-N 0.000 description 1
- SWRJYZLSCGLIIA-UHFFFAOYSA-N [3-chloro-1-(2-methylpropyl)indazol-4-yl]methanol Chemical compound C1=CC=C2N(CC(C)C)N=C(Cl)C2=C1CO SWRJYZLSCGLIIA-UHFFFAOYSA-N 0.000 description 1
- FWKYQZMGRNQSTI-UHFFFAOYSA-N [3-chloro-1-(4-fluoro-2-methylphenyl)indol-6-yl]methanol Chemical compound CC1=CC(F)=CC=C1N1C2=CC(CO)=CC=C2C(Cl)=C1 FWKYQZMGRNQSTI-UHFFFAOYSA-N 0.000 description 1
- IWIZZFXUKLAMLN-UHFFFAOYSA-N [3-fluoro-1-(2-methylpropyl)indazol-4-yl]methanol Chemical compound C1=CC=C2N(CC(C)C)N=C(F)C2=C1CO IWIZZFXUKLAMLN-UHFFFAOYSA-N 0.000 description 1
- YPSMGRHFGCXFGA-UHFFFAOYSA-N [3-fluoro-1-(2-methylpropyl)pyrrolo[2,3-b]pyridin-4-yl]methanol Chemical compound C1=CN=C2N(CC(C)C)C=C(F)C2=C1CO YPSMGRHFGCXFGA-UHFFFAOYSA-N 0.000 description 1
- IAVRHNRKZCTPFJ-UHFFFAOYSA-N [3-fluoro-7-methyl-1-(2-methylpropyl)indazol-4-yl]methanol Chemical compound C1=CC(C)=C2N(CC(C)C)N=C(F)C2=C1CO IAVRHNRKZCTPFJ-UHFFFAOYSA-N 0.000 description 1
- VPSVRSJDDFIDLC-UHFFFAOYSA-N [3-methyl-1-(2-methylpropyl)indazol-5-yl]methanol Chemical compound OCC1=CC=C2N(CC(C)C)N=C(C)C2=C1 VPSVRSJDDFIDLC-UHFFFAOYSA-N 0.000 description 1
- SSRMQGDVNUVBIJ-UHFFFAOYSA-N [3-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C=C2N(CC(C)C)N=C(C)C2=C1 SSRMQGDVNUVBIJ-UHFFFAOYSA-N 0.000 description 1
- TWDPPYZQKOXOCI-UHFFFAOYSA-N [3-methyl-2-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C=CC2=C(C)N(CC(C)C)N=C21 TWDPPYZQKOXOCI-UHFFFAOYSA-N 0.000 description 1
- LZSCTJVVGILHOT-UHFFFAOYSA-N [4-(methylsulfonylmethyl)phenyl]methyl methanesulfonate Chemical compound CS(=O)(=O)CC1=CC=C(COS(C)(=O)=O)C=C1 LZSCTJVVGILHOT-UHFFFAOYSA-N 0.000 description 1
- VUKPMFHZLJRIOU-UHFFFAOYSA-N [5-fluoro-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound FC1=C(CO)C=C2N(CC(C)C)N=CC2=C1 VUKPMFHZLJRIOU-UHFFFAOYSA-N 0.000 description 1
- MORZHWBJLIUMGC-UHFFFAOYSA-N [5-fluoro-1-(4-fluoro-2-methylphenyl)indol-6-yl]methanol Chemical compound CC1=CC(F)=CC=C1N1C2=CC(CO)=C(F)C=C2C=C1 MORZHWBJLIUMGC-UHFFFAOYSA-N 0.000 description 1
- NUFDHWNHEZWBJT-UHFFFAOYSA-N [6-methyl-1-(2-methylpropyl)indazol-5-yl]methanol Chemical compound OCC1=C(C)C=C2N(CC(C)C)N=CC2=C1 NUFDHWNHEZWBJT-UHFFFAOYSA-N 0.000 description 1
- WHGIBWGVRUBRCY-UHFFFAOYSA-N [7-chloro-1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(Cl)=C2N(CC(C)C)N=C1CN1CCOCC1 WHGIBWGVRUBRCY-UHFFFAOYSA-N 0.000 description 1
- YZWZIHZKLVLNIB-UHFFFAOYSA-N [7-methyl-1-(1,3-thiazol-4-ylmethyl)indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CSC=N1 YZWZIHZKLVLNIB-UHFFFAOYSA-N 0.000 description 1
- QVYUIWGVFZTHGG-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1CCOCC1 QVYUIWGVFZTHGG-UHFFFAOYSA-N 0.000 description 1
- KHSSPFJXIJNJTL-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)-3-(piperidin-1-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1CCCCC1 KHSSPFJXIJNJTL-UHFFFAOYSA-N 0.000 description 1
- NNTKYQVZZQXJFC-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)-3-(pyrazol-1-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1C=CC=N1 NNTKYQVZZQXJFC-UHFFFAOYSA-N 0.000 description 1
- UWAJWKNLTCDARC-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)-3-(pyrrolidin-1-ylmethyl)indazol-6-yl]methanol Chemical compound C12=CC=C(CO)C(C)=C2N(CC(C)C)N=C1CN1CCCC1 UWAJWKNLTCDARC-UHFFFAOYSA-N 0.000 description 1
- OHQHVRASBYELKE-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)indazol-4-yl]methanol Chemical compound C1=CC(C)=C2N(CC(C)C)N=CC2=C1CO OHQHVRASBYELKE-UHFFFAOYSA-N 0.000 description 1
- FHRYMEREPLNJOE-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)indazol-5-yl]methanol Chemical compound OCC1=CC(C)=C2N(CC(C)C)N=CC2=C1 FHRYMEREPLNJOE-UHFFFAOYSA-N 0.000 description 1
- JLJCTIGVGLYSDE-UHFFFAOYSA-N [7-methyl-1-(2-methylpropyl)indazol-6-yl]methanol Chemical compound C1=C(CO)C(C)=C2N(CC(C)C)N=CC2=C1 JLJCTIGVGLYSDE-UHFFFAOYSA-N 0.000 description 1
- OFHLHTHFVPXXJM-UHFFFAOYSA-N [7-methyl-1-(pyrazin-2-ylmethyl)indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CN=CC=N1 OFHLHTHFVPXXJM-UHFFFAOYSA-N 0.000 description 1
- RLVZMBXHZWTZBD-UHFFFAOYSA-N [7-methyl-1-(pyridin-3-ylmethyl)indazol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=NN1CC1=CC=CN=C1 RLVZMBXHZWTZBD-UHFFFAOYSA-N 0.000 description 1
- KXMAEIIMXMMQQQ-UHFFFAOYSA-N [7-methyl-1-(pyrimidin-2-ylmethyl)indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=NC=CC=N1 KXMAEIIMXMMQQQ-UHFFFAOYSA-N 0.000 description 1
- AJHDZYNJAGDMMD-UHFFFAOYSA-N [7-methyl-1-(pyrimidin-4-ylmethyl)indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=NC=N1 AJHDZYNJAGDMMD-UHFFFAOYSA-N 0.000 description 1
- HKVKUMPYTYARMC-UHFFFAOYSA-N [7-methyl-1-[(1-methylpyrazol-4-yl)methyl]indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC=1C=NN(C)C=1 HKVKUMPYTYARMC-UHFFFAOYSA-N 0.000 description 1
- TUXDTWYFSWDLRB-UHFFFAOYSA-N [7-methyl-1-[(2-methyl-1,3-thiazol-4-yl)methyl]indol-6-yl]methanol Chemical compound S1C(C)=NC(CN2C3=C(C)C(CO)=CC=C3C=C2)=C1 TUXDTWYFSWDLRB-UHFFFAOYSA-N 0.000 description 1
- GMHKBLLACJKRPT-UHFFFAOYSA-N [7-methyl-1-[(2-methylphenyl)methyl]indol-6-yl]methanol Chemical compound CC1=CC=CC=C1CN1C2=C(C)C(CO)=CC=C2C=C1 GMHKBLLACJKRPT-UHFFFAOYSA-N 0.000 description 1
- INBHYIYMFBUXKI-UHFFFAOYSA-N [7-methyl-1-[(4-methylsulfonylphenyl)methyl]indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(S(C)(=O)=O)C=C1 INBHYIYMFBUXKI-UHFFFAOYSA-N 0.000 description 1
- NQSSKWGVZHOKJG-UHFFFAOYSA-N [7-methyl-1-[(5-methylpyrazin-2-yl)methyl]indol-6-yl]methanol Chemical compound C1=NC(C)=CN=C1CN1C2=C(C)C(CO)=CC=C2C=C1 NQSSKWGVZHOKJG-UHFFFAOYSA-N 0.000 description 1
- BBLRXXWTMLETPW-UHFFFAOYSA-N [7-methyl-1-[(6-methylpyridin-3-yl)methyl]indol-6-yl]methanol Chemical compound C1=NC(C)=CC=C1CN1C2=C(C)C(CO)=CC=C2C=C1 BBLRXXWTMLETPW-UHFFFAOYSA-N 0.000 description 1
- ZZVDXFWGPOPTHZ-UHFFFAOYSA-N [7-methyl-1-[[3-(methylsulfonylmethyl)phenyl]methyl]indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=CC(CS(C)(=O)=O)=C1 ZZVDXFWGPOPTHZ-UHFFFAOYSA-N 0.000 description 1
- OXNBGTWDPMZLHG-UHFFFAOYSA-N [7-methyl-1-[[3-(trifluoromethyl)phenyl]methyl]indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=CC(C(F)(F)F)=C1 OXNBGTWDPMZLHG-UHFFFAOYSA-N 0.000 description 1
- ZPBHIRXRXDZQSV-UHFFFAOYSA-N [7-methyl-1-[[4-(methylsulfonylmethyl)phenyl]methyl]indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(CS(C)(=O)=O)C=C1 ZPBHIRXRXDZQSV-UHFFFAOYSA-N 0.000 description 1
- LNUYQIBYNILONI-UHFFFAOYSA-N [7-methyl-1-[[4-(trifluoromethyl)phenyl]methyl]indol-6-yl]methanol Chemical compound C1=2C(C)=C(CO)C=CC=2C=CN1CC1=CC=C(C(F)(F)F)C=C1 LNUYQIBYNILONI-UHFFFAOYSA-N 0.000 description 1
- LTUGXOBFEGLVQM-UHFFFAOYSA-N [7-methyl-2-(2-methylpropyl)indazol-5-yl]methanol Chemical compound C1=C(CO)C=C(C)C2=NN(CC(C)C)C=C21 LTUGXOBFEGLVQM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- DOIIQEWBHKGFRM-DTQAZKPQSA-N benzyl (e)-3-(4-phenylmethoxyphenyl)prop-2-enoate Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1/C=C/C(=O)OCC1=CC=CC=C1 DOIIQEWBHKGFRM-DTQAZKPQSA-N 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- ZVTQWXCKQTUVPY-UHFFFAOYSA-N chloromethylcyclopropane Chemical compound ClCC1CC1 ZVTQWXCKQTUVPY-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- KAQVFEITQMBSEF-UHFFFAOYSA-N cyclopentyl methanesulfonate Chemical compound CS(=O)(=O)OC1CCCC1 KAQVFEITQMBSEF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZIUFSWWLZLUAND-UHFFFAOYSA-N ethyl 3-(2-fluoro-4-hydroxyphenyl)propanoate Chemical compound CCOC(=O)CCC1=CC=C(O)C=C1F ZIUFSWWLZLUAND-UHFFFAOYSA-N 0.000 description 1
- LKGOWIGLGONACY-UHFFFAOYSA-N ethyl 3-(4-hydroxyphenyl)-3-methoxypropanoate Chemical compound CCOC(=O)CC(OC)C1=CC=C(O)C=C1 LKGOWIGLGONACY-UHFFFAOYSA-N 0.000 description 1
- VRDBGARLKWLHGR-UHFFFAOYSA-N ethyl 3-(4-hydroxyphenyl)butanoate Chemical compound CCOC(=O)CC(C)C1=CC=C(O)C=C1 VRDBGARLKWLHGR-UHFFFAOYSA-N 0.000 description 1
- HZICKANDXKPTFR-UHFFFAOYSA-N ethyl 3-(4-hydroxyphenyl)pentanoate Chemical compound CCOC(=O)CC(CC)C1=CC=C(O)C=C1 HZICKANDXKPTFR-UHFFFAOYSA-N 0.000 description 1
- MHZPUKGGQIJCSJ-UHFFFAOYSA-N ethyl 3-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-3-hydroxypropanoate Chemical compound CCOC(=O)CC(O)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1 MHZPUKGGQIJCSJ-UHFFFAOYSA-N 0.000 description 1
- LRLLEYPUJOAQTK-UHFFFAOYSA-N ethyl 3-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-3-methoxypropanoate Chemical compound CCOC(=O)CC(OC)C1=CC=C(O[Si](C)(C)C(C)(C)C)C=C1 LRLLEYPUJOAQTK-UHFFFAOYSA-N 0.000 description 1
- AGSFEKWJKOEUMJ-UHFFFAOYSA-N ethyl 3-cyano-3-(4-hydroxyphenyl)propanoate Chemical compound CCOC(=O)CC(C#N)C1=CC=C(O)C=C1 AGSFEKWJKOEUMJ-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- DQDWATOXYCARFV-UHFFFAOYSA-M magnesium;2-methanidylpropane;bromide Chemical compound [Mg+2].[Br-].CC(C)[CH2-] DQDWATOXYCARFV-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- WFNAYWFFBCAJDN-NSHDSACASA-N methyl (3s)-3-(4-hydroxyphenyl)-3-(1,2-oxazol-3-yl)propanoate Chemical compound C=1([C@@H](CC(=O)OC)C=2C=CC(O)=CC=2)C=CON=1 WFNAYWFFBCAJDN-NSHDSACASA-N 0.000 description 1
- BENPHURJTUUUSX-NSHDSACASA-N methyl (3s)-3-(4-hydroxyphenyl)hex-4-ynoate Chemical compound COC(=O)C[C@H](C#CC)C1=CC=C(O)C=C1 BENPHURJTUUUSX-NSHDSACASA-N 0.000 description 1
- GKUIXLGJSUWCRB-UHFFFAOYSA-N methyl 1-(2-methylpropyl)indazole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=NN(CC(C)C)C2=C1 GKUIXLGJSUWCRB-UHFFFAOYSA-N 0.000 description 1
- LLBCODWWNGRUSL-UHFFFAOYSA-N methyl 1-(2-methylpropyl)pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC2=C1C=CN2CC(C)C LLBCODWWNGRUSL-UHFFFAOYSA-N 0.000 description 1
- WISOZBQPTHXZNE-UHFFFAOYSA-N methyl 1-(4-fluoro-2-methylphenyl)indole-4-carboxylate Chemical compound C1=CC=2C(C(=O)OC)=CC=CC=2N1C1=CC=C(F)C=C1C WISOZBQPTHXZNE-UHFFFAOYSA-N 0.000 description 1
- BISQABQEUHYCIS-UHFFFAOYSA-N methyl 1-(4-fluoro-2-methylphenyl)indole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C=CN1C1=CC=C(F)C=C1C BISQABQEUHYCIS-UHFFFAOYSA-N 0.000 description 1
- AQZPPBHXMQSJPW-UHFFFAOYSA-N methyl 1-(cyclohexylmethyl)indole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C=CN1CC1CCCCC1 AQZPPBHXMQSJPW-UHFFFAOYSA-N 0.000 description 1
- DYDUCGWFSBYSOM-UHFFFAOYSA-N methyl 1-(cyclopropylmethyl)indazole-4-carboxylate Chemical compound N1=CC=2C(C(=O)OC)=CC=CC=2N1CC1CC1 DYDUCGWFSBYSOM-UHFFFAOYSA-N 0.000 description 1
- ASMGTGUPOOYAIR-UHFFFAOYSA-N methyl 1-[(2,6-dimethylphenyl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=C(C)C=CC=C1C ASMGTGUPOOYAIR-UHFFFAOYSA-N 0.000 description 1
- OPNAGWUUCQBLNV-UHFFFAOYSA-N methyl 1-[(2-chlorophenyl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC=C1Cl OPNAGWUUCQBLNV-UHFFFAOYSA-N 0.000 description 1
- ZLUPOPXDDCHVAC-UHFFFAOYSA-N methyl 1-[(2-fluorophenyl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC=C1F ZLUPOPXDDCHVAC-UHFFFAOYSA-N 0.000 description 1
- YUFOLCBZMWFKPC-UHFFFAOYSA-N methyl 1-[(3,4-difluorophenyl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=C(F)C(F)=C1 YUFOLCBZMWFKPC-UHFFFAOYSA-N 0.000 description 1
- SUNAXBYNGQKFKN-UHFFFAOYSA-N methyl 1-[(3-fluorophenyl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC(F)=C1 SUNAXBYNGQKFKN-UHFFFAOYSA-N 0.000 description 1
- INHABKCESHCIMN-UHFFFAOYSA-N methyl 1-[(4-fluorophenyl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=C(F)C=C1 INHABKCESHCIMN-UHFFFAOYSA-N 0.000 description 1
- VLMKARWPQUGDOF-UHFFFAOYSA-N methyl 1-[(4-fluorophenyl)methyl]indazole-4-carboxylate Chemical compound N1=CC=2C(C(=O)OC)=CC=CC=2N1CC1=CC=C(F)C=C1 VLMKARWPQUGDOF-UHFFFAOYSA-N 0.000 description 1
- XEKOTMAXYUJMBU-UHFFFAOYSA-N methyl 1-[(5-methylpyrazin-2-yl)methyl]indazole-4-carboxylate Chemical compound N1=CC=2C(C(=O)OC)=CC=CC=2N1CC1=CN=C(C)C=N1 XEKOTMAXYUJMBU-UHFFFAOYSA-N 0.000 description 1
- LQIIHBNRFGNILC-UHFFFAOYSA-N methyl 1-[(6-chloropyridin-3-yl)methyl]-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=C(Cl)N=C1 LQIIHBNRFGNILC-UHFFFAOYSA-N 0.000 description 1
- HBGQFCKGJFYFGI-UHFFFAOYSA-N methyl 1-[(6-methylpyridin-3-yl)methyl]indazole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C=NN1CC1=CC=C(C)N=C1 HBGQFCKGJFYFGI-UHFFFAOYSA-N 0.000 description 1
- BDCFTZQPWIHMCI-UHFFFAOYSA-N methyl 1-[[3-(2-tert-butylsilyloxypropan-2-yl)phenyl]methyl]-7-methylindole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CN(C2=C1C)CC1=CC(=CC=C1)C(O[SiH2]C(C)(C)C)(C)C BDCFTZQPWIHMCI-UHFFFAOYSA-N 0.000 description 1
- JOQNTCFAZZFVFL-UHFFFAOYSA-N methyl 1-[[3-(methoxymethyl)phenyl]methyl]-7-methylindole-6-carboxylate Chemical compound COCC1=CC=CC(CN2C3=C(C)C(C(=O)OC)=CC=C3C=C2)=C1 JOQNTCFAZZFVFL-UHFFFAOYSA-N 0.000 description 1
- VYAKGJFJEKSHRC-UHFFFAOYSA-N methyl 1-acetyl-5-fluoroindazole-6-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1C=NN2C(C)=O VYAKGJFJEKSHRC-UHFFFAOYSA-N 0.000 description 1
- ZKORETWXBVNAMC-UHFFFAOYSA-N methyl 1-benzyl-2-(2-hydroxyethyl)indole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C=C(CCO)N1CC1=CC=CC=C1 ZKORETWXBVNAMC-UHFFFAOYSA-N 0.000 description 1
- HADFXDJAGUYECL-UHFFFAOYSA-N methyl 1-benzyl-2-(2-methoxyethyl)indole-6-carboxylate Chemical compound COCCC1=CC2=CC=C(C(=O)OC)C=C2N1CC1=CC=CC=C1 HADFXDJAGUYECL-UHFFFAOYSA-N 0.000 description 1
- BBXKODVWDCXFFT-UHFFFAOYSA-N methyl 1-benzyl-2-[2-(oxan-2-yloxy)ethyl]indole-6-carboxylate Chemical compound C=1C=CC=CC=1CN1C2=CC(C(=O)OC)=CC=C2C=C1CCOC1CCCCO1 BBXKODVWDCXFFT-UHFFFAOYSA-N 0.000 description 1
- SQZHYOUVAHDLSH-UHFFFAOYSA-N methyl 1-benzyl-2-oxo-3h-benzimidazole-5-carboxylate Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2N1CC1=CC=CC=C1 SQZHYOUVAHDLSH-UHFFFAOYSA-N 0.000 description 1
- UXFCCKNUFDYSPK-UHFFFAOYSA-N methyl 1-benzyl-3-fluoro-7-methylindole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C(F)=CN1CC1=CC=CC=C1 UXFCCKNUFDYSPK-UHFFFAOYSA-N 0.000 description 1
- OVEMEDCOEJJPEI-UHFFFAOYSA-N methyl 1-benzyl-5-fluoroindole-6-carboxylate Chemical compound C1=CC=2C=C(F)C(C(=O)OC)=CC=2N1CC1=CC=CC=C1 OVEMEDCOEJJPEI-UHFFFAOYSA-N 0.000 description 1
- PSGUPDKAIXCSSE-UHFFFAOYSA-N methyl 1-benzyl-7-chloroindole-6-carboxylate Chemical compound C12=C(Cl)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC=C1 PSGUPDKAIXCSSE-UHFFFAOYSA-N 0.000 description 1
- WUPVMGHYFHRSTG-UHFFFAOYSA-N methyl 1-benzylbenzimidazole-5-carboxylate Chemical compound C1=NC2=CC(C(=O)OC)=CC=C2N1CC1=CC=CC=C1 WUPVMGHYFHRSTG-UHFFFAOYSA-N 0.000 description 1
- ARTRMRWKXFPTDV-UHFFFAOYSA-N methyl 1-benzylbenzotriazole-5-carboxylate Chemical compound N1=NC2=CC(C(=O)OC)=CC=C2N1CC1=CC=CC=C1 ARTRMRWKXFPTDV-UHFFFAOYSA-N 0.000 description 1
- RTXWJLKCTSAVSF-UHFFFAOYSA-N methyl 1-benzylindazole-4-carboxylate Chemical compound N1=CC=2C(C(=O)OC)=CC=CC=2N1CC1=CC=CC=C1 RTXWJLKCTSAVSF-UHFFFAOYSA-N 0.000 description 1
- RXUWNHHXPPKCCH-UHFFFAOYSA-N methyl 1-benzylindole-4-carboxylate Chemical compound C1=CC=2C(C(=O)OC)=CC=CC=2N1CC1=CC=CC=C1 RXUWNHHXPPKCCH-UHFFFAOYSA-N 0.000 description 1
- FNCZJEGDCTVTQS-UHFFFAOYSA-N methyl 1-butylindazole-4-carboxylate Chemical compound C1=CC=C2N(CCCC)N=CC2=C1C(=O)OC FNCZJEGDCTVTQS-UHFFFAOYSA-N 0.000 description 1
- ZBPQEOBGXUUEIA-UHFFFAOYSA-N methyl 1-methyl-3-(2-methylphenyl)indole-5-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2N(C)C=C1C1=CC=CC=C1C ZBPQEOBGXUUEIA-UHFFFAOYSA-N 0.000 description 1
- JNDWZIOXLKLJOJ-UHFFFAOYSA-N methyl 1-methyl-3-(2-methylpropyl)indazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1N(C)N=C2CC(C)C JNDWZIOXLKLJOJ-UHFFFAOYSA-N 0.000 description 1
- QDEOKAXIASJVKC-UHFFFAOYSA-N methyl 1-methyl-3-propan-2-ylindazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1N(C)N=C2C(C)C QDEOKAXIASJVKC-UHFFFAOYSA-N 0.000 description 1
- AGVBMLRHAQQJKU-UHFFFAOYSA-N methyl 1-methyl-3-propylindazole-7-carboxylate Chemical compound C1=CC=C2C(CCC)=NN(C)C2=C1C(=O)OC AGVBMLRHAQQJKU-UHFFFAOYSA-N 0.000 description 1
- ARLZANUTGUOGEG-UHFFFAOYSA-N methyl 1-methylindazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1N(C)N=C2 ARLZANUTGUOGEG-UHFFFAOYSA-N 0.000 description 1
- VNQGOPQXKHYNEV-UHFFFAOYSA-N methyl 1-propan-2-ylindazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C=NN2C(C)C VNQGOPQXKHYNEV-UHFFFAOYSA-N 0.000 description 1
- WSSANOTXXUKYIK-UHFFFAOYSA-N methyl 1-thiophen-3-ylindole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C=CN1C=1C=CSC=1 WSSANOTXXUKYIK-UHFFFAOYSA-N 0.000 description 1
- NQPIEWBAWBFGOB-UHFFFAOYSA-N methyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC)=CC2=C1 NQPIEWBAWBFGOB-UHFFFAOYSA-N 0.000 description 1
- DRYBMFJLYYEOBZ-UHFFFAOYSA-N methyl 1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=CC2=C1 DRYBMFJLYYEOBZ-UHFFFAOYSA-N 0.000 description 1
- WAYSJYROSIMXRC-UHFFFAOYSA-N methyl 1h-pyrazolo[3,4-b]pyridine-5-carboxylate Chemical compound COC(=O)C1=CN=C2NN=CC2=C1 WAYSJYROSIMXRC-UHFFFAOYSA-N 0.000 description 1
- GSJRGIYKNVTGIW-UHFFFAOYSA-N methyl 2,3-dibenzyl-1-methylindole-5-carboxylate Chemical compound C=1C=CC=CC=1CC=1C2=CC(C(=O)OC)=CC=C2N(C)C=1CC1=CC=CC=C1 GSJRGIYKNVTGIW-UHFFFAOYSA-N 0.000 description 1
- LVLOTHPBAVEMMA-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)cyclopropane-1-carboxylate Chemical compound COC(=O)C1CC1C1=CC=C(O)C=C1 LVLOTHPBAVEMMA-UHFFFAOYSA-N 0.000 description 1
- NQOXEXXDMBLLTO-UHFFFAOYSA-N methyl 2-(5-hydroxy-2,3-dihydro-1h-inden-1-yl)acetate Chemical compound OC1=CC=C2C(CC(=O)OC)CCC2=C1 NQOXEXXDMBLLTO-UHFFFAOYSA-N 0.000 description 1
- QPGZNOAHPLNNPC-UHFFFAOYSA-N methyl 2-(6-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)acetate Chemical compound OC1=CC=C2C(CC(=O)OC)CCCC2=C1 QPGZNOAHPLNNPC-UHFFFAOYSA-N 0.000 description 1
- VFGINLCKFJAUPR-UHFFFAOYSA-N methyl 2-(7-hydroxy-3,4-dihydro-2h-chromen-4-yl)acetate Chemical compound OC1=CC=C2C(CC(=O)OC)CCOC2=C1 VFGINLCKFJAUPR-UHFFFAOYSA-N 0.000 description 1
- SIFVGVVIEPYDIG-UHFFFAOYSA-N methyl 2-[(4-fluorophenyl)methyl]indazole-4-carboxylate Chemical compound C1=C2C(C(=O)OC)=CC=CC2=NN1CC1=CC=C(F)C=C1 SIFVGVVIEPYDIG-UHFFFAOYSA-N 0.000 description 1
- WCHMHZGOYBHXQD-UHFFFAOYSA-N methyl 2-[(5-methylpyrazin-2-yl)methyl]indazole-4-carboxylate Chemical compound C1=C2C(C(=O)OC)=CC=CC2=NN1CC1=CN=C(C)C=N1 WCHMHZGOYBHXQD-UHFFFAOYSA-N 0.000 description 1
- BDAUOQDELOZGLF-UHFFFAOYSA-N methyl 2-[2-(oxan-2-yloxy)ethyl]-1h-indole-6-carboxylate Chemical compound N1C2=CC(C(=O)OC)=CC=C2C=C1CCOC1CCCCO1 BDAUOQDELOZGLF-UHFFFAOYSA-N 0.000 description 1
- VSFYTPXXMLJNAU-UHFFFAOYSA-N methyl 2-amino-3-methylbenzoate Chemical compound COC(=O)C1=CC=CC(C)=C1N VSFYTPXXMLJNAU-UHFFFAOYSA-N 0.000 description 1
- BWLLCIJEGJOSIN-UHFFFAOYSA-N methyl 2-benzylindazole-4-carboxylate Chemical compound C1=C2C(C(=O)OC)=CC=CC2=NN1CC1=CC=CC=C1 BWLLCIJEGJOSIN-UHFFFAOYSA-N 0.000 description 1
- GBECACDDVVYBHV-UHFFFAOYSA-N methyl 2-fluoro-4-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(C)C=C1F GBECACDDVVYBHV-UHFFFAOYSA-N 0.000 description 1
- IQUHJQRBKOPNQC-UHFFFAOYSA-N methyl 3,5-dimethyl-4-nitrobenzoate Chemical compound COC(=O)C1=CC(C)=C([N+]([O-])=O)C(C)=C1 IQUHJQRBKOPNQC-UHFFFAOYSA-N 0.000 description 1
- YBZHSHCFTUGTEF-UHFFFAOYSA-N methyl 3,7-dimethyl-2h-indazole-6-carboxylate Chemical compound CC1=C(C(=O)OC)C=CC2=C(C)NN=C21 YBZHSHCFTUGTEF-UHFFFAOYSA-N 0.000 description 1
- HBLHODDRGSIYJL-UHFFFAOYSA-N methyl 3-(2-methylpropyl)benzotriazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N=NN(CC(C)C)C2=C1 HBLHODDRGSIYJL-UHFFFAOYSA-N 0.000 description 1
- ZNZSOQNMSUOMFY-UHFFFAOYSA-N methyl 3-(4,5-dihydro-1,2-oxazol-3-yl)-3-(4-hydroxyphenyl)propanoate Chemical compound C=1C=C(O)C=CC=1C(CC(=O)OC)C1=NOCC1 ZNZSOQNMSUOMFY-UHFFFAOYSA-N 0.000 description 1
- HEDCOGYMHHXEMP-UHFFFAOYSA-N methyl 3-(bromomethyl)-1-propan-2-ylindazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(CBr)=NN(C(C)C)C2=C1 HEDCOGYMHHXEMP-UHFFFAOYSA-N 0.000 description 1
- MLMFGFGQWLYAQF-UHFFFAOYSA-N methyl 3-(ethoxymethyl)-2h-indazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=C(COCC)NN=C21 MLMFGFGQWLYAQF-UHFFFAOYSA-N 0.000 description 1
- XYECCGJLLGBQQI-UHFFFAOYSA-N methyl 3-(fluoromethyl)-7-methyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(CF)=NN(CC(C)C)C2=C1C XYECCGJLLGBQQI-UHFFFAOYSA-N 0.000 description 1
- KNGHWKMDJFPHTP-UHFFFAOYSA-N methyl 3-(hydroxymethyl)-7-methyl-1-(2-methylpropyl)-2h-indazole-3-carboxylate Chemical compound C1=CC=C(C)C2=C1C(C(=O)OC)(CO)NN2CC(C)C KNGHWKMDJFPHTP-UHFFFAOYSA-N 0.000 description 1
- NGSFBPFLYHNEIC-UHFFFAOYSA-N methyl 3-(methoxymethyl)-2h-indazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=C(COC)NN=C21 NGSFBPFLYHNEIC-UHFFFAOYSA-N 0.000 description 1
- GIYQMVRWQXENGC-UHFFFAOYSA-N methyl 3-(methoxymethyl)-7-methyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(COC)=NN(CC(C)C)C2=C1C GIYQMVRWQXENGC-UHFFFAOYSA-N 0.000 description 1
- TVQCGTIBOJKHTL-UHFFFAOYSA-N methyl 3-(propan-2-yloxymethyl)-2h-indazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=C(COC(C)C)NN=C21 TVQCGTIBOJKHTL-UHFFFAOYSA-N 0.000 description 1
- TVLARZLESLYEOJ-UHFFFAOYSA-N methyl 3-[(3,3-difluoropiperidin-1-yl)methyl]-1-(2-methylpropyl)pyrrolo[2,3-b]pyridine-6-carboxylate Chemical compound C=1N(CC(C)C)C2=NC(C(=O)OC)=CC=C2C=1CN1CCCC(F)(F)C1 TVLARZLESLYEOJ-UHFFFAOYSA-N 0.000 description 1
- VIBYEHJPRZGRDG-UHFFFAOYSA-N methyl 3-[(3,3-difluoropiperidin-1-yl)methyl]-7-methyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1CCCC(F)(F)C1 VIBYEHJPRZGRDG-UHFFFAOYSA-N 0.000 description 1
- CIADEVCBXFWIGK-UHFFFAOYSA-N methyl 3-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-(2-methylpropyl)pyrrolo[2,3-b]pyridine-6-carboxylate Chemical compound C=1N(CC(C)C)C2=NC(C(=O)OC)=CC=C2C=1CN1CCC(F)(F)C1 CIADEVCBXFWIGK-UHFFFAOYSA-N 0.000 description 1
- FZFWOXIRJHWKJF-UHFFFAOYSA-N methyl 3-[(3,3-difluoropyrrolidin-1-yl)methyl]-7-methyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1CCC(F)(F)C1 FZFWOXIRJHWKJF-UHFFFAOYSA-N 0.000 description 1
- YHFQKSWNUANRGH-AWEZNQCLSA-N methyl 3-[[(3s)-3-fluoropyrrolidin-1-yl]methyl]-7-methyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1CC[C@H](F)C1 YHFQKSWNUANRGH-AWEZNQCLSA-N 0.000 description 1
- ADYSZCGUXDZDGN-UHFFFAOYSA-N methyl 3-amino-4-ethylbenzoate Chemical compound CCC1=CC=C(C(=O)OC)C=C1N ADYSZCGUXDZDGN-UHFFFAOYSA-N 0.000 description 1
- WJEBNIVVLJEIKE-UHFFFAOYSA-N methyl 3-amino-4-iodobenzoate Chemical compound COC(=O)C1=CC=C(I)C(N)=C1 WJEBNIVVLJEIKE-UHFFFAOYSA-N 0.000 description 1
- GCLVXDCQEQNQOG-UHFFFAOYSA-N methyl 3-amino-6-fluoro-2-methylbenzoate Chemical compound COC(=O)C1=C(C)C(N)=CC=C1F GCLVXDCQEQNQOG-UHFFFAOYSA-N 0.000 description 1
- ICNPJCNVCQFACF-UHFFFAOYSA-N methyl 3-benzyl-1-methylindole-5-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2N(C)C=C1CC1=CC=CC=C1 ICNPJCNVCQFACF-UHFFFAOYSA-N 0.000 description 1
- CLTUJPAFRJBYQR-UHFFFAOYSA-N methyl 3-bromo-1-methylindazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1N(C)N=C2Br CLTUJPAFRJBYQR-UHFFFAOYSA-N 0.000 description 1
- VPGHQTXRLNUGTM-UHFFFAOYSA-N methyl 3-bromo-1-methylindole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C)C=C(Br)C2=C1 VPGHQTXRLNUGTM-UHFFFAOYSA-N 0.000 description 1
- NNPWBNOSBWTJAJ-UHFFFAOYSA-N methyl 3-butyl-1-methylindazole-7-carboxylate Chemical compound C1=CC=C2C(CCCC)=NN(C)C2=C1C(=O)OC NNPWBNOSBWTJAJ-UHFFFAOYSA-N 0.000 description 1
- KYDGCGUTNXCFSC-UHFFFAOYSA-N methyl 3-chloro-1-(4-fluoro-2-methylphenyl)indole-6-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2C(Cl)=CN1C1=CC=C(F)C=C1C KYDGCGUTNXCFSC-UHFFFAOYSA-N 0.000 description 1
- MZZPKAPXWPCBDF-UHFFFAOYSA-N methyl 3-chloro-2h-indazole-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C(Cl)NN=C12 MZZPKAPXWPCBDF-UHFFFAOYSA-N 0.000 description 1
- DZEXWGIEVQJOLF-UHFFFAOYSA-N methyl 3-fluoro-1-(2-methylpropyl)indazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C(F)=NN2CC(C)C DZEXWGIEVQJOLF-UHFFFAOYSA-N 0.000 description 1
- LWEJYDASXLGZNC-UHFFFAOYSA-N methyl 3-fluoro-1-(2-methylpropyl)pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC2=C1C(F)=CN2CC(C)C LWEJYDASXLGZNC-UHFFFAOYSA-N 0.000 description 1
- WYMKAEDLJDYZFV-UHFFFAOYSA-N methyl 3-fluoro-1-propan-2-ylindazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C(F)=NN2C(C)C WYMKAEDLJDYZFV-UHFFFAOYSA-N 0.000 description 1
- JZONLIVJNYXNBG-UHFFFAOYSA-N methyl 3-formyl-1-(2-methylpropyl)pyrrolo[2,3-b]pyridine-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C=O)=CN(CC(C)C)C2=N1 JZONLIVJNYXNBG-UHFFFAOYSA-N 0.000 description 1
- ZVVUHTSEWDQOHC-UHFFFAOYSA-N methyl 3-formyl-1h-pyrrolo[2,3-b]pyridine-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C=O)=CNC2=N1 ZVVUHTSEWDQOHC-UHFFFAOYSA-N 0.000 description 1
- CDBSKNBUJHKNGF-UHFFFAOYSA-N methyl 3-formyl-2h-indazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=NNC(C=O)=C12 CDBSKNBUJHKNGF-UHFFFAOYSA-N 0.000 description 1
- SLIYCTAECMUSFJ-UHFFFAOYSA-N methyl 3-formyl-7-methyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C=O)=NN(CC(C)C)C2=C1C SLIYCTAECMUSFJ-UHFFFAOYSA-N 0.000 description 1
- QSNIBGRJIJDFMY-UHFFFAOYSA-N methyl 3-formyl-7-methyl-2h-indazole-6-carboxylate Chemical compound CC1=C(C(=O)OC)C=CC2=C(C=O)NN=C21 QSNIBGRJIJDFMY-UHFFFAOYSA-N 0.000 description 1
- FLANMXUHLXKUJP-UHFFFAOYSA-N methyl 3-methyl-1-propan-2-ylindazole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=NN(C2=CC1)C(C)C)C FLANMXUHLXKUJP-UHFFFAOYSA-N 0.000 description 1
- XVFLIJVBTLWDRP-UHFFFAOYSA-N methyl 3-methyl-1-propan-2-ylindazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C)=NN(C(C)C)C2=C1 XVFLIJVBTLWDRP-UHFFFAOYSA-N 0.000 description 1
- GTXVRIUISHNWMC-UHFFFAOYSA-N methyl 3-methyl-2h-indazole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1C(C)=NN2 GTXVRIUISHNWMC-UHFFFAOYSA-N 0.000 description 1
- ARSRTLJLMXSRPV-UHFFFAOYSA-N methyl 4-amino-3,5-dimethylbenzoate Chemical compound COC(=O)C1=CC(C)=C(N)C(C)=C1 ARSRTLJLMXSRPV-UHFFFAOYSA-N 0.000 description 1
- YAGPCEXMZGXMLN-UHFFFAOYSA-N methyl 4-ethyl-3-nitrobenzoate Chemical compound CCC1=CC=C(C(=O)OC)C=C1[N+]([O-])=O YAGPCEXMZGXMLN-UHFFFAOYSA-N 0.000 description 1
- JEGPFOWHUQYGMT-UHFFFAOYSA-N methyl 5-amino-2-fluoro-4-methylbenzoate Chemical compound COC(=O)C1=CC(N)=C(C)C=C1F JEGPFOWHUQYGMT-UHFFFAOYSA-N 0.000 description 1
- ZTOQQKWNYMVOFS-UHFFFAOYSA-N methyl 5-fluoro-1h-indazole-6-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1C=NN2 ZTOQQKWNYMVOFS-UHFFFAOYSA-N 0.000 description 1
- XGDODTXPAIMYNR-UHFFFAOYSA-N methyl 5-fluoro-1h-indole-6-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1C=CN2 XGDODTXPAIMYNR-UHFFFAOYSA-N 0.000 description 1
- PFDISZUFMYIFJO-UHFFFAOYSA-N methyl 5-fluoro-7-methyl-1h-indole-6-carboxylate Chemical compound COC(=O)C1=C(F)C=C2C=CNC2=C1C PFDISZUFMYIFJO-UHFFFAOYSA-N 0.000 description 1
- AHUSRDRRSOGNGS-UHFFFAOYSA-N methyl 7-chloro-1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(Cl)C(C(=O)OC)=CC=C2C=1CN1CCOCC1 AHUSRDRRSOGNGS-UHFFFAOYSA-N 0.000 description 1
- PMOJSTDKUMMQCB-UHFFFAOYSA-N methyl 7-chloro-1-(4-fluorophenyl)indole-6-carboxylate Chemical compound C12=C(Cl)C(C(=O)OC)=CC=C2C=CN1C1=CC=C(F)C=C1 PMOJSTDKUMMQCB-UHFFFAOYSA-N 0.000 description 1
- KXNQRKIBEQIWBM-UHFFFAOYSA-N methyl 7-chloro-1-(cyclohexylmethyl)indole-6-carboxylate Chemical compound C12=C(Cl)C(C(=O)OC)=CC=C2C=CN1CC1CCCCC1 KXNQRKIBEQIWBM-UHFFFAOYSA-N 0.000 description 1
- NPZNTYHTVYUQAT-UHFFFAOYSA-N methyl 7-chloro-1-thiophen-3-ylindole-6-carboxylate Chemical compound C12=C(Cl)C(C(=O)OC)=CC=C2C=CN1C=1C=CSC=1 NPZNTYHTVYUQAT-UHFFFAOYSA-N 0.000 description 1
- DXFDMUNWSRVKAX-UHFFFAOYSA-N methyl 7-chloro-3-formyl-1-(2-methylpropyl)indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C=O)=NN(CC(C)C)C2=C1Cl DXFDMUNWSRVKAX-UHFFFAOYSA-N 0.000 description 1
- DJGYCCREFDXCPM-UHFFFAOYSA-N methyl 7-chloro-3-formyl-2h-indazole-6-carboxylate Chemical compound ClC1=C(C(=O)OC)C=CC2=C(C=O)NN=C21 DJGYCCREFDXCPM-UHFFFAOYSA-N 0.000 description 1
- YNNHPWXVRNQZDM-UHFFFAOYSA-N methyl 7-methyl-1-(1,3-thiazol-4-ylmethyl)indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CSC=N1 YNNHPWXVRNQZDM-UHFFFAOYSA-N 0.000 description 1
- YZGVQSCPLJGWMV-UHFFFAOYSA-N methyl 7-methyl-1-(2-methylpropyl)-3-(methylsulfonyloxymethyl)indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(COS(C)(=O)=O)=NN(CC(C)C)C2=C1C YZGVQSCPLJGWMV-UHFFFAOYSA-N 0.000 description 1
- LTIGBQVLPASHLN-UHFFFAOYSA-N methyl 7-methyl-1-(2-methylpropyl)-3-(morpholin-4-ylmethyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1CCOCC1 LTIGBQVLPASHLN-UHFFFAOYSA-N 0.000 description 1
- WMSRIQAURUOAOQ-UHFFFAOYSA-N methyl 7-methyl-1-(2-methylpropyl)-3-(piperidin-1-ylmethyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1CCCCC1 WMSRIQAURUOAOQ-UHFFFAOYSA-N 0.000 description 1
- FXFFSZKYUOWOON-UHFFFAOYSA-N methyl 7-methyl-1-(2-methylpropyl)-3-(pyrazol-1-ylmethyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1C=CC=N1 FXFFSZKYUOWOON-UHFFFAOYSA-N 0.000 description 1
- YDRULCKSRIJELW-UHFFFAOYSA-N methyl 7-methyl-1-(2-methylpropyl)-3-(pyrrolidin-1-ylmethyl)indazole-6-carboxylate Chemical compound N=1N(CC(C)C)C2=C(C)C(C(=O)OC)=CC=C2C=1CN1CCCC1 YDRULCKSRIJELW-UHFFFAOYSA-N 0.000 description 1
- FHYWPZJVAKGHRE-UHFFFAOYSA-N methyl 7-methyl-1-(pyrazin-2-ylmethyl)indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CN=CC=N1 FHYWPZJVAKGHRE-UHFFFAOYSA-N 0.000 description 1
- JXYOJPNNCGGZIE-UHFFFAOYSA-N methyl 7-methyl-1-[(2-methyl-1,3-thiazol-4-yl)methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CSC(C)=N1 JXYOJPNNCGGZIE-UHFFFAOYSA-N 0.000 description 1
- PLWKVVOKHKNTQI-UHFFFAOYSA-N methyl 7-methyl-1-[(2-methylphenyl)methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC=C1C PLWKVVOKHKNTQI-UHFFFAOYSA-N 0.000 description 1
- OFLKNOYXRFDIFK-UHFFFAOYSA-N methyl 7-methyl-1-[(5-methylpyrazin-2-yl)methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CN=C(C)C=N1 OFLKNOYXRFDIFK-UHFFFAOYSA-N 0.000 description 1
- MWISGWGQYHJRLI-UHFFFAOYSA-N methyl 7-methyl-1-[(6-methylpyridin-3-yl)methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=C(C)N=C1 MWISGWGQYHJRLI-UHFFFAOYSA-N 0.000 description 1
- JQGOWCBPCXQCLC-UHFFFAOYSA-N methyl 7-methyl-1-[[3-(methylsulfonylmethyl)phenyl]methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC(CS(C)(=O)=O)=C1 JQGOWCBPCXQCLC-UHFFFAOYSA-N 0.000 description 1
- CZVWGHMKVRMRFL-UHFFFAOYSA-N methyl 7-methyl-1-[[3-(trifluoromethyl)phenyl]methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=CC(C(F)(F)F)=C1 CZVWGHMKVRMRFL-UHFFFAOYSA-N 0.000 description 1
- PZVZVFDZAMVONN-UHFFFAOYSA-N methyl 7-methyl-1-[[4-(methylsulfonylmethyl)phenyl]methyl]indole-6-carboxylate Chemical compound C12=C(C)C(C(=O)OC)=CC=C2C=CN1CC1=CC=C(CS(C)(=O)=O)C=C1 PZVZVFDZAMVONN-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- CXLKSNKWHULUKA-UHFFFAOYSA-N n-(2,5-dimethylphenyl)acetamide Chemical compound CC(=O)NC1=CC(C)=CC=C1C CXLKSNKWHULUKA-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- NNOQIGNUIUKVDJ-UHFFFAOYSA-N oxolan-2-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCCO1 NNOQIGNUIUKVDJ-UHFFFAOYSA-N 0.000 description 1
- ZVOOAGUSNWNCIO-UHFFFAOYSA-N oxolan-3-ylmethyl methanesulfonate Chemical compound CS(=O)(=O)OCC1CCOC1 ZVOOAGUSNWNCIO-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- TVZQQCAMWMLAKR-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)pyrazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=C(CBr)C=N1 TVZQQCAMWMLAKR-UHFFFAOYSA-N 0.000 description 1
- PFSBCJLKNNNAAJ-UHFFFAOYSA-N tert-butyl-[[3-(chloromethyl)phenyl]methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(CCl)=C1 PFSBCJLKNNNAAJ-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, or pharmaceutically acceptable salts and isomers thereof, and the pharmaceutical compositions containing them.
- Diabetes negatively impacts many people's health and induces various complications. Diabetes is divided into type 1 diabetes and type 2 diabetes. Type 1 diabetes is presented when insulin is not produced due to destruction of pancreatic cells. Type 2 is presented when insulin is not produced for other reasons or the body is not responding to insulin. Type 2 diabetes is found in 90% or more of diabetic patients.
- Sulfonylureas promoting insulin secretion from pancreatic cells
- biguanide suppressing glucose production in the liver
- ⁇ -glucosidase inhibitor inhibiting glucose absorption in the intestines
- thiazolidine derivatives and the like are currently used for the treatment of diabetes.
- Incretin-related drugs such as DPPIV inhibitors or Exenatide have recently entered the market.
- GPR40 is a G-protein-coupled receptor.
- GPR40 receptor is highly expressed in the pancreas, and it has been found that ligands for GPR40 receptor are saturated free fatty acids having 12-16 carbon atoms and unsaturated fatty acids having 18-22 carbon atoms. And it is confirmed that long-chain FFAs activate GPR40 receptor depending on blood glucose concentration, thereby stimulating insulin secretion from the beta cells of the pancreas via experiments that selectively inhibit the expression of GPR40 receptor in the pancreas using siRNA (small interfering RNA) technology and that measure how insulin secretion by blood glucose changes from beta cells of the pancreas in the presence of free fatty acids.
- siRNA small interfering RNA
- GPR40 agonists have a blood glucose concentration-dependent insulin-secretion stimulating activity, and thus are useful for the treatment and prevention of diabetes and complications thereof.
- the object of the present invention is to provide novel compounds of Formula (1) as GPR40 receptor agonists.
- Another object of the present invention is to provide a method for preparing the compounds of Formula (1).
- Still another object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of diabetes and complications of diabetes, which comprises as active components the compounds of Formula (1), and a method for preparing the composition.
- a still further object of the present invention is to provide a method for preventing and treating diabetes and complications of diabetes which uses the compounds of Formula (1) as active components.
- the compound of the present invention is a GPR40 receptor agonist.
- the present invention provides a compound of Formula (1), or pharmaceutically acceptable salts or isomers thereof.
- X represents C or N
- Z represents C, N or O
- Q represents O or NH
- W represents C, N, C-alkyl or C-halogen
- R1 represents H, alkyl, heteroalkyl, aryl, heterocycle, aryl-alkyl or heterocycle-alkyl,
- R2 represents H, alkyl, heteroalkyl or halogen
- R3 represents H, alkyl or halogen
- R4 represents H, O, alkyl or halogen
- R5 represents H, alkyl, alkoxy, CN, heterocycle or C ⁇ C-Me,
- R4 and R5 can be connected together to form 5- or 6-membered ring
- R6 represents H or alkyl
- R5 and R6 can be connected together to form 3-membered ring.
- the structure of is preferably selected from the following structures:
- E represents H, alkyl or halogen
- G represents alkyl, heteroalkyl or halogen
- alkyl when used alone or in combination with “heteroalkyl,” means a linear, branched or cyclic hydrocarbon radical, preferably a linear or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or a cyclic saturated hydrocarbon radical having from from 3 to 6 carbon atoms bonded to a linear and/or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms.
- Each carbon atom can be optionally substituted with one or more cyano, hydroxy, C 1-6 alkoxy, oxo, halogen, or sulfonyl unsubstituted or substituted with alkyl and the like.
- alkoxy means -O-alkyl, and alkyl is as defined above.
- heteroalkyl means an alkyl comprising one or more, preferably one to four heteroatoms selected from N, O and S.
- aryl means an aromatic group including phenyl, naphthyl and the like, and preferably means 6- to 10-membered aromatic groups.
- Aryl may be optionally substituted with one or more halogen, alkyl, haloalkyl, alkoxy, or sulfonyl unsubstituted or substituted with alkyl and the like.
- heterocycle refers to a saturated, partially saturated or aromatic 3- to 14-membered ring containing 1 to 4 heteroatoms selected from N, O and S, which can optionally fused with benzo or C 3-8 cycloalkyl.
- Examples of monocyclic heterocycle include oxetane, tetrahydrofuran, piperidine, morpholine, thiomorpholine, pyrrolidine, imidazolidine, piperazine, thiazole, oxazole, thiophene, furane, pyrrole, imidazole, isoxazole, pyrazole, triazole, thiadiazole, tetrazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine and the like, but is not limited thereto.
- bicyclic heterocycle examples include indole, indazole, azaindole, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzothiazole, benzothiadiazole, benzotriazole, quinoline, isoquinoline, purine, furopyridine and the like, but is not limited thereto.
- Heterocycle may be optionally substituted with alkyl, halogen, heteroalkyl and the like.
- halo(gen) refers to a substituent selected from the group consisting of fluoro, chloro, bromo or iodo.
- the term “the compounds of Formula (1)” is used to mean all the compounds of Formula (1), including the pharmaceutical salts and isomers thereof.
- the compounds according to the present invention can form pharmaceutically acceptable salts thereof.
- the pharmaceutically acceptable salts comprise acid-addition salts formed by acids containing pharmaceutically acceptable anions and forming nontoxic acid-addition salts ⁇ for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid and the like, organic carbonic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid or sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or naphthalenesulfonic acid, preferably acid-addition salts formed by sulfuric acid, methanesulfonic acid or hydrogen halide acid and the like.
- the compounds according to the present invention can have an asymmetric carbon center, they can exist as R- or S-isomers, racemic mixtures, diastereoisomer mixtures or each diastereoisomer, all of which are within the scope of the present invention. That is, if the asymmetric carbon(s) is included in the structure of Formula (1), as long as the direction is not described separately, it must be understood that all stereoisomers are included.
- Representative compounds of Formula 1 according to the present invention include, but are not limited to, the following compounds:
- the present invention also provides a process for preparing a compound of Formula (1).
- the method for preparing the compounds of Formula (1) is explained based on exemplary reaction schemes in order to illustrate the present invention.
- a person skilled in the art could prepare the compounds of Formula (1) by various methods based on the structure of Formula (1), and such methods should be interpreted as being within the scope of the present invention. That is, the compounds of Formula (1) may be prepared by the methods described herein or by combining various methods disclosed in the prior art, which should be interpreted as being within the scope of the present invention.
- all substituents are as previously defined above.
- the compound of Formula (1) according to the present invention may be obtained via hydrolysis of ester groups using compound (2) as shown in Reaction Scheme 1.
- Compound (2) may be obtained via a coupling reaction of compound (3) and compound (4) or a coupling reaction of compound (5) and compound (6).
- a is a reducing agent such as sodium triacetoxyborohydride ⁇ NaBH(OAc) 3 ⁇ and the like,
- b is a binding agent such as 1,1’-(azodicarbonyl)dipiperidine (ADD) and the like and a phosphine such as tributylphosphin (Bu 3 P) and the like,
- ADD 1,1’-(azodicarbonyl)dipiperidine
- phosphine such as tributylphosphin (Bu 3 P) and the like
- c is a reagent providing a leaving group such as methanesulfonylchloride and the like; and a base such as metal carbonate (for example, potassium carbonate) and the like,
- d is a base such as metal hydroxide (for example, sodium hydroxide) and the like,
- R1 ⁇ R6 are the same as defined in Formula (1), and
- R7 is H, or alkyl such as methyl or ethyl and the like.
- Compounds of Formula (1) may be obtained by reacting compound (2) in a solvent under heating or at room temperature in the presence of a base.
- the base is preferably aqueous solution of sodium hydroxide or lithium hydroxide and the like.
- the solvent is preferably tetrahydrofuran, alcohols such as methanol, or mixtures thereof.
- Compound (2) may be obtained via a reductive alkylation between the aldehyde group of compound (3) and amine group of compound (4) in a solvent using a reducing agent.
- the available reducing agent is sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride and the like.
- the solvent is preferably dichloroethane or chloroform.
- Compound (2) can also be obtained via a coupling reaction between compound (5) and compound (6) under Mitsunobu condition.
- Mitsunobu condition is widely known in the art, there are numerous methods and reagents. Among them, binding reaction is included between the alcohol compound (5) and the phenol compound (6) using a phosphine such as tributylphosphin, triphenylphosphine and the like, and 1,1’-(azodicarbonyl)dipiperidine (ADD) or diethyl azodicarboxylate (DEAD) as a binding agent.
- the solvent is preferably toluene, tetrahydrofuran and the like.
- it can be obtained by binding the phenol compound (6) with compound (5) wherein the alcohol group is changed to a leaving group with the appropriate brominating agents, chlorinating agents or methanesulfonylation agents.
- Compound (3) can be prepared by the method described in Reaction Scheme 2, and compound (4) is commercially available.
- a is an alkylation agent such as R1-OSO 2 CH 3 , R1-halogen and the like, and a base such as sodium hydride,
- b is an arylating agent such as R1-halogen and the like, cyclohexane 1,2-diamine, potassium phosphate tribasic and copper iodide, and
- R1 ⁇ R3 are the same as defined in Formula (1).
- compound (3) may be obtained by the alkylation or arylation of compound (7).
- Compound (7) is a compound commercially available.
- Alkylation condition is well known in the art, and it is possible to obtain by reacting compound (7) with an alkylating agent having a leaving group such as a halogen or methanesulfonate in the presence of a base such as sodium hydride or potassium carbonate in a solvent.
- the solvent is preferably tetrahydrofuran, dimethylformamide or a mixture thereof.
- Arylation condition is well known in the art and comprises a reaction between compound (7) and aryl halide in the presence of cyclohexane 1,2-diamine, potassium phosphate tribasic and copper iodide.
- the solvent is preferably tetrahydrofuran or dioxane.
- Compound (5) can be prepared by the method described in the following Reaction Schemes 3 and 4, and compound (6) may be prepared by known methods.
- a is a reducing agent such as sodium borohydride (NaBH 4 ), lithium borohydride (LiBH 4 ) or lithium aluminum hydride (LiAlH 4 ),
- R1 ⁇ R3 are the same as defined in Formula (1), and
- R7 is H or alkyl such as methyl or ethyl and the like.
- compound (5) may be obtained by reduction of the aldehyde group of compound (3) or the ester group of compound (8) using a reducing agent.
- Sodium borohydride (NaBH 4 ), lithium borohydride (LiBH 4 ) or lithium aluminum hydride (LiAlH 4 ) and the like may be used as the reducing agent.
- tetrahydrofuran may be used as the solvent.
- Compound (8) may be selected from compounds which can be prepared by the method described in the following Reaction Schemes 5 to 14.
- b is a reducing agent such as sodium borohydride (NaBH 4 ) or lithium borohydride (LiBH 4 ), and
- R1 ⁇ R3 are the same as defined in Formula (1).
- compound (5) can be obtained by reacting the acid group of compound (9) with alkyl chloroformate in the presence of a base to prepare the anhydride group and then reducing it to alcohol groups using a reducing agent.
- the base is preferably triethylamine or N-methylmorpholine.
- the reducing agent is preferably sodium borohydride (NaBH 4 ) or lithium borohydride (LiBH 4 ).
- the solvent is preferably tetrahydrofuran.
- Compound (9) can be purchased or can be selected from compounds which can be prepared by the method described in the following Reaction Schemes 5 to 14.
- a is a cyanide such as zinc cyanide (ZnCN 2 ), and a palladium catalyst such as palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ ,
- b is a basic aqueous solution, such as sodium hydroxide,
- d is R1-OSO 2 CH 3 or R1-halogen, and a base such as sodium hydride,
- R1 is the same as defined in Formula (1), and
- R7 is H or alkyl such as methyl or ethyl.
- Compound (10) is typically available for purchase.
- Compound (11) can be obtained by reacting the bromide group of compound (10) with cyanide under a palladium catalyst.
- Palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ is the most commonly used palladium catalyst, and the solvent is preferably dimethylformamide or N-methylpyrrolidone.
- Compound (12) can be obtained by changing the carbonitrile group of compound (11) to acid group using an acidic or basic aqueous solution and then esterifying it with methanol or ethanol under acid catalyst such as anhydrous hydrochloric acid or anhydrous sulfuric acid. It can be also obtained via the methyl esterfication reaction of the acid group and diazomethane in the solvent of tetrahydrofuran or dichloromethane.
- the acidic solution used in the condition for making acid group is preferably an aqueous solution of sulfuric or hydrochloric acid, and as the basic aqueous solution, sodium hydroxide or lithium hydroxide aqueous solution is generally used.
- Compound (13) may be prepared using compound (10) by the alkylating or arylating method used to prepare the compound (3).
- Compound (14) can be prepared using compound (13) under the same condition that is used for preparing compound (11).
- Compound (15) can be prepared using compound (12) by the alkylating or arylating method used to prepare the compound (3) or using compound (14) by the method by which compound (12) is prepared.
- R1 is the same as defined in Formula (1), and
- R7 is H or alkyl such as methyl or ethyl.
- Compound (16) is typically available for purchase.
- Compound (17) can be prepared by reacting the nitrobenzene compound (16) and vinyl magnesium bromide with the method described in WO 2008/0221091.
- Compound (18) may be made via an esterification reaction of compound (17).
- the esterification reaction may be carried out using ethanol or methanol under the condition of the anhydrous sulfuric acid or hydrochloric acid. Alternatively, it can be performed using diazomethane in tetrahydrofuran or dichloromethane.
- a is N,N-dimethylformamide dimethyl acetal
- c is R1-OSO 2 CH 3 or R1-halogen and a base such as sodium hydride,
- R3 is the same as defined in Formula (1), and
- R7 is H or alkyl such as methyl or ethyl.
- Compound (19) is commercially available or can be prepared by the method described in WO 2010/089127.
- the compound (20) can be prepared by reacting the methyl group of compound (19) with N,N-dimethylformamide dimethyl acetal according to the method described in WO 2010/054138.
- Compound (21) may be prepared by reacting compound (20) with hydrogen gas under Pd/C catalyst.
- the suitable solvent is ethyl acetate, ethanol, etc.
- Compound (22) may be prepared by alkylation or arylation of compound (21) according to the method used for compound (3).
- a is R8-C ⁇ CH, copper (I) iodide (CuI), bis(triphenylphosphine) palladium (II) dichloride ⁇ Pd(Ph 3 P) 2 Cl 2 ⁇ ,
- c is tetrabutylammonium fluoride
- d is R1-OSO 2 CH 3 or R1-halogen and sodium hydride
- R3 is the same as defined in Formula (1),
- R7 is H or alkyl such as methyl or ethyl
- R8 is trimethylsilyl ⁇ (CH 3 ) 3 Si ⁇ , alkyl or heteroalkyl.
- Compound (23) can be purchased or can be prepared by the method described in Tetrahedron Letters, 38 (14), 2439, 1997.
- Compound (24) can be made according to the method described in Journal of Organic Chemistry, 4 (18), 7052, 2009 by reacting R8-C ⁇ CH with compound (23) in the presence of copper (I) iodide (CuI), bis(triphenylphosphine) palladium (II) dichloride ⁇ Pd(Ph 3 P) 2 Cl 2 ⁇ and a base.
- the base is preferably triethylamine or diethylamine, and as the solvent N,N-dimethylformamide or tetrahydrofuran can be used.
- Compound (25) can be prepared by reacting compound (24) with tetrabutylammonium fluoride according to the method described in Example 58 of WO 2010/123975.
- Compound (26) may be prepared by alkylation or arylation of compound (25) according to the method used for compound (3).
- a is a halogenating agent such as N-fluoro-2,4,6-trimethyl pyridinium triplate or chlorine (Cl 2 ),
- b is R1-Br, and a metal acid catalyst such as zinc bromide (ZnBr 2 ),
- c is a halogenating agent such as N-bromosuccinimide; R10-boronic acid and palladium tetrakistriphenylphosphine ⁇ Pd(Ph 3 ) 4 ⁇ ,
- R1 and R3 are the same as defined in Formula (1),
- R7 is H or alkyl such as methyl or ethyl
- R9 is H or halogen
- R10 is halogen, alkyl, aryl or aryl-alkyl.
- Compound (27) can be synthesized by carrying out one reaction under any of a to c reaction conditions.
- the halogenation (the reaction condition of a) of compound (26) can be carried out using a fluorinating reagent (for example, N-fluoro-2,4,6-trimethyl pyridinium triplate), chlorine or brominating reagent (for example, N- bromosuccinimide, bromine).
- a fluorinating reagent for example, N-fluoro-2,4,6-trimethyl pyridinium triplate
- chlorine or brominating reagent for example, N- bromosuccinimide, bromine
- the alkylation (the reaction condition of b) of compound (26) can be carried out by reacting with an alkyl-halogen compound (for example, benzyl bromide) in the presence of a metal acid catalyst such as zinc bromide (ZnBr 2 ).
- an alkyl-halogen compound for example, benzyl bromide
- a metal acid catalyst such as zinc bromide (ZnBr 2 ).
- the arylation (the reaction condition of c) of compound (26) can be carried out by brominating the indole compound and then reacting with R10-boronic acid and a base (for example, palladium phosphate tribasic) under a palladium tetrakistriphenylphosphine ⁇ Pd(Ph 3 ) 4 ⁇ catalyst.
- a base for example, palladium phosphate tribasic
- a is acetic anhydride(Ac 2 O), isoamyl nitrite and potassium acetate (KOAc)
- b is a cyanide such as zinc cyanide (ZnCN 2 ), and a palladium catalyst such as palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ ,
- c is a base such as sodium hydroxide
- e is palladium/carbon (Pd/C) and hydrogen
- R3 is the same as defined in Formula (1),
- R7 is H or alkyl such as methyl or ethyl
- R11 is alkyl or aryl-alkyl.
- Compound (28) is commercially available, or can be prepared by a known method.
- Compound (29) can be prepared using the indazole synthesis method well known in the art.
- the indazole synthesis conditions include the condition that the 1-amino-2-alkylphenyl compound (28) is reacted with acetic anhydride(Ac 2 O) in the presence of potassium acetate (KOAc), and then it is reacted with isoamyl nitrite.
- Compound (30) may be obtained by reacting the bromide group of compound (29) with cyanide under a palladium catalyst.
- a palladium catalyst palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ is commonly used, and the solvent is preferably dimethylformamide or N-methylpyrrolidone.
- Compound (31) is commercially available or can be prepared by the method as described in US 2010/0040554.
- Compound (32) can be prepared by reduction of the compound (31) with hydrogen gas under Pd/C catalyst.
- the compound (33) is commercially available, or can be prepared by changing the carbonitrile of compound (30) to the acid group using an acidic or basic aqueous solution and then esterifying it with alcohol under acid catalyst or diazomethane. It can also be made using the compound (32) under the conditions by which to prepare compound (29) or by the method described in WO 2008/001883.
- a is R1-amine
- c is sodium nitride (NaNO 2 ) and an acidic aqueous solution such as hydrochloric acid,
- d is triethylorthoformate and an acidic aqueous solution such as p-toluenesulfonic acid,
- f is R11-halogen, and a base such as sodium hydride,
- R1 and R3 are the same as defined in Formula (1),
- R7 is H or alkyl such as methyl or ethyl
- R11 is alkyl or aryl-alkyl.
- Compound (34) is commercially available or can be prepared by a known method.
- Compound (35) can be prepared by reacting compound (34) with amine according to the method described in WO 2007/095340.
- Compound (36) can be prepared by reduction of compound (35) with hydrogen gas under Pd/C catalyst.
- Compound (37) can be prepared by reacting compound (36) with sodium nitride (NaNO 2 ) under an acidic condition (for example, hydrochloric acid), according to the method described in WO 2010/027500.
- an acidic condition for example, hydrochloric acid
- Compound (38) can be prepared by reacting compound (36) with triethylorthoformate under an acidic condition (for example, p-toluenesulfonic acid), according to the method described in WO 2009/129335.
- an acidic condition for example, p-toluenesulfonic acid
- Compound (39) can be prepared by reacting compound (36) with triphosgene according to the method described in US 2008/0249101.
- Compound (40) can be prepared by reacting compound (39) with an alkylating agent (for example, methyl iodide) in the presence of a base (for example, sodium hydride).
- an alkylating agent for example, methyl iodide
- a base for example, sodium hydride
- b is zinc cyanide (ZnCN 2 ) and palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ ,
- c is a basic aqueous solution such as sodium hydroxide
- R1 and R3 are the same as defined in Formula (1),
- R7 is H or alkyl such as methyl or ethyl
- R11 is alkyl or aryl-alkyl.
- Compound (41) is commercially available or can be prepared by the method described in US 2008/0153813.
- Compound (42) can be prepared by reacting compound (41) with R1-hydrazine and then reacting with zinc cyanide (ZnCN 2 ) under palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ , or it can be prepared by reacting R1-hydrazine after reacting zinc cyanide (ZnCN 2 ).
- Compound (43) can be prepared by changing the carbonitrile group of compound (42) to the acid group using an acidic or basic aqueous solution, and then esterifying it with alcohol under acid catalyst or diazomethane.
- a ammonia
- NCS N-chlorosuccinimide
- c is zinc cyanide (ZnCN 2 ) and palladium tetrakistriphenylphosphine ⁇ Pd(PPh 3 ) 4 ⁇ ,
- e is diazomethane (CH 2 N 2 )
- R3 is the same as defined in Formula (1),
- R7 is H or alkyl such as methyl or ethyl
- R11 is alkyl or aryl-alkyl.
- Compound (44) is commercially available or can be prepared by the method described in WO 95/04739.
- Compound (45) can be prepared by reacting compound (44) with ammonia and then N-chlorosuccinimide (NCS) according to the method described in Organic Letter, 12(23), 6300, 2011.
- Compound (46) can be prepared using compound (45) according to the method by which compound (12) was prepared.
- the compounds of Formula (1) can be separated or purified from the reaction products by conventional methods such as recrystallization, ionospheresis, silica gel column chromatography or ion-exchange chromatography.
- the compounds according to the present invention can be prepared by a variety of methods, which should be interpreted as being within the scope of the present invention in connection with the preparation of the compounds of Formula (1).
- the compounds of Formula (1), the pharmaceutically acceptable salts and isomers thereof are useful for the treatment and prevention for the diseases associated with GPR40 receptor.
- the compound of Formula (1) according to the present invention has GPR40 receptor modulating activity and is especially useful as a GPR40 receptor agonist.
- the compound of formula (1) according to the present invention has an excellent GPR40 receptor modulating activity in mammals, particularly in humans, and thus is useful as a therapeutic agent for the treatment or prevention of GPR40 receptor-related diseases which can be treated by controlling the efficacy of the GPR40 receptor.
- the compound according to the present invention is useful as insulin secretion regulating agents, preferably insulin secretagogues, hypoglycemic agents and pancreatic beta-cell protective agents.
- the compound of the present invention shows blood glucose concentration-dependent insulin secretion stimulating activity based on GPR40 receptor agonist activity, and thus it is useful as an insulin secretagogue that does not cause side effects such as hypoglycemia ⁇ namely, as a therapeutic agent for the treatment or prevention of diabetes, high blood sugar, glucose tolerance, and impaired fasting blood glucose. It is also effective in the treatment or prevention of diabetes complications such as hyperlipidemia, hypertension, retinopathy, renal failure and obesity.
- the diabetes complications treatable by the compound of the present invention include, but are not limited to, hyperlipidemia, hypertension, retinopathy, renal failure, obesity, etc.
- the relevance between the said diseases and the modulation of GPR40 receptor has already been known in the art and disclosed in detail in documents such as WO 2004/041266, WO 2004/106276, WO 2005/063729 and WO 2008/001931.
- the present invention also provides a pharmaceutical composition as a GPR40 agonist comprising an effective amount of the compound of Formula (1), pharmaceutically acceptable salts or isomers thereof and a pharmaceutically acceptable carrier.
- the pharmaceutical composition comprising the compound of Formula (1) can be used for the treatment or prevention of diseases or conditions which can be treated by modulation of the GPR40 receptor such as diabetes, high blood sugar, glucose tolerance, impaired fasting blood glucose, diabetes complications, hyperlipidemia, hypertension, retinopathy, renal failure, obesity, etc., and is particularly useful for the treatment or prevention of type 2 diabetes.
- the present invention provides a method for preparing the composition for preventing or treating diabetes and/or complications of diabetes which comprises the step of mixing the compound of Formula (1), a pharmaceutically acceptable salt or isomer thereof as an active component and a pharmaceutically acceptable carrier.
- the “pharmaceutical composition” can include other chemical components such as carriers, diluents, etc., in addition to the active component of the present invention. Accordingly, the pharmaceutical composition can include pharmaceutically acceptable carriers, diluents, excipients or combinations thereof as necessary.
- the pharmaceutical composition facilitates the administration of compounds into the body. Various methods for administering the compounds include, but are not limited to, oral, injection, aerosol, parenteral and local administration.
- carriers means compounds that facilitate the addition of compounds into the cell or tissue.
- dimethylsulfoxide is a conventional carrier facilitating the administration of various organic compounds into the living cell or tissue.
- the term “diluents” means compounds that not only stabilize a biologically active form but are also diluted in solvent dissolving the compounds. Dissolved salts in buffer are used as diluents in this field.
- a conventionally used buffer is a phosphate buffer saline that copies salt form in bodily fluid. Since buffer solution can control the pH of the solution at low concentration, buffer diluents hardly modify the biological activity of compounds.
- pharmaceutically acceptable means such property that does not impair the biological activity and physical property of compounds.
- the compounds according to the present invention can be formulated as various pharmaceutically administered dosage forms.
- an active component specifically, the compound of Formula (1), a pharmaceutically acceptable salt or isomer thereof ⁇ is mixed with selected pharmaceutically acceptable carriers considering the dosage form to be prepared.
- the pharmaceutical composition of the present invention can be formulated as injections, oral preparations and the like, as needed.
- the compounds of the present invention can be formulated by conventional methods using known pharmaceutical carriers and excipients, and inserted into a unit or multi-unit containers.
- the formulations may be solution, suspension or emulsion in oil or aqueous solvent and include conventional dispersing agents, suspending agents or stabilizing agents.
- the formulation may be, for example, dry powder form which is dissolved in sterilized pyrogen-free water before use.
- the compounds of the present invention can be formulated into suppositories by using a conventional suppository base such as cocoa butter or other glycerides.
- Solid forms for oral administration include capsules, tablets, pills, powders and granules. Capsules and tablets are preferred. Tablets and pills are preferably enteric-coated.
- Solid forms are manufactured by mixing the compounds of the present invention with at least one carrier selected from inert diluents such as sucrose, lactose or starch, lubricants such as magnesium stearate, disintegrating agents, binders and the like.
- carrier selected from inert diluents such as sucrose, lactose or starch, lubricants such as magnesium stearate, disintegrating agents, binders and the like.
- the compounds according to the present invention and the composition comprising them can be administered in combination with other drugs ⁇ for example, other antidiabetics, as required.
- the dose of the compounds of Formula (1) is determined by a physician’s prescription considering the patient’s body weight, age and disease condition.
- a typical dose for adults is in the range of about 1 to 500 mg per day according to the frequency and intensity of administration.
- a typical daily dose of intramuscular or intravenous administration for adults is in the range of about 1 to 300 mg per day which can be administered in divided unit dosage. Some patients need a higher daily dose.
- treatment is used to mean deterring, delaying or ameliorating the progress of diseases in a subject exhibiting symptoms of diseases.
- prevention is used to mean deterring, delaying or ameliorating the sign of diseases in a subject at risk of exhibiting symptoms of diseases, even if he or she does not exhibit the symptoms.
- Reagents and starting materials can be obtained readily commercially. Others can be produced by synthetic methods described in the following Examples, including known synthetic methods for structurally similar compounds. Unless otherwise noted, compounds used as starting materials are known ones or those which can be prepared by known synthetic methods or similar methods from known compounds.
- M means molar concentration
- N means normal concentration
- room temperature means 1 to 40°C.
- 1-H-indole-6-carbaldehyde (320mg, 2.2mmol) was dissolved in dimethylformamide (2ml), and isopropyl iodide (0.33ml, 3.3mmol) and sodium hydride (104mg, 2.6mmol) were slowly added thereto at 0°C, and then the mixture was stirred for 8 hours at 50°C. 1N hydrochloric acid solution was added thereto, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. Filtrate was distilled under reduced pressure and separated by column chromatography to obtain the title compound (300mg, 73%).
- N-chlorosuccinimide N-chlorosuccinimide (NCS, 474mg, 3.5mmol) was added dropwise thereto, and then the mixture was stirred for 2 hours at 70°C. After completion of the reaction, water was added thereto and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. Filtrate was distilled under reduced pressure and separated by column chromatography to obtain the title compound (800mg, 76%).
- N-chlorosuccinimide (NCS, 132mg, 1.0mmol) was added dropwise thereto, and then the mixture was stirred for 4 hours at room temperature. After completion of the reaction, water was added thereto and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. Filtrate was distilled under reduced pressure and separated by column chromatography to obtain the title compound (40mg, 30%).
- N-chloro-succinimide (NCS, 40mg, 0.30mmol) was added dropwise thereto. The mixture was stirred for 4 hours at 60°C. Water was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. Filtrate was distilled under reduced pressure and separated by column chromatography to obtain the title compound (70mg, 89%).
- the compound (200mg, 1.06mmol) obtained from the Preparation Example 50-1 was dissolved in dioxane (7ml). Benzyl bromide (0.25ml, 2.11mmol) and zinc bromide (ZnBr 2 , 140mg, 0.53mmol) were added thereto, and the mixture was stirred for 3 hours at 60°C. Water was added thereto, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. Filtrate was distilled under reduced pressure and separated by column chromatography to obtain the mixture of the title compound and 2,3-dibenzyl-1-methyl-1H-indole-5-carboxylic acid methyl ester.
- 1-Benzyl-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid was dissolved in methylenechloride (20ml) and 0.25M solution of diazomethane in diethyl ether (5.0ml, 1.38mmol) was slowly added dropwise. The mixture was stirred for 30 minutes at room temperature, and then distilled under reduced pressure to obtain 1-benzyl-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid methyl ester (310mg, 100%).
- the first compound that passed through the column chromatography was 1-benzyl-1H-indazole-6-carboxylic acid methyl ester (209mg, 46%), and the second one was 2-benzyl-1H-indazole-6-carboxylic acid methyl ester (160mg, 35%).
- N-methyl morpholine (0.50g, 4.95mmmol) and isobutylchloroformate (0.62g, 4.54mmol) were added dropwise at 0°C.
- the mixture was filtered to remove insoluble solids.
- sodium borohydride (0.31g, 8.26mmol) was added and the mixture was stirred for 3 hours.
- the reaction was terminated with an aqueous solution of ammonium chloride, and the mixture was extracted with ethyl acetate.
- the extract was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. Filtrate was distilled under reduced pressure and separated by column chromatography to obtain the title compound (0.61g, 62%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
- A compound of Formula (1), or pharmaceutically acceptable salts or isomers thereof:[Formula (1)]wherein,X represents C or N,Y represents C, N, C=O or C-halogen,Z represents C, N or O,Q represents O or NH,W represents C, N, C-alkyl or C-halogen,R1 represents H, alkyl, heteroalkyl, aryl, heterocycle, aryl-alkyl or heterocycle-alkyl,R2 represents H, alkyl, heteroalkyl or halogen,R3 represents H, alkyl or halogen,R4 represents H, O, alkyl or halogen,R5 represents H, alkyl, alkoxy, CN, heterocycle or C≡C-Me,R4 and R5 can be connected together to form 5- or 6-membered ring,R6 represents H or alkyl, andR5 and R6 can be connected together to form 3-membered ring.
- The compound, or pharmaceutically acceptable salts or isomers thereof according to Claim 1, wherein the compound is selected from the following compounds:3-{4-[(1-isopropyl-1H-indol-6-ylmethyl)-amino-phenyl}-propanoic acid;3-{4-[(1-benzyl-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-{4-[(1-thiophen-3-yl-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-{4-[(1-phenethyl-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-{4-[(1-benzyl-3-chloro-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-{4-[(1-benzyl-2,3-dichloro-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-{4-[(1-benzyl-7-chloro-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-{4-[(7-chloro-1-thiophen-3-yl-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;3-(4-{[7-chloro-1-(4-fluoro-phenyl)-1H-indol-6-ylmethyl]-amino}-phenyl)-propanoic acid;3-(4-{[1-(4-fluoro-phenyl)-1H-indol-6-ylmethyl]-amino}-phenyl)-propanoic acid;3-{4-[(7-chloro-1-cyclohexyl methyl-1H-indol-6-ylmethyl)-amino]-phenyl}-propanoic acid;[6-(1-benzyl-3-chloro-1H-indol-6-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;3-[4-(1-thiophen-3-yl-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;3-{4-[1-(4-fluoro-phenyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-propanoic acid;3-[4-(1-benzyl-7-methyl-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;3-[4-(7-methyl-1-thiophen-3-yl-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;3-{4-[1-(4-fluoro-2-methyl-phenyl)-1H-indol-6-ylmethoxy]-phenyl}-propanoic acid;3-[4-(1-benzyl-7-chloro-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;3-[4-(1-cyclohexyl methyl-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;3-[4-(3-benzyl-1-methyl-1H-indol-5-ylmethoxy)-phenyl]-propanoic acid;3-[4-(1-methyl-3-o-tolyl-1H-indol-5-ylmethoxy)-phenyl]-propanoic acid;3-{4-[3-chloro-1-(4-fluoro-2-methyl-phenyl)-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;3-{4-[5-fluoro-1-(4-fluoro-2-methyl-phenyl)-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;{6-[1-(4-fluoro-2-methyl-phenyl)-1H-indol-6-ylmethoxy]-2,3-dihydro-benzofuran-3-yl}-acetic acid;(S)-3-[4-(1-benzyl-7-methyl-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(4-fluoro-2-methyl-phenyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(4-methanesulfonyl-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(4-methoxy-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(4-trifluoromethyl-benzyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3-methoxymethyl-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-indol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(4-fluoro-2-methyl-phenyl)-1H-indol-4-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(2,6-difluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-benzyl-2-(2-methoxy-ethyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3-methanesulfonylmethyl-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(2-methyl-benzyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(2-fluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(2-chloro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(2,6-dimethyl-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-7-chloro-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-5-fluoro-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(3-fluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(3-trifluoromethyl-benzyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(5-methyl-pyrazin-2-ylmethyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(4-methanesulfonylmethyl-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(6-chloro-pyridin-3-ylmethyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(2-benzyl-2H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-5-fluoro-7-methyl-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(4-fluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3,4-difluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3,5-difluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(2,4-difluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;3-[4-(1-benzyl-1H-indol-4-ylmethoxy)-2-fluoro-phenyl]-propanoic acid;3-[4-(1-benzyl-7-methyl-1H-indol-6-ylmethoxy)-2-fluoro-phenyl]-propanoic acid;(S)-3-[4-(7-methyl-1-thiazol-4-ylmethyl-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(2-methyl-thiazol-4-ylmethyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(2-benzyl-2H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H- indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(7-methyl-1-pyrazin-2-ylmethyl-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(7-methyl-1-pyrimidin-4-ylmethyl-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-3-fluoro-7-methyl-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(1-methyl-1H-pyrazol-4-ylmethyl)-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(7-methyl-1-pyrimidin-2-ylmethyl-1H-indol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;3-[4-(1-benzyl-1H-indazol-6-ylmethoxy)-phenyl]-3-(4,5-dihydro-isoxazol-3-yl)-propanoic acid;(S)-3-{4-[1-(4-fluoro-benzyl)-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[2-(4-fluoro-benzyl)-2H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-pyrimidin-2-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl}-hex-4-ynoic acid;(S)-3-[4-(2-pyrimidin-2-ylmethyl-2H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-pyrazin-2-ylmethyl-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(4-fluoro-benzyl)-1H-indazol-4-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[2-(4-fluoro-benzyl)-2H-indazol-4-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(5-methyl-pyrazin-2-ylmethyl)-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[2-(5-methyl-pyrazin-2-ylmethyl)-2H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-pyrimidin-4-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(2-pyrimidin-4-ylmethyl-2H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(5-methyl-pyrazin-2-ylmethyl)-1H-indazol-4-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[2-(5-methyl-pyrazin-2-ylmethyl)-2H-indazol-4-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-pyridin-3-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(2-pyridin-3-ylmethyl-2H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[7-methyl-1-(6-methyl-pyridin-3-ylmethyl)-1H-indol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(1-methyl-1H-pyrazol-4-ylmethyl)-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-7-methyl-1H-indol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-{4-[1-(4-fluoro-benzyl)-7-methyl-1H-indol-6-ylmethoxy]-phenyl}-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(1-benzyl-1H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-{4-[1-(4-fluoro-benzyl)-1H-indazol-6-ylmethoxy]-phenyl}-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(1-isobutyl-1H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(2-isobutyl-2H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-isoxazol-3-yl-3-[4-(7-methyl-1-pyrazin-2-ylmethyl-1H-indol-6-ylmethoxy)-phenyl]-propanoic acid;(S)-3-[4-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-isoxazol-3-yl-3-{4-[7-methyl-1-(5-methyl-pyrazin-2-ylmethyl)-1H-indol-6-ylmethoxy]-phenyl}-propanoic acid;(S)-3-{4-[1-(6-methyl-pyridin-3-ylmethyl)-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-indazol-4-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-{4-[1-(4-fluoro-benzyl)-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy]-phenyl}-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(1-isopropyl-1H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(1-cyclopropylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(1-isobutyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(2-isopropyl-2H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;[6-(1-isopropyl-1H-indazol-6-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;(S)-3-isoxazol-3-yl-3-[4-(1-methyl-1H-indazol-6-ylmethoxy)-phenyl]-propanoic acid;(S)-3-[4-(1H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-[4-(1-cyclopentylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-3-isoxazol-3-yl-propanoic acid;(S)-3-isoxazol-3-yl-3-[4-(1-pyrazin-2-ylmethyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy)-phenyl]-propanoic acid;[6-(1-benzyl-1H-indazol-6-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;3-[4-(1-benzyl-1H-indazol-6-ylmethoxy)-2-fluoro-phenyl]-propanoic acid;3-[4-(1-cyclopentylmethyl-1H-indazol-6-ylmethoxy)-2-fluoro-phenyl]-propanoic acid;[6-(1-cyclopentylmethyl-1H-indazol-6-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;[5-(1-benzyl-1H-indazol-6-ylmethoxy)-indan-1-yl]-acetic acid;[6-(1-benzyl-1H-indazol-6-ylmethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-acetic acid;(S)-3-[4-(1-benzyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(2-benzyl-2H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[6-(2-benzyl-2H-indazol-6-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;(S)-3-[4-(1-isobutyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;3-[4-(1-benzyl-1H-indazol-6-ylmethoxy)-phenyl]-butyric acid;[5-(1-benzyl-1H-indazol-5-ylmethoxy)-indan-1-yl]-acetic acid;[6-(1-benzyl-1H-indazol-5-ylmethoxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-acetic acid;[7-(1-benzyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;[6-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;(S)-3-[4-(1-benzyl-5-fluoro-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-indol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-benzotriazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-1H-benzoimidazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-7-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(2-benzyl-7-methyl-2H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[6-(1-benzyl-7-methyl-1H-indazol-5-ylmethoxy)-2,3-dihydro-benzofuran-3-yl]-acetic acid;[6-(1-benzyl-7-methyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-[4-(1-isobutyl-7-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-isobutyl-7-methyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-[4-(1-isobutyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-isobutyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-[4-(1-phenethyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-phenethyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-{4-[1-(3-methyl-butyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;7-[1-(3-methyl-butyl)-1H-indazol-5-ylmethoxy]-chroman-4-yl}-acetic acid;(S)-3-[4-(1-cyclohexyl methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-cyclohexyl methyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-[4-(2-isobutyl-7-methyl-2H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-pyridine-2-ylmethyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-pyridine-2-ylmethyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-[4-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-1H-pyrrolo[2,3-b]pyridin-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-benzyl-7-methyl-1H-indol-6-ylmethoxy)-chroman-4-yl]-acetic acid;[7-(2-benzyl-7-methyl-2H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;(S)-3-[4-(1-pyridin-3-ylmethyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;[7-(1-pyridin-3-ylmethyl-1H-indazol-5-ylmethoxy)-chroman-4-yl]-acetic acid;7-[1-(2-ethoxy-ethyl)-1H-indazol-5-ylmethoxy]-chroman-4-yl}-acetic acid;(S)-3-[4-(5-fluoro-1-isobutyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(tetrahydrofuran-2-ylmethyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3-methanesulfonyl-propyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(tetrahydrofuran-3-ylmethyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[2-(tetrahydrofuran-3-ylmethyl)-2H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;3-[4-(1-benzyl-1H-indazol-5-ylmethoxy)-phenyl]-3-methoxy-propanoic acid;(S)-3-[4-(1-isobutyl-1H-pyrazolo[3,4-b]pyridin-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(2-ethoxy-ethyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;3-[4-(1-benzyl-1H-indazol-5-ylmethoxy)-phenyl]-butyric acid;3-[4-(1-benzyl-1H-indazol-5-ylmethoxy)-phenyl]-pentanoic acid;(S)-3-{4-[2-(2-ethoxy-ethyl)-2H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-benzyl-3-methyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;3-[4-(1-benzyl-1H-indazol-5-ylmethoxy)-phenyl]-3-cyano-propanoic acid;(S)-3-[4-(1-cyclopentylmethyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopentyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopropylmethyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-isobutyl-3H-benzotriazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;2-[4-(1-benzyl-1H-indazol-6-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid;(S)-3-[4-(1-isobutyl-7-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopentylmethyl-7-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopentyl-7-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopentyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopentylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(2-methanesulfonyl-ethyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(2-methoxy-ethyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3-methoxy-propyl)-1H-indazol-5-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[1-(3-methyl-oxetan-3-ylmethyl)-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(2-isobutyl-3-methyl-2H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-isobutyl-benzo[d]isoxazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[1-(2,2-dimethyl-propyl)-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-6-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-3-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-isobutyl-1-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-3-methyl-1H-indazol-5-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3-methoxymethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-fluoro-1-isobutyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-ethoxymethyl-1-isobutyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-chloro-1-isobutyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3-isopropoxymethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-fluoro-1-isopropyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-bromo-1-methyl-1H-indazol-7-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3-methoxymethyl-7-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-butyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-butyl-3-fluoro-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopropylmethyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-cyclopropylmethyl-3-fluoro-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-chloro-1-methyl-1H-indazol-7-ylmethoxy)-methyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-3-pyrazol-1-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-fluoro-1-methyl-1H-indazol-7-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-1H-pyrrolo[2,3-b]pyridin-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-butyl-3-methyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-butyl-1-methyl-1H-indazol-7-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-isobutyl-1-methyl-1H-indazol-7-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-7-methyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-isopropyl-1-methyl-1H-indazol-7-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-methyl-3-propyl-1H-indazol-7-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-7-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3,7-dimethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-fluoro-1-isobutyl-7-methyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-ethyl-3-fluoro-7-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-7-methyl-3-morpholin-4-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(7-chloro-1-isobutyl-3-morpholin-4-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-7-methyl-3-pyrrolidin-1-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-7-methyl-3-piperidin-1-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-3-morpholin-4-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-7-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(7-methyl-1-propyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-fluoromethyl-1-isobutyl-7-methyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-7-methyl-1H-indazol-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(1-isopropyl-1H-pyrrolo[2,3-b]pyridin-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(3-fluoro-1-isobutyl-1H-pyrrolo[2,3-b]pyridin-4-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-[4-(7-methyl-1-pyridin-3-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[3-(3,3-difluoro-piperidin-1-ylmethyl)-1-isobutyl-7-methyl-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-[4-(1-isobutyl-7-methyl-3-pyrazol-1-ylmethyl-1H-indazol-6-ylmethoxy)-phenyl]-hex-4-ynoic acid;(S)-3-{4-[3-((S)-3-fluoro-pyrrolidin-1-ylmethyl)-1-isobutyl-7-methyl-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[3-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1-isobutyl-7-methyl-1H-indazol-6-ylmethoxy]-phenyl}-hex-4-ynoic acid;(S)-3-{4-[3-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1-isobutyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy]-phenyl}-hex-4-ynoic acid; and(S)-3-{4-[3-(3,3-difluoro-piperidin-1-ylmethyl)-1-isobutyl-1H-pyrrolo[2,3-b]pyridin-6-ylmethoxy]-phenyl}-hex-4-ynoic acid.
- The compound or pharmaceutically acceptable salts or isomers thereof according to any one of Claims 1 to 3, wherein the compound is for the treatment of diabetes.
- A pharmaceutical composition comprising the compound, pharmaceutically acceptable salts or isomers thereof according to any one of Claims 1 to 3 and a pharmaceutically acceptable carrier.
- An insulin secretagogue or hypoglycemic agent comprising as an active ingredient, the compound, pharmaceutically acceptable salts or isomers thereof according to any one of Claims 1 to 3.
- A GPR40 receptor agonist comprising the compound, pharmaceutically acceptable salts or isomers thereof according to any one of Claims 1 to 3 as an active ingredient.
- A pharmaceutical composition for preventing or treating diseases or disorders selected from the group consisting of diabetes, high blood sugar, glucose tolerance, and impaired fasting blood glucose and diabetes complications, comprising the compound, pharmaceutically acceptable salts or isomers thereof according to any one of Claims 1 to 3 as an active ingredient.
- The pharmaceutical composition according to Claim 8 wherein the diabetes complication is hyperlipidemia, hypertension, retinopathy, renal failure or obesity.
- A method for treating diseases or disorders selected from the group consisting of diabetes, high blood sugar, glucose tolerance, impaired fasting blood glucose and diabetes complications in mammals comprising administration of the compound, pharmaceutically acceptable salts or isomers thereof according to any one of Claims 1 to 3 to the mammals.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13852767.6A EP2917180A4 (en) | 2012-11-09 | 2013-11-08 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
US14/441,591 US9988379B2 (en) | 2012-11-09 | 2013-11-08 | GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
AU2013341945A AU2013341945B2 (en) | 2012-11-09 | 2013-11-08 | GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
MX2015005418A MX2015005418A (en) | 2012-11-09 | 2013-11-08 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient. |
JP2015541689A JP6442787B2 (en) | 2012-11-09 | 2013-11-08 | GPR40 receptor agonist, method for producing the same, and pharmaceutical composition containing the same as an active ingredient |
CN201380064394.0A CN104837816A (en) | 2012-11-09 | 2013-11-08 | GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing same as active ingredient |
RU2015121948A RU2650506C2 (en) | 2012-11-09 | 2013-11-08 | Gpr40 receptor agonist, methods of preparing same, and pharmaceutical compositions containing same as active ingredient |
BR112015010314-6A BR112015010314B1 (en) | 2012-11-09 | 2013-11-08 | COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISONERS THEREOF, PHARMACEUTICAL COMPOSITION, INSULIN SECRETAGOGUE OR HYPOGLYCEMIC AGENT, AND, GPR40 RECEIVER AGONIST |
CA2889505A CA2889505C (en) | 2012-11-09 | 2013-11-08 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0127005 | 2012-11-09 | ||
KR20120127005 | 2012-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014073904A1 true WO2014073904A1 (en) | 2014-05-15 |
Family
ID=50684927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/010135 WO2014073904A1 (en) | 2012-11-09 | 2013-11-08 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
Country Status (12)
Country | Link |
---|---|
US (1) | US9988379B2 (en) |
EP (1) | EP2917180A4 (en) |
JP (2) | JP6442787B2 (en) |
KR (1) | KR101984629B1 (en) |
CN (2) | CN104837816A (en) |
AU (1) | AU2013341945B2 (en) |
BR (1) | BR112015010314B1 (en) |
CA (1) | CA2889505C (en) |
MX (1) | MX2015005418A (en) |
RU (1) | RU2650506C2 (en) |
TW (1) | TWI692469B (en) |
WO (1) | WO2014073904A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015097713A1 (en) | 2013-11-14 | 2015-07-02 | Cadila Healthcare Limited | Novel heterocyclic compounds |
US9120793B2 (en) | 2013-12-13 | 2015-09-01 | Eli Lilly And Company | Triazolo-pyridine compound |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019863A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
WO2016057731A1 (en) * | 2014-10-08 | 2016-04-14 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes |
JP2017507115A (en) * | 2014-01-10 | 2017-03-16 | イーライ リリー アンド カンパニー | Isopropyltriazolopyridine compound |
JP2017516771A (en) * | 2014-05-22 | 2017-06-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antidiabetic tricyclic compound |
WO2017180571A1 (en) * | 2016-04-11 | 2017-10-19 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes |
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
EP3281937A1 (en) | 2016-08-09 | 2018-02-14 | Dompé farmaceutici S.p.A. | Sulfonamides as gpr40- and gpr120-agonists |
WO2018048762A1 (en) * | 2016-09-06 | 2018-03-15 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
WO2018048763A1 (en) * | 2016-09-06 | 2018-03-15 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11279702B2 (en) | 2020-05-19 | 2022-03-22 | Kallyope, Inc. | AMPK activators |
US11407768B2 (en) | 2020-06-26 | 2022-08-09 | Kallyope, Inc. | AMPK activators |
US11512065B2 (en) | 2019-10-07 | 2022-11-29 | Kallyope, Inc. | GPR119 agonists |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101942752B1 (en) * | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Thioaryl derivatives as gpr120 agonists |
TWI692469B (en) * | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
KR101939657B1 (en) * | 2013-02-20 | 2019-01-17 | 주식회사 엘지화학 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
CN107176944B (en) * | 2016-03-11 | 2020-05-01 | 中国科学院上海药物研究所 | Thiophene carboxylic acid compound or derivative thereof, pharmaceutical composition, preparation method and application thereof |
CN109516914A (en) * | 2017-09-20 | 2019-03-26 | 华东师范大学 | Phenylpropiolic acid micromolecular organic compound and its preparation method and use |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004739A1 (en) | 1993-08-05 | 1995-02-16 | Merck & Co., Inc. | 3-aryl or heteroaryl-7-heteroaralkylamido cephalosporin compounds, compositions and methods of use |
WO2004041266A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
WO2004106276A1 (en) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005066136A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
WO2005086661A2 (en) | 2004-02-27 | 2005-09-22 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
WO2007095340A2 (en) | 2006-02-15 | 2007-08-23 | Dendreon Corporation | Small-molecule modulators of trp-p8 activity |
WO2008001883A1 (en) | 2006-06-29 | 2008-01-03 | Nissan Chemical Industries, Ltd. | α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT |
WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2008021091A2 (en) | 2006-08-11 | 2008-02-21 | Packetvideo Corp. | 'system and method for delivering interactive audiovisual experiences to portable devices' |
WO2008066097A1 (en) * | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
US20080153813A1 (en) | 2006-12-21 | 2008-06-26 | Alcon Manufacturing, Ltd. | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS |
US20080249101A1 (en) | 2007-04-04 | 2008-10-09 | Konrad Bleicher | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES |
WO2009054479A1 (en) | 2007-10-26 | 2009-04-30 | Japan Tobacco Inc. | Spiro-ring compound and use thereof for medical purposes |
WO2009129335A2 (en) | 2008-04-15 | 2009-10-22 | Pharmacyclics, Inc. | Selective inhibitors of histone deacetylase |
US20100040554A1 (en) | 2008-07-01 | 2010-02-18 | Board Of Regents | Conjugates of photo-activatable dyes |
WO2010027500A1 (en) | 2008-09-08 | 2010-03-11 | Signal Pharmaceuticals, Llc | Aminotriazolopyridines and their use as kinase inhibitors |
WO2010054138A2 (en) | 2008-11-06 | 2010-05-14 | Vertex Pharmaceuticals, Incorporated | Modulators of atp-binding cassette transporters |
WO2010080537A1 (en) * | 2008-12-18 | 2010-07-15 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2010089127A1 (en) | 2009-02-06 | 2010-08-12 | Grünenthal GmbH | Substituted spiro-amides as b1r modulators |
WO2010123975A1 (en) | 2009-04-22 | 2010-10-28 | Resverlogix Corp. | Novel anti-inflammatory agents |
US8003648B2 (en) | 2006-09-07 | 2011-08-23 | Amgen Inc. | Heterocyclic GPR40 modulators |
US20110313003A1 (en) * | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2011159297A1 (en) * | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2012011125A1 (en) | 2010-07-23 | 2012-01-26 | Connexios Life Sciences Pvt. Ltd. | Agonists of gpr40 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8750298A (en) * | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
CA2509202A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
JP4875978B2 (en) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | Aminophenylpropanoic acid derivatives |
JP2010524932A (en) * | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | Substituted biphenylphenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
TWI692469B (en) * | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
KR101939657B1 (en) * | 2013-02-20 | 2019-01-17 | 주식회사 엘지화학 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
-
2013
- 2013-11-05 TW TW102140079A patent/TWI692469B/en active
- 2013-11-08 RU RU2015121948A patent/RU2650506C2/en active
- 2013-11-08 EP EP13852767.6A patent/EP2917180A4/en active Pending
- 2013-11-08 CA CA2889505A patent/CA2889505C/en active Active
- 2013-11-08 BR BR112015010314-6A patent/BR112015010314B1/en active IP Right Grant
- 2013-11-08 WO PCT/KR2013/010135 patent/WO2014073904A1/en active Application Filing
- 2013-11-08 KR KR1020130135196A patent/KR101984629B1/en active IP Right Grant
- 2013-11-08 US US14/441,591 patent/US9988379B2/en active Active
- 2013-11-08 CN CN201380064394.0A patent/CN104837816A/en active Pending
- 2013-11-08 JP JP2015541689A patent/JP6442787B2/en active Active
- 2013-11-08 CN CN201910092489.2A patent/CN110003169A/en active Pending
- 2013-11-08 MX MX2015005418A patent/MX2015005418A/en unknown
- 2013-11-08 AU AU2013341945A patent/AU2013341945B2/en active Active
-
2018
- 2018-07-26 JP JP2018140278A patent/JP2018184454A/en active Pending
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004739A1 (en) | 1993-08-05 | 1995-02-16 | Merck & Co., Inc. | 3-aryl or heteroaryl-7-heteroaralkylamido cephalosporin compounds, compositions and methods of use |
WO2004041266A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
WO2004106276A1 (en) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005066136A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005086661A2 (en) | 2004-02-27 | 2005-09-22 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
WO2007095340A2 (en) | 2006-02-15 | 2007-08-23 | Dendreon Corporation | Small-molecule modulators of trp-p8 activity |
WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2008001883A1 (en) | 2006-06-29 | 2008-01-03 | Nissan Chemical Industries, Ltd. | α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT |
WO2008021091A2 (en) | 2006-08-11 | 2008-02-21 | Packetvideo Corp. | 'system and method for delivering interactive audiovisual experiences to portable devices' |
US8003648B2 (en) | 2006-09-07 | 2011-08-23 | Amgen Inc. | Heterocyclic GPR40 modulators |
WO2008066097A1 (en) * | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
US20080153813A1 (en) | 2006-12-21 | 2008-06-26 | Alcon Manufacturing, Ltd. | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS |
US20080249101A1 (en) | 2007-04-04 | 2008-10-09 | Konrad Bleicher | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES |
WO2009054479A1 (en) | 2007-10-26 | 2009-04-30 | Japan Tobacco Inc. | Spiro-ring compound and use thereof for medical purposes |
WO2009129335A2 (en) | 2008-04-15 | 2009-10-22 | Pharmacyclics, Inc. | Selective inhibitors of histone deacetylase |
US20100040554A1 (en) | 2008-07-01 | 2010-02-18 | Board Of Regents | Conjugates of photo-activatable dyes |
WO2010027500A1 (en) | 2008-09-08 | 2010-03-11 | Signal Pharmaceuticals, Llc | Aminotriazolopyridines and their use as kinase inhibitors |
WO2010054138A2 (en) | 2008-11-06 | 2010-05-14 | Vertex Pharmaceuticals, Incorporated | Modulators of atp-binding cassette transporters |
WO2010080537A1 (en) * | 2008-12-18 | 2010-07-15 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2010089127A1 (en) | 2009-02-06 | 2010-08-12 | Grünenthal GmbH | Substituted spiro-amides as b1r modulators |
WO2010123975A1 (en) | 2009-04-22 | 2010-10-28 | Resverlogix Corp. | Novel anti-inflammatory agents |
US20110313003A1 (en) * | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2011159297A1 (en) * | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2012011125A1 (en) | 2010-07-23 | 2012-01-26 | Connexios Life Sciences Pvt. Ltd. | Agonists of gpr40 |
Non-Patent Citations (7)
Title |
---|
ACS MED. CHEM. LETT., vol. 290, 2010, pages 50 |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, 2012, pages 1267 - 1270 |
JOURNAL OF ORGANIC CHEMISTRY, vol. 4, no. 18, 2009, pages 7052 |
ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 9, 2011, pages 4570 |
ORGANIC LETTER, vol. 12, no. 23, 2011, pages 6300 |
See also references of EP2917180A4 |
TETRAHEDRON LETTERS, vol. 38, no. 14, 1997, pages 2439 |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10011609B2 (en) | 2013-11-14 | 2018-07-03 | Cadila Healthcare Limited | Heterocyclic compounds |
US10246470B2 (en) | 2013-11-14 | 2019-04-02 | Cadila Healthcare Limited | Heterocyclic compounds |
WO2015097713A1 (en) | 2013-11-14 | 2015-07-02 | Cadila Healthcare Limited | Novel heterocyclic compounds |
US9120793B2 (en) | 2013-12-13 | 2015-09-01 | Eli Lilly And Company | Triazolo-pyridine compound |
JP2017507115A (en) * | 2014-01-10 | 2017-03-16 | イーライ リリー アンド カンパニー | Isopropyltriazolopyridine compound |
JP2017516771A (en) * | 2014-05-22 | 2017-06-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antidiabetic tricyclic compound |
WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019863A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
US10131651B2 (en) | 2014-08-08 | 2018-11-20 | Merck Sharp & Dohme Corp. | [7,6]-fused bicyclic antidiabetic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016057731A1 (en) * | 2014-10-08 | 2016-04-14 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes |
US9790198B2 (en) | 2014-10-08 | 2017-10-17 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
US10662170B2 (en) | 2014-10-08 | 2020-05-26 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
US10131648B2 (en) | 2014-10-08 | 2018-11-20 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
WO2017180571A1 (en) * | 2016-04-11 | 2017-10-19 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes |
US10106553B2 (en) | 2016-04-11 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
US10508090B2 (en) | 2016-08-09 | 2019-12-17 | Dompé Farmaceutici S.P.A. | Sulfonamides as GPR40- and GPR120-agonists |
EP3281937A1 (en) | 2016-08-09 | 2018-02-14 | Dompé farmaceutici S.p.A. | Sulfonamides as gpr40- and gpr120-agonists |
WO2018029150A1 (en) | 2016-08-09 | 2018-02-15 | Dompe' Farmaceutici S.P.A. | Sulfonamides as gpr40- and gpr120-agonists |
US11098016B2 (en) | 2016-09-06 | 2021-08-24 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
US10214493B2 (en) | 2016-09-06 | 2019-02-26 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
WO2018048762A1 (en) * | 2016-09-06 | 2018-03-15 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
US10774048B2 (en) | 2016-09-06 | 2020-09-15 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
AU2017324724B2 (en) * | 2016-09-06 | 2020-11-12 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
WO2018048763A1 (en) * | 2016-09-06 | 2018-03-15 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
US10000473B2 (en) | 2016-09-06 | 2018-06-19 | Janssen Pharmaceutica Nv | Indazole derivatives useful as glucagon receptor antagonists |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11512065B2 (en) | 2019-10-07 | 2022-11-29 | Kallyope, Inc. | GPR119 agonists |
US11279702B2 (en) | 2020-05-19 | 2022-03-22 | Kallyope, Inc. | AMPK activators |
US11851429B2 (en) | 2020-05-19 | 2023-12-26 | Kallyope, Inc. | AMPK activators |
US11407768B2 (en) | 2020-06-26 | 2022-08-09 | Kallyope, Inc. | AMPK activators |
Also Published As
Publication number | Publication date |
---|---|
CN104837816A (en) | 2015-08-12 |
KR101984629B1 (en) | 2019-05-31 |
MX2015005418A (en) | 2015-07-23 |
KR20140060242A (en) | 2014-05-19 |
CA2889505A1 (en) | 2014-05-15 |
TW201427943A (en) | 2014-07-16 |
TWI692469B (en) | 2020-05-01 |
AU2013341945B2 (en) | 2018-07-12 |
CA2889505C (en) | 2020-12-29 |
EP2917180A1 (en) | 2015-09-16 |
BR112015010314B1 (en) | 2021-11-16 |
US9988379B2 (en) | 2018-06-05 |
BR112015010314A8 (en) | 2018-08-14 |
CN110003169A (en) | 2019-07-12 |
RU2650506C2 (en) | 2018-04-16 |
JP2018184454A (en) | 2018-11-22 |
AU2013341945A1 (en) | 2015-05-14 |
JP2016503409A (en) | 2016-02-04 |
BR112015010314A2 (en) | 2017-07-11 |
RU2015121948A (en) | 2017-01-10 |
JP6442787B2 (en) | 2018-12-26 |
US20150291584A1 (en) | 2015-10-15 |
EP2917180A4 (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014073904A1 (en) | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient | |
WO2010093191A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2011043568A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
AU2014260605B2 (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | |
EP3362445A1 (en) | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
WO2015137750A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
WO2013073875A1 (en) | Novel antiviral pyrrolopyridine derivative and a production method for same | |
WO2013081400A2 (en) | Novel benzamide derivative and use thereof | |
WO2015102426A1 (en) | Novel indole derivative compound and pharmaceutical composition comprising the same | |
WO2022035303A1 (en) | Novel dioxoloisoquinolinone derivatives and use thereof | |
EP3681877A1 (en) | Pyrazole derivative compound and use thereof | |
AU2021226297B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
WO2021162493A1 (en) | Protein kinase degradation inducing compound, and use thereof | |
WO2012030170A2 (en) | Novel compound acting as a cannabinoid receptor-1 inhibitor | |
AU2021327622B2 (en) | Novel compounds having inhibitory activity on prostaglandin E2 receptor and uses thereof | |
WO2020022787A1 (en) | Novel imidazole derivative having jnk inhibitory activity, and pharmaceutical composition comprising same | |
WO2021221445A1 (en) | Compound as ubr box domain ligand | |
AU2021255176B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
WO2021246781A1 (en) | Pyridine derivatives as immunomodulators | |
EP4038062A1 (en) | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | |
WO2023074936A1 (en) | Bifunctional compound using ubr box domain-binding ligand | |
WO2022250224A1 (en) | Piperidinedione derivative | |
WO2021096335A1 (en) | Novel quinoline compound and use thereof | |
WO2021107656A2 (en) | Novel quercetin redox derivative and use thereof as bet inhibitor | |
WO2022098108A1 (en) | Nlrp3 protein degradation inducing compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13852767 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2889505 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/005418 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015/05513 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2015541689 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14441591 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013341945 Country of ref document: AU Date of ref document: 20131108 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013852767 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015121948 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015010314 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015010314 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150506 |